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Nicotinic acetylcholine receptors (nAChRs) are typical ligand-gated ion channels 
that evoke cation-selective currents across the plasma membrane. On exposure to 
agonists, nAChR exists in an active, open state, and elicits rapid depolarization of 
neurons. In addition to acute ionic responses, it has been widely recognized that 
nAChRs mediate long-term modification of cell functions. Persistent stimulation of 
nAChRs for a longer period occurs during habitual tobacco smoking as well as dur-
ing acetylcholinesterase (AChE) inhibitor therapy for Alzheimer’s disease. Long- 
term tobacco smoking, nicotine application, or exposure to AChE inhibitors induces 
upregulation of nAChRs and, in most cases, facilitates cellular responses. Such 
long-term nAChR stimulation contributes to the elaboration of complex intracellu-
lar signals, resulting in functional changes in cells expressing nAChRs in the central 
nervous system (CNS). The concept of nAChRs as ligand-gated ion channels gen-
erating rapid ionic currents is likely to be supplemented with more complex mecha-
nisms, in which nAChRs are important elements triggering intracellular signaling 
toward gradual alteration of cellular functions. Neuroprotection is one of the major 
effects of gradual functional modification induced by nicotine and AChE inhibitors 
including donepezil, which is used in the treatment of Alzheimer’s disease.
The goal of this book is to describe current knowledge on roles and mechanisms 
of signal transduction triggered by nAChR stimulation in neuroprotection against 
toxic effects of risk factors of neurodegenerative diseases. The major topic of this 
book is neuroprotection mediated by nAChRs in neurodegenerative diseases such as 
Alzheimer’s disease. Authors of this book are members of research projects sup-
ported by the Smoking Research Foundation (SRF), Japan. The SRF project titles 
are “Functional changes induced by long-term stimulation of nAChRs,” “Brain 
nicotinic acetylcholine receptors and Alzheimer’s disease – for the proposal of inno-
vative therapeutic strategies,” and “Smoking and nervous system.” The authors 
acknowledge support over many years from SRF.
In response to rapidly evolving areas in clinical and laboratory neuropharmacol-
ogy and neurochemistry, we provide an in-depth coverage of nAChR-mediated neu-
roprotection in basic research and of future developments in clinical application of 
effective neuroprotective strategies in neurodegenerative diseases. We hope that our 
vi
work will result in an increased interest in the fascinating subject of nicotinic neu-
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Abstract The nicotinic acetylcholine receptor (nAChR) is a typical ion channel 
type receptor. nAChR agonists such as nicotine evoke rapid excitatory responses in 
order of milliseconds. In addition to acute responses, sustained stimulation of 
nAChRs induces delayed cellular responses leading to neuroprotection via intracel-
lular signal pathways probably triggered by Ca2+ influx. The most predominant sub-
types of nAChRs expressed in the central nervous system (CNS) are α4 (known as 
α4β2) and α7 nAChRs. Long-term exposure to nicotine or acetylcholinesterase 
(AChE) inhibitors exerts protection against neurotoxicity induced by glutamate, 
β-amyloid, and other toxic insults. Nicotinic neuroprotection is mediated by α7 
nAChR which shows high Ca2+ permeability, though contribution of α4 nAChR to 
nicotinic neuroprotection has also been suggested. Agonist stimulation of these 
receptors leads to activation of the phosphoinositide 3-kinase (PI3K)-Akt signaling 
pathway, downstream of neurotrophin receptors. AChE inhibitors including done-
pezil which is used for treatment of Alzheimer’s disease, also activate PI3K-Akt 
pathway via nAChRs. Neuroprotective effects induced by long-term nAChR stimu-
lation indicate that CNS nAChRs play important roles in promotion of neuronal 
survival under pathophysiological conditions such as brain ischemia and neurode-
generative diseases. Elucidation of neuroprotective mechanisms of nAChRs may 
enable development of novel therapies for neurodegenerative diseases.
Keywords Acetylcholine · Acetylcholinesterase · Neuroprotection · Nicotine · 
Nicotinic
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1.1  Introduction
Acetylcholine (ACh) is a small molecule with a simple chemical structure compris-
ing an ester of choline and acetic acid. This molecule plays a crucial role in main-
taining homeostasis and brain functions by acting as a neurotransmitter in the 
peripheral nervous system including motor nerves and the autonomic and the cen-
tral nervous system (CNS). ACh is synthetized by choline acetyltransferase with 
choline and acetyl coenzyme A as substrates (Fig. 1.1). ACh released from nerve 
endings upon nerve excitation is rapidly degraded by acetylcholinesterase (AChE) 
into choline and acetic acid. ACh released in the synaptic cleft acts as an agonist to 
its specific receptors to evoke various cellular responses. ACh receptors are divided 
into two major classes, nicotinic ACh receptors (nAChRs) and muscarinic ACh 
receptors (mAChRs). The names of these receptors are derived from their specific 
agonists; nicotine contained in tobacco leaves and muscarine isolated from poison-
ous mushrooms, Amanita muscaria. nAChRs are ligand-gated ion channels, which 
evoke rapid depolarization responses to elicit neuronal excitation or skeletal muscle 
contraction. On the other hand, mAChRs are representative G-protein-coupled 
receptors classified as M1–M5 (Caulfield and Birdsall 1998). M1, M3, and M5 recep-
tors interact with Gq-type G proteins and primarily cause excitatory responses, 
whereas M2 and M4 receptors interact with Gi/Go type G proteins and cause sup-
pressive responses such as hyperpolarization. Responses mediated by mAChRs are 
relatively slow whereas opening of ligand-gated channels of nAChRs induces rapid 
cellular responses in the order of milliseconds.
nAChRs are highly expressed in skeletal muscle and the nervous system. 
Recently, expression of nAChRs in immune cells and glial cells has also attracted 
attention for potential therapeutic targeting in inflammation and neurodegenerative 





















Fig. 1.1 Synthesis and metabolism of acetylcholine (ACh). Choline acetyltransferase (ChAT) and 
acetylcholinesterase (AChE) are involved in synthesis and metabolism of ACh. ACh is synthesized 
from Acetyl coenzyme A (Acetyl-CoA) and Choline, releasing Coenzyme A (HS-CoA)
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nAChRs are grouped into muscle-type (Nm), peripheral neuronal-type (Nn), and cen-
tral neuronal-type (CNS) based on their distribution, subunit composition, and 
selective antagonists, as per the classification in Goodman & Gilman’s “The 
Pharmacological Basis of Therapeutics” (12th Edition, 2011). In their classification, 
CNS AChRs are further divided into two subtypes: (α4)2(β2)3 (α-bungarotoxin- 
insensitive) and (α7)5 (α-bungarotoxin-sensitive). Nn AChRs are widely expressed 
in autonomic ganglia and the adrenal medulla. CNS AChRs are expressed in neu-
rons and glia of various brain areas. One of the typical antagonists of Nm AChRs is 
d-tubocurarine, a toxic alkaloid derived from an arrow poison and clinically used as 
a non-depolarizing blocking agent of the neuromuscular junction. Hexamethonium 
and mecamylamine are selective antagonists of Nn and CNS AChRs.
In all types of nAChRs, agonists such as ACh itself or nicotine-induced ion chan-
nel opening and evoke influx of Na+ and Ca2+. This triggers cell depolarization and 
turns on various functional switches (Albuquerque et al. 2009). Nicotinic choliner-
gic responses correlated with fast neurotransmission are easily detected in the end-
plate at the neuromuscular junction and ganglion cells of the sympathetic nerves. 
By contrast, it is relatively difficult to detect postsynaptic nicotinic responses of 
neurons in the CNS because most neuronal nAChRs quickly desensitized when 
exposed to nicotinic agonists (Albuquerque et  al. 2009; Alkondon et  al. 1998; 
Frazier et  al. 1998). Development of drug-delivery devices that allow fast drug 
delivery and removal has made it possible to detect fast responses mediated by func-
tional CNS nAChRs. While peripheral nAChRs are involved in rapid responses such 
as skeletal muscle contraction, nAChRs expressed in the CNS tend to be involved in 
relatively slow functional changes. For example, in the cerebral cortex, persistent 
nAChR stimulation triggers signals to the phosphoinositide 3-kinase (PI3K) cas-
cade, which contributes to neuroprotection (Kihara et al. 2001; Dajas-Bailador and 
Wonnacott 2004). In the hippocampal neurons, nAChRs induce long-term potentia-
tion of synaptic transmission (Kenney and Gould 2008). nAChRs regulate dopa-
mine release in the striatum (Exley and Cragg 2008). Moreover, nAChRs are one of 
the important factors regulating memory and addiction (Molas et  al. 2017; Nees 
2015). Thus, in addition to rapid responses such as membrane depolarization 
induced by inward currents via ion channels, nAChR can generate longer-lasting 
effects in the CNS neurons, where rapid cation influx may trigger activation of com-
plex intracellular signaling pathways.
1.2  Structural and Pharmacological Characterization 
of Nicotinic Acetylcholine Receptors
nAChRs are classified as members of the cysteine-loop (Cys-loop) family of ligand- 
gated ion channels (Sine and Eagle 2006; Tsetlin et al. 2011). The Cys-loop ligand- 
gated channels, also known as Cys-loop receptors, play prominent roles in generating 
excitatory and inhibitory postsynaptic potentials in the nervous system. nAChRs, 
1 Overview
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γ-aminobutyric acid type A (GABAA) receptors, glycine receptors, and 
5- hydroxytryptamine type-3 (5-HT3) receptors are classified as Cys-loop receptors. 
These receptors are composed of five subunits, forming a pentameric conformation 
around a central water-filled pore. The Cys-loop receptors have structurally com-
mon features with a characteristic loop formed by a disulfide bond between two 
cysteine residues. In nAChRs, the two cysteine residues separate 13 highly con-
served amino acids located in the extracellular N-terminal domain of the α-subunit. 
The four hydrophobic transmembrane domains are estimated to form α-helices that 
make up the ion channel pore. The channel pore is lined with residues from the 
second transmembrane domain (TM2) from each of the five subunits of the recep-
tors. The extracellular domain is largely composed of the N-terminus with binding 
sites for agonists.
The International Union of Basic and Clinical Pharmacology Committee on 
Receptor Nomenclature and Drug Classification (NC-IUPHAR, URL: http://www.
guidetopharmacology.org/nciuphar.jsp) recommends a nomenclature and classifica-
tion scheme for nAChRs based on subunit composition of known, naturally occur-
ring and/or heterologously-expressed nAChR subtypes. A total of 17 subunits 
(α1–10, β1–4, γ, δ, and ε) have been identified in nAChRs. All subunits except α8, 
which is present in avian species, have been identified in mammals. ACh-binding 
sites are found at interfaces of the α subunit and the δ or γ subunit in Nm AChRs, and 
at interfaces of the α subunit and β subunit or two adjacent α subunits in Nn and CNS 
AChRs (Fig.  1.2). All α subunits possess two tandem cysteine residues near the 
ACh-binding site. By contrast, β, γ, δ, and ε subunits lack these cysteine residues. 
Nm AChRs of adult animals possess the stoichiometry (α1)2β1δε while Nm AChRs 
expressed in embryonic muscles and denervated adult muscles possess the stoichi-
ometry (α1)2β1γδ (Lukas et al. 1999). Other types of nAChRs are predominantly 
expressed in neurons (Table 1.1). They are assembled as combinations of α2–α6 and 
β2–β4 subunits or α7, α8, and α9 subunits forming functional homo-oligomers. Nm 
AChRs and some subtypes of CNS AChRs (α7, α8, α9, and α10) are sensitive to 
α-bungarotoxin, a well-known neurotoxic protein derived from the venom of kraits. 














Fig. 1.2 Examples of subunit assembly and location of agonist-binding sites. Large circles indi-
cate subunits of nicotinic acetylcholine receptor (nAChR). Small filled circles indicate binding 
sites of acetylcholine. Muscle-type AChR (Nm AChR), central nervous system AChR (CNS AChR)
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For α2, α3, α4, and β2 and β4 subunits, pairwise combinations of α and β (e.g., α3β4 
and α4β2) are sufficient to form a functional receptor in vitro, but more complex 
isoforms may exist in vivo. Among those subunit combinations, the α3β4 subunit 
combination is dominant in nAChRs of autonomic ganglia neurons. The α5 and β3 
subunits participate in formation of functional hetero-oligomeric receptors when 
they are expressed as a third subunit with another α and β pair such as α4α5αβ2, 
α4αβ2β3, and α5α6β2. The α6 subunit can form a functional receptor when co- 
expressed with β4 in vitro. The α7 subunit forms functional homo-oligomers. This 
subunit can also combine with a β subunit to form a hetero-oligomeric assembly 
such as α7β2. The α8 and α9 subunits show similar properties to the α7 subunit. For 
functional expression of the α10 subunit, co-assembly with α9 is necessary.
Subtypes of nAChRs can be classified based on the predominant α-subunits 
(α1–α10) because the α subunit plays a key role in agonist binding to trigger ion 
channel opening, and subtype-selective antagonists like α-bungarotoxin distinguish 
receptors based on the α subunit combination (see Table 1.1). As per this receptor 
classification, Nm AChRs can be defined as α1 nAChRs, because the α1 subunit is 
highly expressed only in skeletal muscle and other α subunits are not detected in 
this tissue. Nn and CNS AChRs can be broadly classified into two subgroups, α2–α6 
nAChRs, formed from the combination of α- and β-subunits, and α7–α9 nAChRs, 
forming homo-oligomers. The former subgroup, α2–α6 nAChRs, is insensitive to 
α-bungarotoxin whereas the latter subgroup, α7–α9 nAChRs, is sensitive to the toxin. 
Ion channels of homo-oligomeric receptors α7–α9 show high Ca2+ permeability. 
The α5 and α6 hetero-oligomeric receptors also show high Ca2+ permeability. 













α2 α2β2, α2β4 Low CNS Insensitive






α5 α3β2α5, α3β4α5, 
(α4)2(β2)2α5
High Autonomic ganglion, 
CNS
Insensitive
α6 α6β2β3, α6α4β2β3 High CNS Insensitive
α7 (α7)5 High CNS, Non-neuronal 
cells
Sensitive
α8 (avian only) (α8)5 High CNS Sensitive
α9 (α9)5, α9α10 High Mechanosensory hair 
cells
Sensitive





Among those neuronal receptors, α3 nAChR is highly expressed in autonomic ganglia 
though this subtype is also expressed in CNS. The most predominant subtypes of 
nAChRs expressed in CNS are α4, known as α4β2 and α7 nAChRs (Dani 2015). 
Expression of both subunits is detected across wide areas of the CNS (Table 1.2). 
In the cerebral cortex, α2 and α5 subunits are also detected. Accumulating evidence 
also suggests anti-inflammatory and neuroprotective roles of α7 nAChR expressed 
in immune cells and glial cells (Egea et al. 2015; Morioka et al. 2015).
1.3  Neuroprotection Mediated by Nicotinic Acetylcholine 
Receptors
It is widely recognized that glutamate acts as an excitatory neurotransmitter but also 
exerts excitatory neurotoxicity in pathological conditions such as ischemia 
(Meldrum and Garthwaite 1990; Duggan and Choi 1994; Brassai et al. 2015). In 
addition to cerebral ischemia, glutamate neurotoxicity is also considered as one of 
the risk factors for neurodegenerative diseases, such as Alzheimer’s disease and 
Parkinson’s disease. Involvement of the cholinergic system in glutamate neurotox-
icity was first reported in Mattson’s study (1989), showing that glutamate neurotox-
icity in the hippocampus was enhanced by mAChR stimulation. Olney et al. (1991) 
showed evidence suggesting that N-methyl-D-aspartate (NMDA) receptor blockade 
by MK801 induces disinhibition of the central cholinergic system and causes exces-
sive stimulation of mAChRs. They hypothesized that MK801 occasionally induces 
neurotoxicity instead of neuroprotection due to such an indirect mAChR stimula-
tion. Thus, it is likely that mAChRs facilitate neuronal death in pathological states 
where glutamate neurotoxicity causes neurodegeneration.
On the other hand, accumulating evidence has suggested that nAChRs play a 
protective role in glutamate neurotoxicity. Approximately two decades ago, Akaike 
et al. (1994) and Kaneko et al. (1997) reported that glutamate neurotoxicity in the 
Table 1.2 Distribution of nAChR in CNS
α2 α3 α4 α5 α6 α7
Cortex Cortex Cortex Cortex
















Spinal cord Spinal cord Spinal cord
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cerebral cortex was suppressed by nicotine and other nAChR agonists. Because 
NMDA receptors are acknowledged as a predominant route of glutamate cytotoxicity 
in the cerebral cortex, nicotine was suggested to prevent glutamate neurotoxicity by 
exerting a protective action against NMDA receptor-mediated intracellular responses 
to induce neuronal death. The neuroprotective effect of nicotine was antagonized by 
hexamethonium and mecamylamine, which are Nn and CNS nAChR antagonists, 
respectively, indicating that nicotine induces neuroprotection by its selective action 
on nAChRs. To our knowledge, our study (Akaike et al. 1994) was the first evidence 
for the neuroprotective role of nAChRs in the CNS. In this study, nicotine markedly 
reversed glutamate cytotoxicity, whereas muscarine exacerbated it. Carbachol, 
which acts on both nicotinic and muscarinic receptors, reduced glutamate cytotox-
icity although its effect was less potent than that of nicotine. These observations 
indicate that nAChRs and mAChRs exert opposing effects on glutamate cytotoxic-
ity. Moreover, findings of nAChR-mediated neuroprotection suggested a role of 
nicotinic cholinergic system in promoting neuronal survival under pathological 
conditions such as brain ischemia. A characteristic feature of the neuroprotective 
action of nicotine was that long-term exposure of more than an hour was necessary 
to ameliorate glutamate neurotoxicity. Following our findings in the cerebral cortex, 
neuroprotective effects mediated by nAChRs have been detected in various areas of 
the brain, including the hippocampus (Dajas-Bailador et  al. 2000; Liu and Zhao 
2004), the striatum (Ohnishi et al. 2009), dopaminergic neurons in the substantia 
nigra (Takeuchi et al. 2009), and the spinal cord (Nakamizo et al. 2005; Toborek 
et  al. 2007). Nicotinic neuroprotection detected in those studies is estimated to 
be mediated by nAChR expressed in neurons though contribution of microglia 
activation by α7 nAChR in nicotinic neuroprotection is also suggested (Morioka 
et al. 2015).
It is unlikely that nicotine-induced protection against glutamate neurotoxicity is 
due to its direct action on NMDA receptors though there are some reports indicating 
that nicotine partially inhibits NMDA receptors. Aizenman et al. (1991) have dem-
onstrated that nicotinic agonists partially inhibit whole cell NMDA-induced 
responses in cultured cortical neurons. Akaike et al. (1991) also reported modula-
tory action of cholinergic drugs on NMDA responses in the nucleus basalis of 
Meynert neurons. These studies suggest that nicotinic agonists have properties to 
directly interact with NMDA receptors and modulate their function. In this case, 
concomitant application of nicotine and glutamate or short-term nicotine exposure 
should affect glutamate neurotoxicity by direct modification of NMDA receptors. 
However, as described above, long-term exposure for more than an hour is neces-
sary to detect nicotinic neuroprotection (Akaike et al. 1994; Kaneko et al. 1997). 
Moreover, nicotine-induced protection against glutamate cytotoxicity was antago-
nized by CNS nAChR antagonists. Therefore, persistent stimulation of nAChRs, but 
not direct inhibition of NMDA receptors is estimated to be the major route of 
nicotine- induced neuroprotection though direct interaction of nicotine with NMDA 
receptors may potentiate nicotine-induced neuroprotection.
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In the forebrain including the cerebral cortex, α7 nAChRs, homo-oligomers of 
α7 subunits and α4β2 nAChRs, hetero-oligomers of α4 and β2 subunits are the 
major subtypes among CNS nAChRs (Albuquerque et al. 2009; Zoli et al. 2015). It 
has been reported that nicotine-induced protection against glutamate neurotoxicity 
was antagonized by selective α7 nAChR antagonists α-bungarotoxin and 
 methyllycaconitine, as well as by the selective α4β2 nAChR antagonist dihydro-β-
erythroidine (Kaneko et  al. 1997). The α7 nAChR has attracted more attention 
because its mechanisms are thought to be involved in Alzheimer’s disease and 
β-amyloid (Aβ), a well-known risk factor of Alzheimer’s disease, is bound to α7 
nAChRs under several conditions including in post-mortem Alzheimer’s disease 
brains (Wang et  al. 2000; Parri et  al. 2011). A selective α7 nAChR agonist, 
3-(2,4)-dimethoxybenzylidene anabaseine (DMXB), exhibits potent neuroprotec-
tive action on glutamate neurotoxicity in  vitro and brain ischemia in  vivo 
(Shimohama et al. 1998). Aβ-induced neurotoxicity was suppressed by nicotine and 
DMXB (Kihara et  al. 1997). Protective effects of nicotine and DMXB against 
Aβ-induced toxicity were antagonized by α-bungarotoxin, indicating that stimula-
tion of α7 nAChRs is essential in suppressing Aβ-induced neurotoxicity. It is widely 
accepted that the β sheet conformation of Aβ is necessary in eliciting its neurotoxic-
ity (Fändrich et al. 2011). Nicotine might influence the β sheet conformation of Aβ 
to attenuate its toxicity or to modulate survival signals. However, it has been reported 
that neither nicotine nor DMXB influences the β sheet conformation (Kihara et al. 
1999). Thus, signal transduction downstream of α7 nAChRs is likely to be involved 
in the protective effect of nicotine against Aβ neurotoxicity.
1.4  Intracellular Signal Transduction Triggered by Nicotinic 
Acetylcholine Receptors
On exposure to agonists, nAChR exists in an active, open state, and elicits rapid 
depolarization in order of milliseconds. Thus, nAChR is classified as an excitatory 
receptor that evokes rapid excitation in neuronal, muscular, and secreting cells. 
Progressive decline of agonist-evoked current indicates closure of the channel. 
Upon further exposure to agonists, nAChRs exist in desensitized, non-functional 
states. Besides such short-term response, it is also recognized that nAChRs mediate 
long-term modification of cell functions via specific signaling pathways (Dajas- 
Bailador and Wonnacott 2004). nAChRs, especially α7 nAChRs, generate specific 
and complex Ca2+ signals that include adenylyl cyclase, protein kinase A, protein 
kinase C, Ca2+-calmodulin-dependent kinase, and phosphatidylinositol 3-kinase (PI3K) 
(Fig.  1.3). These phosphorylated downstream targets activate cellular signaling 
related to exocytosis and extracellular signal-regulated mitogen-activated protein 
kinase (ERK)-linked neuronal functions. Kihara et al. (2001) showed that α7 nAChR 
stimulation promoted PI3K-Akt signal transduction and inhibited Aβ neurotoxicity. 
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PI3K phosphorylates Akt (or known as protein kinase B), a serine/threonine kinase. 
Activation of PI3-Akt cascade stimulates B-cell lymphoma 2 (Bcl-2) family mem-
bers, which act as anti-apoptotic factors. It has been shown that Fyn, a member of 
the non-receptor type Src tyrosine kinase family, is associated with α7 nAChRs, 
though it is not clear whether other Src family members are involved in the cascade 
downstream of nAChRs. A relationship between nAChRs and Fyn was also impli-
cated in a study, showing that catecholamine release induced by nicotine was depen-
dent on the presence of Fyn and extracellular Ca2+ (Allen et al. 1996). In the study 
by Kihara et al. (2001), an inhibitor of Src tyrosine kinase reduced Akt phosphoryla-
tion. In addition, PI3K and Fyn were physically associated with α7 nAChRs. These 
findings suggest that nAChR stimulation causes Akt phosphorylation via signal 
transduction through Fyn to PI3K. Ca2+ influx through the α7 nAChR ion channels 
might contribute to this process. It has been proposed that PI3K-Akt activation leads 
to up-regulation of Bcl-2 to promote neuronal survival (Matsuzaki et  al. 1999; 
Kihara et al. 2001).
The intracellular signal pathway downstream of CNS nAChRs is known as a 
major pathway of neuroprotective action of neurotrophins including nerve growth 
factor (NGF) and brain-derived neurotrophic factor (BDNF) (Dajas-Bailador and 





















Fig. 1.3 Nicotinic acetylcholine receptor (nAChR)-mediated signaling pathway in the brain. 
Adenylate cyclase (AC), acetylcholine (ACh), nAChR, AKT8 virus oncogene cellular homolog 
(Akt), B-cell lymphoma 2 (Bcl-2), calcium/calmodulin-dependent protein kinase (CaMK), cal-
cium/calmodulin-dependent protein kinase kinase (CaMKK), cAMP-responsive element binding 
protein (CREB), extracellular signal-regulated kinase (ERK), Fgr/Yes-related novel protein (Fyn), 
Janus-activated kinase (JAK), MAPK/ERK kinase (MEK), nicotinic acetylcholine receptor 
(nAChR), phosphoinositide 3-kinase (PI3K), protein kinase A (PKA), SH2-containing collagen- 
related proteins (Shc), tropomyosin receptor kinase (Trk)
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differentiation of central and peripheral neurons. The PI3K/Akt signaling cascades 
play a key role in neuronal survival due to neurotrophins (Chan et al. 2014). It has 
been reported that NGF and BDNF prevent glutamate neurotoxicity in a time- 
dependent manner, exhibiting significant neuroprotection in a period >1  h 
(Shimohama et al. 1993a, b; Kume et al. 1997, 2000). Each neurotrophin interacts 
with specific tropomyosin receptor kinase (Trk) receptors. Trk receptors show 
selectivity to members of the neurotrophin family. TrkA, TrkB, and TrkC serve as 
preferential receptors for NGF, BDNF, and neurotrophin-3, respectively (Kalb 
2005). In contrast to these high-affinity receptors, the low-affinity neurotrophin 
receptor, p75, interacts with all neurotrophin members. BDNF promotes survival of 
neurons via TrkB in several brain regions including the cerebral cortex. Moreover, 
nAChRs appear to transduce survival signals similar to signals downstream of the 
Trk receptors of neurotrophins (Dajas-Bailador and Wonnacott 2004). Thus, nico-
tine and neurotrophins show similar properties in terms of time-course and signal 
pathways of neuroprotection.
1.5  Acetylcholinesterase Inhibitors Used for Treatment 
of Alzheimer’ Disease
The finding that glutamate neurotoxicity is suppressed by continuous stimulation of 
nAChRs suggests a possible function of the nicotinic cholinergic system as a factor 
promoting neuron survival in the CNS. AChE inhibitors including donepezil, which 
easily permeates the blood–brain barrier, are used for Alzheimer’s disease. Takada 
et al. (2003) reported that in cultured cortical neurons, AChE inhibitors including 
donepezil, galantamine, and tacrine inhibited glutamate neurotoxicity, though con-
comitant addition of AChE inhibitors and glutamate did not exhibit neuroprotection. 
Neuroprotective effects of AChE inhibitors were antagonized by Nn and CNS AChR 
antagonists including mecamylamine and methyllycaconitine, but not by a mAChR 
antagonist, scopolamine. Thus, AChE inhibitors appeared to possess neuroprotec-
tive effects similar to properties of nicotinic neuroprotection. AChE inhibitors such 
as donepezil remarkably suppress apoptosis of neurons induced by long-term 
administration of low concentrations of glutamate. Investigation of the involvement 
of PI3K on the protective action of AChE inhibitors revealed that the neuroprotec-
tive action of donepezil and galantamine is associated with Fyn, Janus Activating 
Kinase 2 (JAK2), and PI3K (Takada-Takatori et al. 2006; Akaike et al. 2010). In 
addition, these central AChE inhibitors promoted phosphorylation of Akt and 
increased the expression level of Bcl-2 protein. These results indicate that the PI3K- 
Akt signaling pathway is important for protection mechanisms of AChE inhibitors.
nAChRs are also recognized as major functional molecules mediating pharma-
cological action of tobacco smoking. Nicotine is a major ingredient of tobacco 
and stimulates all subtypes of nAChRs, though nicotine induces more rapid 
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desensitization of nAChRs than ACh (Albuquerque et  al. 2009). Several clinical 
studies have shown a negative correlation between prevalence of sporadic Parkinson’s 
disease and smoking history in relation to nAChR and neurodegenerative diseases, 
although no clear conclusion can be reached as to the relationship between 
Alzheimer’s disease and smoking (Godwin-Austen et al. 1982; Tanner et al. 2002; 
Ulrich et al. 1997). Moreover, galantamine, possessing allosteric potentiating action 
on α7 nAChR, is used as a treatment for Alzheimer’s disease (Albuquerque et al. 
2001; Santos et  al. 2002). Interestingly, long-term tobacco smoking or nicotine 
application induces up-regulation of nAChRs and, in most cases, facilitates their 
functions (Brody et al. 2013; Govind et al. 2009). This phenomenon is quite unique 
because, in most neuronal receptors including mAChRs, long-term receptor stimu-
lation by specific agonists usually induces down-regulation of receptors and reduc-
tion of receptor functions. Moreover, AChE inhibitors including donepezil induce 
significant up-regulation of nAChRs (Kume et  al. 2005; Takada-Takatori et  al. 
2010). Activation of the PI3-Akt pathway is necessary for nAChR up-regulation 
following long-term donepezil exposure. Receptor up-regulation following long-
term exposure to nicotine and AChE inhibitors may be linked to diverse properties 
of nAChRs, from enhancement of learning and memory to addiction and neuropro-
tection, although precise mechanisms of up-regulation are not fully understood.
1.6  Conclusion
Nicotine induces fast nAChR currents of the order of milliseconds, while sustained 
nicotine exposure induces delayed intracellular responses. Neuroprotection is one 
of the dominant delayed responses mediated by CNS nAChRs. Mechanisms of neu-
roprotective effects exerted by persistent nAChR stimulation cannot be described 
only by simple excitatory reactions following depolarization induced by ion chan-
nel openings, but rather by activation of the intracellular PI3K-Akt signaling path-
way leading to up-regulation of the anti-apoptotic protein Bcl-2. α7 nAChR, which 
shows high Ca2+ permeability, plays a crucial role in nicotinic neuroprotection. The 
metabolic change with Ca2+ as the second messenger may play an important role in 
triggering signals downstream of nAChRs. Therefore, it can be proposed that 
nAChRs are apparently implicated in two types of cellular functions; one for fast 
depolarization and the other for slow intracellular responses leading to neuroprotec-
tion (Fig. 1.4). Nicotine and other nAChR agonists evoke both acute and delayed 
responses; the former involves receptor desensitization and the latter involves recep-
tor up-regulation. On the other hand, AChE inhibitors directly or indirectly stimu-
late nAChRs without evoking apparent acute responses (Akaike et  al. 2010; 
Takada-Takatori et al. 2010). Neuroprotection and nAChR up-regulation by long- 
term exposure to AChE inhibitors, used in treatment of Alzheimer’s disease, suggest 
that CNS nAChRs are an important component of defense mechanisms of neurons 
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against risk factors of neurodegeneration in pathophysiological conditions. 
Manipulation of neuroprotective properties of nAChRs may be a novel therapeutic 
approach for treatment of neurodegenerative diseases including Alzheimer’s 
disease.
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Chapter 2
In Vivo Imaging of Nicotinic Acetylcholine 
Receptors in the Central Nervous System
Masashi Ueda, Yuki Matsuura, Ryosuke Hosoda, and Hideo Saji
Abstract Nicotinic acetylcholine receptors (nAChRs) in the central nervous sys-
tem are involved in higher brain function, i.e., memory, cognition, learning, among 
others. These receptors also exert various pharmacological effects, such as neuro-
protection and antinociception. Therefore, elucidating the localization and/or 
expression level of nAChRs in the brain is useful to clarify functions regulated by 
nAChRs, under physiological and pathological conditions. “Molecular imaging” is 
a powerful tool that enables one to noninvasively obtain information from living 
subjects. Many signal types, such as, radiation, nuclear magnetic resonance, fluo-
rescence, bioluminescence, and ultrasound, are commonly used for molecular 
imaging. Among them, nuclear medical molecular imaging, which uses radioactive 
imaging probes, has a great advantage due to its high sensitivity and the fact that it 
is a quantitative approach. Many nuclear medical imaging probes targeting nAChRs 
have been developed and some of them have successfully visualized nAChRs in the 
animal and human brain. Moreover, changes in nAChR density under pathological 
conditions have been detected in patients. This chapter summarizes the history and 
recent advance of nAChR imaging.
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Nicotinic acetylcholine receptors (nAChRs) are pentameric ligand-gated ion chan-
nels. To date, a total of 17 subunits (α1–α10, β1–β4, γ, δ, and ε) have been identified 
(Nemecz et al. 2016) and nAChRs are formed from various combinations of these 
subunits. nAChRs are located in the central and peripheral nervous systems. In the 
central nervous system (CNS), nAChRs not only play a role in higher brain func-
tion, but also exert various pharmacological effects (Graef et  al. 2011). The two 
major subtypes of nAChRs found in the mammalian CNS are heteromeric α4β2 
nAChRs and homomeric α7 nAChRs (Terry et al. 2015). Therefore, assessing the 
localization and/or expression level of both subtypes in the CNS is of great interest 
since it enables us to elucidate the functions they regulate, under physiological and 
pathological conditions.
Molecular imaging is defined as the visualization, characterization, and measure-
ment of biological processes at the molecular and cellular levels in humans and 
other living systems (Mankoff 2007). The localization and/or density of nAChRs in 
the human brain can be evaluated in a noninvasive way using molecular imaging 
techniques that specifically target nAChRs. Several imaging techniques, such as 
nuclear medical imaging, magnetic resonance imaging, optical imaging, and ultra-
sound, are commonly used for molecular imaging. Among them, nuclear medical 
molecular imaging, which uses radioactive imaging probes, is greatly advantageous 
due to its high sensitivity and the fact that it is a quantitative approach. The follow-
ing imaging modalities are used for nuclear medical molecular imaging: positron 
emission tomography (PET) and single-photon emission computed tomography 
(SPECT). The principles and characteristics of PET and SPECT are summarized in 
the next section. Many probes for nAChR imaging using PET and SPECT have 
been developed. Some of them have successfully visualized nAChRs in the animal 
and human brain. Moreover, changes in nAChR density under pathological condi-
tions have been detected in patients. The history and recent advances in molecular 
imaging that target nAChRs are summarized in later sections.
2.2  Nuclear Medical Imaging Modality
2.2.1  Positron Emission Tomography (PET)
PET is a nuclear medical imaging technique used to noninvasively acquire images 
that correspond to physiological and pathological functions in a living body.
Image acquisition using PET is initiated with the injection or inhalation of a 
positron-emitting radiopharmaceutical. The scan is started after a delay ranging 
from seconds to minutes to allow the transport to or uptake by the organ of interest. 
When the positron-emitting radioisotope decays, it emits a positron, which travels a 
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short distance before an electron-positron annihilation event occurs. This  annihilation 
event produces two high-energy photons (511 keV) propagating in nearly opposite 
directions. Therefore, a PET detector targets the detection of this annihilation radia-
tion of 511 keV. If two photons are detected within a short (~10 ns) time- window, 
an event is recorded along the line connecting the two detectors. Summing many 
such events results in quantities that approximate line integrals through the radioiso-
tope distribution. No collimator is required for the PET scanner because collimation 
is done electronically, leading to relatively high sensitivity. If they are suitably cali-
brated, PET images yield quantitative estimates of the concentration of the radioac-
tive imaging probe at specific locations within the body.
Non-radioactive carbon, nitrogen, oxygen, and fluorine generally consist in 
many compounds of biological interest and/or pharmaceuticals. Positron-emitting 
radionuclides of carbon, nitrogen, oxygen, and fluorine also exist, and can therefore 
be readily incorporated into a wide variety of useful radioactive imaging probes. 
Table 2.1 outlines several positron-emitting radioisotopes. This is, however, not an 
exhaustive list of positron-emitting radioisotopes, since many other positron- 
emitters have been recently produced on small medical cyclotrons with 10–20 MeV 
protons (Nickles 1991, 2003). The major disadvantage of PET is its cost. The short 
half-life of most positron emitting isotopes requires an on-site cyclotron, and the 
scanners themselves are significantly more expensive than single-photon cameras. 
Nevertheless, PET is widely used in research studies and there is growing clinical 
acceptance of its findings, primarily for the diagnosis and staging of cancer.
2.2.2  Single-Photon Emission Computed Tomography 
(SPECT)
Most of the clinical procedures using tracers to visualize specific tissue binding 
sites is performed using planar gamma-camera imaging, SPECT, and PET. Even 
after the recent explosive growth of clinical PET, the imaging of single-photon emit-
ting radiopharmaceuticals with gamma cameras, both in planar mode or with 
SPECT, constitutes the largest fraction of clinical nuclear medicine. Many clinically 
established radiopharmaceuticals for SPECT are commercially available and are 
commonly used in imaging departments. Single-photon emitting radionuclides that 
are used as labels for tracer molecules often have sufficiently long half-lives to 
Table 2.1 Major 
radioisotopes used for 
positron emission 
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allow the long-distance transportation. Alternatively, they can be obtained on site 
via generator systems. Tracers for SPECT can often be readily prepared on site 
using commercial reagents and kits. Therefore, in contrast with PET, the infrastruc-
ture associated with cyclotron production is not required.
A key element of the SPECT camera is its collimator design, which eliminates 
all photons that are not traveling normal to the detector surface. The presence of a 
collimator limits the direction of the incoming photons. Without this, it becomes 
extremely difficult to determine the origin of detected photons. The collimator 
design largely determines not only the overall spatial resolution but also the radia-
tion count efficiency of the system. The challenge, however, is that increasing the 
efficiency by expanding hole size of the collimator, will result in a low resolution. 
Further, the low sensitivity and efficiency mean that studies must be acquired for a 
relatively long time to accumulate sufficient counts. The only alternative would be 
to increase the administered activity, but this is limited by the radiation dose admin-
istered to the patient.
Radionuclides for SPECT have a relatively longer half-life than those for PET. It 
is preferential to have medium gamma ray energy (100–200 keV) for SPECT imag-
ing. It is well recognized that PET has a higher resolution, higher sensitivity, and a 
better quantitation capability than SPECT. However, more hospitals are equipped 
with SPECT scanners, making the use of SPECT as a routine procedure more prac-
tical. Commonly used radionuclides for SPECT imaging are listed in Table 2.2.
2.3  Imaging Probes for Nicotinic Acetylcholine Receptors
2.3.1  Imaging Probes for the α4β2 Subtype
Many efforts have been dedicated to the development of PET and SPECT probes 
targeting α4β2 nAChRs. Several probes have been successfully used to noninva-
sively image α4β2 nAChRs in the brains of healthy people and also detect changes 
in the expression of α4β2-nAChR in the brains of patients with various diseases. 
Based on the structure of the parent compound, the probes can roughly be classified 
as follows: nicotine, A-85380, and epibatidine. The characteristics of these probes 
are summarized in this section and their chemical structures are shown in Fig. 2.1.
Table 2.2 Major 
radioisotopes used for 
single-photon emission 
computed tomography 
(SPECT) in a clinical setting
Radionuclide Half-life (h) Gamma ray energy (keV)
67Ga 78.3 93, 185, 300
99mTc 6.01 141
111In 67.3 171, 245
123I 13.3 159
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2.3.1.1  Nicotine Derivatives
Nicotine was firstly selected as a parent backbone to visualize nAChRs. Saji et al. 
synthesized (S)- and (R)-11C-nicotine by methylation of (S)- and (R)-nornicotine, 
respectively, using 11C-methyl iodide. They then evaluated its biodistribution in 
mice. After an injection of (S)-11C-nicotine, the order of regional uptake of radioac-
tivity was as follows: cortex > thalamus > striatum > cerebellum. This uptake was 
displaced by the treatment of excess amount of unlabeled (S)-nicotine, but not by 
(R)-nicotine. (R)-11C-nicotine showed less uptake and regional differences in the 
brain than (S)-11C-nicotine (Saji et al. 1992). Nordberg et al. reported similar results 
using PET imaging in the rhesus monkey. After an injection of (S)-11C-nicotine, the 
radioactivity in the brain peaked within 1–2 min and then rapidly declined. The 
highest accumulation of the probe was found in the occipital cortex and thalamus, 
while an intermediate and low accumulation of probe was found in the frontal cor-
tex and white matter, respectively. Pretreatment with (S)-nicotine decreased the 
uptake of (S)-11C-nicotine by 30%. In contrast, there was no regional difference in 
the distribution of (R)-11C-nicotine (Nordberg et al. 1989). These findings indicated 
the specific binding of (S)-11C-nicotine to nAChRs in vivo. However, it the amount 
of specific binding is low and results of (S)-11C-nicotine in human PET studies are 
controversial.
2.3.1.2  A-85380 Derivatives
A-85380 [3-(2(S)-azetidinylmethoxy)pyridine] was developed in Abbott 
Laboratories. It showed 25-fold greater affinity to α4β2 nAChRs than nicotine did. 
The affinity of A-85380 to α4β2 nAChRs was comparable to that of epibatidine. 
Fig. 2.1 Chemical structures of imaging probes targeting α4β2 nicotinic acetylcholine receptors 
(nAChRs)
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However, compared to the affinity of epibatidine, the affinities of A-85380 to other 
nicotinic receptor subtypes, such as α3β4, α7, and muscle type, were tenfold or less 
(Sullivan et  al. 1996; Rueter et  al. 2006). Therefore, A-85380 is a more α4β2- 
nAChR specific ligand than epibatidine. To date, radioiodinated and radiofluori-
nated A-85380 derivatives have been developed as SPECT and PET imaging probes, 
respectively, targeting α4β2 nAChRs.
A-85380-Derived SPECT Probe
The introduction of 123I into five-position of pyridine ring of A-85380 yielded 5-[123I]
iodo-A-85380 (123I-5IA) for SPECT imaging of α4β2 nAChRs. The affinity of 
123/125I-5IA for α4β2 nAChRs was as extremely high (Ki = 10 pM) as that of epiba-
tidine (Ki = 8 pM), when evaluated using rat brain homogenates. In contrast, the Ki 
values of 5IA for α3β4, α7, and muscle-type were 51, 250, and 1400 nM, respec-
tively. Thus, the affinity ratios of α4β2-to-other subtype were calculated with 5100, 
25,000, and 140,000, respectively (Mukhin et al. 2000). These results indicated that, 
despite the introduction of iodine to the parent backbone, 123I-5IA maintained both 
the affinity and selectivity to α4β2 nAChRs.
In a biodistribution study in mice, the highest amount of 125I-5IA accumulated in 
the thalamus (14.9% injected dose per gram of tissue [ID/g] at 60 min), while the 
accumulation was moderate in the cortex (8.5%ID/g at 60 min) and lowest in the 
cerebellum (2.4%ID/g at 60 min). Pretreatment with nAChR agonists (A-85380, 
(S)-nicotine, or cytisine) significantly reduced the accumulation of 125I-5IA in the 
brain (Musachio et al. 1998). Saji et al. reported similar results in a study using rats. 
After injection of 125I-5IA, the order of regional accumulation of radioactivity was 
followed: thalamus > cortex > striatum > cerebellum. This regional distribution was 
highly correlated with the nAChR density, which was determined using in vitro [3H]
cytisine binding. Further, SPECT imaging with 123I-5IA clearly visualized the 
common marmoset brain. The radioactivity accumulation in the thalamus, which 
was higher than that in the cerebellum, decreased to the cerebellar level after the 
administration of cytisine (Saji et al. 2002). SPECT imaging of α4β2 nAChRs in 
the baboon brain was also successfully performed (Musachio et  al. 1999; Fujita 
et al. 2000).
For the toxicity assessment of 5IA, behavior and physiological parameters (i.e., 
respiratory rate, heart rate, arterial blood pressure, and blood gas parameters) were 
examined. ICR mice that were injected intravenously 10 μg/kg of 5IA showed tran-
sient decrease in spontaneous locomotion. SD rats intravenously injected 5IA at 
2 μg/kg and 5 μg/kg tended to have an increased respiratory rate. Conversely, no 
abnormal behavior was observed in mice injected 1 μg/kg of 5IA and their physio-
logical parameters were maintained at normal levels. Therefore, the no observed 
effect level (NOEL) of 5IA was considered as 1 μg/kg (Ueda et al. 2004).
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A-85380-Derived PET Probes
Two types of A-85380-based PET probes have been developed, i.e., 2-[18F]fluoro- 
A- 85380 (18F-2FA) and 6-[18F]fluoro-A-85380 (18F-6FA). Both probes show prom-
ising properties for in vivo imaging of α4β2 nAChRs.
The Ki value of 18F-2FA, which was determined in rat brain homogenates, using 
in vitro competitive binding assay with 3H-epibatidine, was 46 pM (Koren et  al. 
1998). The radioactivity accumulation in the thalamus and cerebellum, at 60 min 
after intravenous injection of 18F-2FA, was approximately 6%ID/g and 1%ID/g, 
respectively, (Horti et al. 1998). These values were approximately half a degree of 
125I-5IA, indicating lower brain penetration of 18F-2FA compared to 123/125I-5IA. An 
in  vivo blocking study performed in rats revealed that pretreatment with α4β2- 
nAChR ligands (nicotine, epibatidine, cytisine, or non-radioactive 2FA) reduced 
regional brain uptake of 18F-2FA by 45–85%. Conversely, pretreatment with 
α7-nAChR ligand (methyllycaconitine) and 5-hydroxytryptamine-3 (5-HT3)-
receptor ligand (granisetron) did not affect the accumulation of 18F-2FA (Doll et al. 
1999). Therefore, it was proved that 18F-2FA specifically bound to α4β2 nAChRs 
in vivo. Approximately twofold higher radioactivity was accumulated in the thala-
mus compared to the cerebellum in a PET imaging study performed using baboons 
(Valette et al. 1999). A toxicological study showed that intravenous injection of 2FA 
(0.8–10  μmol/kg) caused abnormal behavior in mice. However, a tracer dose 
(approximately 1 nmol/kg) of 18F-2FA did not show signs of toxicity (Horti et al. 
1998). Moreover, 2FA demonstrated no mutagenic properties evaluated by micro-
nucleus and Ames tests (Valette et al. 2002).
The Ki value of 18F-6FA was 25 pM determined by in vitro competitive binding 
assay using 3H-epibatidine and rat brain homogenates (Koren et al. 1998). The brain 
uptake of 18F-6FA was slight higher than that of 18F-2FA. The radioactivity accumu-
lation in the thalamus and cerebellum was approximately 8%ID/g and 1.5%ID/g, 
respectively, at 60 min after intravenous injection. Pretreatment with α4β2-nAChR 
ligands (nicotine and cytisine) reduced regional brain uptake of 18F-6FA by 44–92% 
(Scheffel et al. 2000). There was a higher accumulation of 18F-6FA in the thalamus 
than the cerebellum on PET imaging of the baboon brain. Compared with 18F-2FA, 
the peak uptake was similar for both tracers. However, compared to 18F-2FA, 18F- 
6FA showed slightly faster kinetics (peak uptake in the thalamus was at 55–65 min 
and 60–80 min after the injection of 18F-6FA and 18F-2FA, respectively) and better 
contrast (thalamus-to-cerebellum ratio at 180 min was 2.5–3.5 and 1.9–2.1 for 18F- 
6FA and 18F-2FA, respectively) (Ding et al. 2000). However, one drawback of 18F- 
6FA compared to 18F-2FA may be its associated toxicity. Although a tracer dose 
(0.3 nmol/kg) of 18F-6FA showed no signs of toxicity, higher doses (1.3 μmol/kg) of 
it induced increase in breathing and heart rate and severe seizures, while doses of 
2.0 μmol/kg led to certain, immediate death. The approximate LD50 dose for intra-
venously injected 6FA was estimated to be 1.74 μmol/kg, which was approximately 
one-ninth that of 2FA (15 μmol/kg) in mice (Scheffel et al. 2000).
2 In Vivo Imaging of Nicotinic Acetylcholine Receptors in the Central Nervous System
24
2.3.1.3  Epibatidine Derivatives
Epibatidine is an alkaloid that was isolated from the Ecuadorian poison frog 
Epipedobates anthonyi in 1992 (Fitch et  al. 2010). It is one of the most potent 
nAChR agonists. Its agonistic potency is greater than that of A-85380 and nicotine 
(Anderson et al. 2000). Several epibatidine-based imaging probes have been devel-
oped, and one of them, (−)-18F-flubatine, was recently applied in a first-in-human 
study.
(−)-18F-flubatine is formally known as (−)-18F-norchloro-fluoro-homoepibatidine 
[(−)-18F-NCFHEB]. This probe was first reported in 2004. The binding affinity of 
(+)-enantiomer (Ki = 64 pM) and (−)-enantiomer (Ki = 112 pM) to human α4β2 
nAChRs was five to ten times lower than that of epibatidine (Ki = 14 pM). However, 
given that the affinity of both enantiomers to human α3β4 nAChR was 65 times 
lower than that of epibatidine, this resulted in a 14-fold increase in α4β2 nAChR- 
specificity of flubatine compared to epibatidine (Deuther-Conrad et al. 2004). In a 
biodistribution study in mice, the brain uptake of (+)-18F-flubatine (7.45%ID/g at 
20  min) and (−)-18F-flubatine (5.60%ID/g at 20  min) was greater than that of 
18F- 2FA (3.20%ID/g at 20 min). Pre- and co-injection of 2FA decreased the brain 
uptake of (−)-18F-flubatine by approximately 60%, indicating specific binding of 
(−)-18F-flubatine to α4β2 nAChRs in vivo (Deuther-Conrad et al. 2008). The results 
of PET imaging with 18F-flubatine in the porcine brain corroborated with the results 
of a biodistribution study performed in mice. The brain uptake was highest for 
(+)-18F-flubatine, intermediate for (−)-18F-flubatine, and lowest for 18F-2FA, in all 
the examined regions (i.e., the thalamus, caudate/putamen, and cerebellum). Among 
these three probes, (−)-18F-flubatine showed the fastest equilibrium of specific bind-
ing (Brust et al. 2008). Since the drawback of using 18F-2FA in clinical PET studies 
is its slow kinetics, (−)-18F-flubatine has the potential to overcome this challenge. 
PET imaging in the rhesus monkey revealed that the regional distribution of 
(−)-18F-flubatine (i.e., thalamus > cortex/striatum > cerebellum) corroborated with 
the known distribution of α4β2 nAChRs: (Hockley et al. 2013). The toxicological 
effects of flubatine were evaluated by extended single dose toxicity studies. Wistar 
rats were intravenously injected with (−)-flubatine, at a dose of 24.8 μg/kg or more, 
and with (+)-flubatine, at a dose of 12.4 μg/kg or more, presented with symptoms 
that included tachypnea, labored breathing, and cyanosis. However, no symptoms 
were detected in rats injected (−)-flubatine and (+)-flubatine, at a dose of 6.2 μg/kg 
and 1.55 μg/kg, respectively. Therefore, the NOEL of (−)- and (+)-flubatine was 
considered as 6.2 and 1.55 μg/kg, respectively (Smits et al. 2014).
2.3.2  Imaging Probes for the α7 Subtype
Compared to α4β2-nAChR imaging probes, several promising probes were not as 
effective at targeting α7 nAChRs. However, the chemical structure of some probes 
that reached first-in-human studies is outlined in Fig. 2.2.
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11C-CHIBA-1001 is the first α7-nAChR imaging probe to be used in humans 
(Toyohara et  al. 2009). The IC50 value of CHIBA-1001 for 125I-α-bungarotoxin, 
which is a selective antagonist for α7 nAChRs binding to rat brain homogenates, 
was 45.8 nM, indicating the high affinity of CHIBA-1001 to α7 nAChRs. The dis-
tribution of radioactivity matched the regional distribution of α7 nAChRs in a PET 
imaging study using 11C-CHIBA-1001 in a conscious monkey. Moreover, the uptake 
of 11C-CHIBA-1001 in the brain was inhibited by pretreatment with SSR180711, a 
selective α7-nAChR agonist, in a dose-dependent manner. It was however, not 
affected by A-85380, a selective α4β2-nAChR agonist (Hashimoto et al. 2008). The 
percentage of inhibition after treatment of SSR180711 (5  mg/kg) was approxi-
mately 40%.
Two dibenzothiophene-based probes that show a high affinity to α7 nAChRs 
were recently developed. These probes are 18F-ASEM and 18F-DBT-10, which is a 
para-isomer of 18F-ASEM. The Ki value of ASEM for 125I-α-bungarotoxin binding 
to the HEK293 cells stably expressing α7 nAChRs was 0.3 nM. A PET imaging 
study of the baboon clearly demonstrated its highest uptake in the thalamus and the 
lowest in the cerebellum. The uptake of 18F-ASEM in the baboon brain was inhib-
ited by the injection of SSR180711, in a dose-dependent manner (Horti et al. 2014). 
The percentage of inhibition following SSR180711 (5  mg/kg) treatment was 
approximately 80%, which was greater than that of 11C-CHIBA-1001.
In a binding assay using SH-SY5Y cells stably expressing α7 nAChRs and 
3H-methyllycaconitine, 18F-DBT-10 demonstrated a high affinity (Ki = 0.60 nM) for 
α7 nAChRs, which was comparable to 18F-ASEM (Ki = 0.84 nM). PET imaging of 
the rhesus monkey brain clearly revelated its highest uptake in the thalamus and 
lowest update in the cerebellum. The brain uptake of 18F-DBT-10 was inhibited by 
the administration of ASEM, in a dose-dependent manner (Hillmer et al. 2016b). 
Hillmer et  al. directly compared the in vivo kinetic properties of 18F-ASEM and 
18F- DBT- 10  in identical rhesus monkeys and concluded that the two radiotracers 
were highly similar (Hillmer et al. 2017).
Fig. 2.2 Chemical structures of imaging probes targeting α7 nicotinic acetylcholine receptors 
(nAChRs)
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2.4  Nicotinic Acetylcholine Receptor Imaging in Human 
Brain
2.4.1  (S)-11C-Nicotine
There are contrary reports regarding whether (S)-11C-nicotine show specific binding 
to nAChRs in the human brain. Nybäck et al. performed (S)- and (R)-11C-nicotine- 
PET in healthy male smokers and nonsmokers. Although (S)-11C-nicotine demon-
strated a higher uptake than (R)-11C-nicotine, the co-administration of nonradioactive 
(S)-nicotine did not affect the time-activity curves of (S)-11C-nicotine. A kinetic 
analysis based on a two-compartment model revealed that the brain uptake of (S)-
11C-nicotine was mainly determined using cerebral blood flow (CBF) (Nyback et al. 
1994). Muzic et al. performed a similar study and demonstrated that the pharmaco-
kinetics of (S)-11C-nicotine could be well described using a two-compartment 
model, which was in accordance with the findings of Nybäck et al. Although the 
(S)-nicotine challenge induced a significant decrease in the distribution volume 
(DV) of (S)-11C-nicotine, this decrease was small (Muzic et al. 1998). Therefore, 
both research groups concluded that (S)-11C-nicotine was not a suitable tracer for 
PET studies of nAChRs in the human brain.
In contrast, Nordberg et al. developed a method for kinetic analysis of (S)-11C- 
nicotine including compensation for the influence of CBF.  They determined the 
CBF of each participant using 11C-butanol- or 15O-water-PET and compensated the 
rate constant of (S)-11C-nicotine transport from tissue to blood using the CBF. In this 
analysis, a low rate constant corresponded to high (S)-11C-nicotine binding in the 
brain. They revealed that the CBF-compensated rate constants were significantly 
and negatively correlated with cognitive function of patients with Alzheimer’s dis-
ease (Nordberg et al. 1995; Kadir et al. 2006).
2.4.2  123I-5IA
Fujita et  al. performed SPECT imaging and quantified the α4β2 nAChRs in the 
human brain using 123I-5IA. A total of six healthy nonsmokers (two men and four 
women) participated in both a bolus and bolus-plus-constant infusion (B/I) study. 
Although the B/I study was not successfully applied, due to the slow kinetics of 123I- 
5IA, regional DV values were successfully measured in the bolus study. The 
researchers applied one- and two-tissue compartment models to determine kinetic 
parameters of 123I-5IA.  The two-tissue compartment model provided better 
goodness- of-fit than the one-tissue compartment model, but the difference in the 
goodness-of-fit was relatively small. The obtained DV values were well-correlated 
between the two models. The DV values determined by two-tissue compartment 
model were highest in the thalamus (51 mL/cm3), intermediate in putamen (27  mL/
cm3) and pons (32  mL/cm3), slightly lower in cortical regions (17–20  mL/cm3) 
(Fujita et al. 2003b).
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Our research group also performed a similar study. Data from six healthy non-
smokers (five men and one woman), imaged using 123I-5IA-SPECT, were analyzed 
with kinetic (one- and two-tissue compartment models) and Logan graphical tests 
(Logan et  al. 1990). Figure  2.3a shows representative serial SPECT images. In 
 contrast to the study performed by Fujita et al., two-tissue compartment analysis 
could not provide adequate rate constants. However, one-tissue compartment analysis 
could fit the data appropriately and regional DV values were successfully determined. 
Fig. 2.3 Typical single-photon emission computed tomography (SPECT) images with 123I-5IA 
and the correlation between distribution volumes of 123I-5IA and reported nicotinic acetylcholine 
receptor (nAChR) density in the human brain. (a) Serial SPECT images obtained from a healthy 
human following the 123I-5IA injection. Although blood flow-dependent distribution of radioactiv-
ity was observed at 10 min, the specificity of the radioactivity distribution for α4β2-nAChR in the 
thalamus (the arrows) could be distinguished in a time-dependent manner. (b) Correlation between 
distribution volumes (DV) of 123I-5IA estimated using one-tissue compartment analysis and the 
reported nAChR density in the human brain. The Y-axis indicate DV values of 123I-5IA and X-axis 
represent the α4β2 nAChR density in postmortem brains determined by 3H-nicotine binding assay 
(Shimohama et al. 1986). The correlation coefficient was 0.95, indicating a highly significant cor-
relation between the two parameters (P < 0.05)
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The obtained DV values were the highest in the thalamus (34 mL/g), intermediate 
in basal ganglia (17 mL/g) and brain stem (25 mL/g), and slightly lower in cortical 
regions (13–14 mL/g). These data correlated well with the nAChR densities, which 
was measured using 3H-nicotine (Fig.  2.3b, R = 0.95, P  < 0.05), indicating the 
validity of the analysis method. Moreover, similar DV values were successfully 
estimated using a graphical analysis (Mamede et al. 2004).
2.4.3  18F-2FA
Data from seven healthy male volunteers were compared using a compartmental 
kinetic analysis and Logan graphical analysis to quantify regional cerebral DV val-
ues of 18F-2FA. PET scans were performed up to 240 min after the administration of 
18F-2FA, but the maximal concentration could not always be observed in the thala-
mus due to the slow kinetics of 18F-2FA. Kinetic analysis revealed that the two- 
tissue compartment model was more accurate than the one-tissue compartment 
model to describe the PET data. The obtained DV values were the highest in the 
thalamus (15 mL/mL), and lower in the cerebellum, striatum, and cortical regions 
(5–7 mL/mL). These data were consistent with the known densities of nAChRs in 
the human brain that were measured using 3H-epibatidine. The DV values obtained 
by the Logan graphical analysis were slightly lower than those obtained by the two- 
tissue compartmental kinetic analysis. This could be attributed to noise-induced 
bias. Therefore, the two-tissue compartmental kinetic analysis seems a more reli-
able method to estimate regional DV values of 18F-2FA (Gallezot et al. 2005).
A simplified analysis method has been developed to easily quantify α4β2 
nAChRs with 18F-2FA-PET. Ten normal volunteers (six men and four women) were 
recruited for 2-h PET scan. Simplified DV values were defined as the ratio of radio-
activity in the brain to that in arterial plasma at 90–120 min post-injection. Two- 
tissue compartment and Logan graphical analyses were also conducted on the data. 
DV values in the frontal cortex and cerebellum determined using the simplified 
method were significantly correlated with those calculated using the two-tissue 
compartment analysis and Logan graphical analysis (r > 0.88). Therefore, this sim-
plified approach may be useful for quantifying cortical nAChRs and suitable for 
routine clinical application (Mitkovski et al. 2005).
2.4.4  (−)-18F-Flubatine
A first-in-human PET study with (−)-18F-Flubatine was reported in 2015 (Sabri 
et al. 2015). Dynamic PET imaging, lasting 270 min, was performed on 12 healthy 
male non-smoking participants, following a bolus injection of (−)-18F-Flubatine 
intravenously. In humans, (−)-18F-Flubatine is very stable against metabolism. 
Radiometabolite analysis of plasma demonstrated that almost 90% and 85% of 
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(−)-18F-Flubatine existed in an intact form, at 90 min and 270 min after the injec-
tion, respectively. The tracer kinetics were well-described by both the one-tissue 
compartment and two-tissue compartment analyses, though the relative standard 
deviation of DV values determined by the two-tissue compartment analysis was 
much larger. The DV values were the highest in the thalamus (27 mL/cm3), interme-
diate in regions like midbrain, striatum, and cerebellum (11–14 mL/cm3), slightly 
lower in cortical regions (8–10 mL/cm3), and lowest in the corpus callosum (6 mL/
cm3). These values were highly correlated with in vitro measurements of regional 
nAChR densities in the postmortem human brain using (±)-3H-epibatidine (Marutle 
et al. 1998). DV values could be reliably estimated within 90 min for all the regions 
examined, demonstrating the faster kinetic property of (−)-18F-Flubatine in humans.
Another research group performed (−)-18F-Flubatine-PET in humans using a 
bolus-plus-infusion (B/I) paradigm, which could establish the true equilibrium 
between a probe in the plasma and at nAChRs in the brain. The DV values in the 
extrathalamic grey matter regions obtained from the B/I study corroborated well 
with those estimated by the two-tissue compartment analysis and multilinear analy-
sis of the bolus data. The equilibrium in the thalamus, however, could not estab-
lished under the B/I paradigm adopted in this study. The research group also 
assessed the probe’s sensitivity to ACh fluctuations following physostigmine treat-
ment in humans. PET acquisition with the B/I paradigm was performed and 1.5 mg 
of physostigmine was infused from 125 to 185  min. The DV values of 
(−)-18F-Flubatine in the cortex, striatum, and cerebellum decreased by 2.8–6.5%. 
This difference was small since only a low dose to avoid peripheral side effects. 
However, this finding suggested that (−)-18F-Flubatine is probably sensitive to 
changes in acetylcholine levels in humans (Hillmer et al. 2016a).
2.4.5  α7-nAChR Imaging Probes
11C-CHIBA-1001 is the first α7-nAChR imaging probe to be used in humans. In the 
human brain, 11C-CHIBA-1001 was widely distributed in all brain regions, includ-
ing the cerebellum where uptake was low like in the monkey brain. This discrep-
ancy could be attributed to species difference since it was in line with the result of a 
postmortem study, which demonstrated that the level of 125I-α- bungarotoxin binding 
in the cerebellum was comparable to that in the cortex (Toyohara et al. 2009). Thus, 
this probe can be used to measure the occupancy rate of α7 nAChRs in the human 
brain. Ishikawa et al. examined the effect of tropisetron and ondansetron on PET 
imaging with 11C-CHIBA-1001  in healthy non-smoking male participants. 
Tropisetron has a high affinity for both 5-HT3 receptors and α7 nAChRs, while 
ondansetron only has a high affinity for 5-HT3 receptors. Two serial PET scans were 
performed before and after an oral administration of these medications. Tropisetron 
decreased the total distribution volume of 11C-CHIBA-1001 in the human brain, in 
a dose-dependent manner, while ondansetron had no effect (Ishikawa et al. 2011).
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18F-ASEM is another α7-nAChR imaging probe used in human PET imaging. 
The regional distribution of 18F-ASEM in the brain was consistent with the expres-
sion of α7-nAChR in the post-mortem human brain. The cerebral cortex and puta-
men showed higher DV values (>20 mL/mL), while the caudate, cerebellum, and 
corpus callosum showed lower DV values (<15 mL/mL). Both one-tissue compart-
ment and two-tissue compartment analyses fitted the data well and provided similar 
DV values. The average test-retest variability was 10.8%, indicating accurate esti-
mation of DV values. However, this study was only performed on a limited number 
of participants (n  =  2) (Wong et  al. 2014). Another research group performed a 
18F-ASEM-PET in humans in 2017. In this study, one-tissue compartment analysis, 
rather than two-two compartment analysis, was the more suitable analysis method 
for the quantification of 18F-ASEM kinetic parameters. However, since the one- 
tissue compartment analysis could produce a biased result in regions with high 
uptake of the probe, the authors finally chose a multilinear analysis method. The 
calculated DV values were higher in the cerebral cortex and putamen (>25 mL/cm3) 
and lower in the caudate and cerebellum (19–21 mL/cm3). The test-retest variability 
between the four participants was 11.7 ± 9.8% (Hillmer et al. 2017).
2.5  Alteration of Nicotinic Acetylcholine Receptor Density
2.5.1  Alzheimer’s Disease (AD)
Memory impairment is the main symptom of AD, which is a progressive neurode-
generative disorder. Since nAChRs play a role in higher brain functions, such as 
cognition and memory, changes in the expression of nAChRs in AD is of great inter-
est. Postmortem studies have demonstrated reduced activity of α4β2 nAChRs in 
patients with AD (Martin-Ruiz et al. 2000). O’Brien et al. recruited patients with 
AD, at the mild–moderate stages of illness and normal elderly controls, for a 
123I-5IA-SPECT study. Compared to that in the controls, significant reductions in 
123I-5IA binding were identified in the frontal cortex, striatum, and pons in patients 
with AD. There were no significant correlations with clinical or cognitive measures, 
which could be attributed to homogeneous stages of illness of the patients (O’Brien 
et al. 2007). In our study, DV values of 123I-5IA in the cortical regions and thalamus 
in patients with AD were also decreased compared to that in age-matched healthy 
participants (Fig. 2.4) (Hashikawa et al. 2002; Ueda 2016).
AD is a progressive neurodegenerative disorder. The symptoms of AD are pre-
ceded by years of neurodegeneration in the brain. Mild cognitive impairment (MCI) 
is a clinically detectable initial stage of cognitive deficits and is considered as an 
intermediate state between healthy aging and AD. Therefore, if an nAChR abnor-
mality is detected in patients with MCI, it will be an important biomarker at the 
earliest stage of the disease. It could consequently be used as a predictive biomarker 
to determine patients with MCI who are at risk for developing AD. Using 18F-2FA- 
PET, Sabri et al. demonstrated a significant reduction in α4β2-nAChR availability 
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in the cortical regions, caudate head, and hippocampus, in patients with AD and 
MCI (Sabri et al. 2008). Kendziorra et al. also performed a 18F-2FA-PET study on 
patients with MCI and AD, and age-matched healthy controls. The availability of 
α4β2-nAChR in the cortical regions, caudate, and hippocampus in patients with AD 
and MCI significantly decreased. More interestingly, compared to controls, patients 
with MCI who converted to AD showed a significantly low α4β2-nAChR availabil-
ity in the above three regions. In contrast, the α4β2-nAChR availability of patients 
with MCI with stable cognitive course was also lower than that of controls, but the 
difference was not statistically significant (Kendziorra et al. 2011). However, other 
studies report conflicting results. The availability of α4β2 nAChRs in patients with 
MCI and at an early stage of AD were demonstrated to be maintained at a control 
level, using 123I-5IA-SPECT (Mitsis et al. 2009) and 18F-2FA-PET (Ellis et al. 2008).
2.5.2  Other Causes of Dementia
Although vascular dementia (VaD) is one of the most common causes of dementia 
in older people, the cholinergic involvement in VaD remains controversial. Some 
studies reported cholinergic loss (Gottfries et al. 1994), while others failed to dem-
onstrate a cholinergic deficit in patients with VaD (Perry et al. 2005). Using 123I-5IA- 
SPECT imaging, Colloby et al. demonstrated reductions in uptake of 123I-5IA in the 
Fig. 2.4 Typical single-photon emission computed tomography (SPECT) images and mean distri-
bution volumes of 123I-5IA in age-matched healthy participant and patients with Alzheimer’s dis-
ease (AD). (a) Representative 123I-5IA SPECT images of an age-matched healthy participant and a 
patient with AD. (b) Mean distribution volumes of 123I-5IA in age-matched healthy participants 
and patients with AD. Each bar represents an average of ten healthy participants and eight patients, 
and each error bar represents the SD (*P < 0.05 vs. healthy subject). ctx cortex
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dorsal thalamus and right caudate of patients with VaD, compared to that in age- 
matched healthy participants (Colloby et  al. 2011). Another study revealed that, 
overall, 125I-5IA binding in postmortem brains did not significantly differ between 
patients with VaD and age-matched healthy participants (Pimlott et  al. 2004). 
However, an 11% reduction in 125I-5IA binding was also demonstrated in the dorsal 
thalamus of patients with VaD. Nonetheless, the small sample size may have reduced 
statistical power.
Dementia with Lewy bodies (DLB) is the second most common cause of degen-
erative dementia in older people. It is well-known that cholinergic deficits are 
involved in DLB. O’Brien et al. performed a 123I-5IA-SPECT study in patients with 
DLB and similarly aged controls. Compared to that in controls, the uptake of 123I- 
5IA were significantly reduced in the frontal, striatal, temporal, and cingulate 
regions of patients with DLB (O’Brien et al. 2008). These findings were consistent 
with the findings obtained by a 125I-5IA binding study using postmortem brains, 
where a significant reduction of 125I-5IA binding was also observed in the striatum, 
entorhinal cortex, and substantia nigra (Pimlott et al. 2004).
2.5.3  Parkinson’s Disease (PD)
In addition to the dopaminergic system, cholinergic neurons also play an important 
role in PD. Postmortem studies demonstrated widespread decrease in the expression 
of nAChR in the cortical and striatal regions of patients with PD (Rinne et al. 1991). 
Fujita et  al. successfully detected this decrease in living patients with PD using 
123I-5IA-SPECT. A decrease of 3–9% and 15% in DV values was found in the corti-
cal regions and thalamus, respectively, in patients with PD. However, this decrease 
was small and not statistically significant compared to healthy participants (Fujita 
et al. 2006). Oishi et al. also reported similar results using 123I-5IA-SPECT. Patients 
with PD demonstrated a statistically significant decrease (20–25%) in the brainstem 
and frontal cortex, compared with that in the control group (Oishi et al. 2007). The 
difference in the SPECT scan procedure and/or withdrawal duration of antiparkin-
sonian medication may account for the discrepancy of the results obtained by the 
two studies.
Using 18F-2FA PET, Meyer et al. estimated DV values in each brain region of 
patients with PD and healthy volunteers. They used the corpus callosum as a refer-
ence region, and the binding potential (BP) was calculated as follows: BP = (DV 
value in each brain region)/(DV value in the corpus callosum) – 1 (Brody et  al. 
2006). The BP values in patients with PD were significantly decreased (30–50%) in 
broad brain regions, such as cortical regions, caudate nucleus, midbrain, and cere-
bellum (Meyer et al. 2009).
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2.5.4  Other Diseases
2.5.4.1  Alcohol Abuse
Although ethanol binding sites have not been identified in nAChRs, prolonged alco-
hol exposure reportedly increased agonist binding to α4β2 nAChRs (Robles and 
Sabria 2006). Therefore, Esterlis et al. examined α4β2-nAChR availability in heavy 
drinking nonsmokers and age- and sex-matched control nonsmokers (Esterlis et al. 
2010). The nine participants who met the criteria for current alcohol abuse and two 
subjects who met criteria for current alcohol dependence were included in the 
123I-5IA-SPECT study. There were no significant differences in the availability of 
α4β2-nAChR between the two groups. However, as the authors noted, a larger study 
is warranted to explore effects of heavy alcohol drinking. In fact, recent PET and 
SPECT studies performed in nonhuman primates indicated a decrease in α4β2- 
nAChR availability after chronic ethanol consumption (Cosgrove et  al. 2010; 
Hillmer et al. 2014).
2.5.4.2  Autosomal Dominant Nocturnal Frontal Lobe Epilepsy
Nocturnal frontal lobe epilepsy is a common non-lesional focal epilepsy (Provini 
et al. 1999). There are more than a hundred families with autosomal dominant noc-
turnal frontal lobe epilepsy (ADNFLE) and mutations in the genes encoding the α4 
or β2 subunit of nAChR have been identified in several ADNFLE families (Picard 
and Scheffer 2005). Therefore, Picard et  al. performed 18F-2FA-PET imaging to 
measure the density of α4β2 nAChRs in eight ADNFLE patients and seven age- 
matched participants (Picard et  al. 2006). Participants in both groups were non-
smokers. The DV values in patients with ADNFLE significantly increased in the 
epithalamus, ventral mesencephalon, and cerebellum, but decreased in the right 
dorsolateral prefrontal region. The downregulation of nAChR density in the pre-
frontal cortex is consistent with focal epilepsy involving the frontal lobe. The upreg-
ulation of nAChR density in the midbrain may be involved in the pathogenesis of 
ADNFLE through the role of cholinergic neurons ascending from the brainstem.
2.5.4.3  Major Depressive Disorders
Since hyperactivity of cholinergic neurons plays a pathophysiological role in 
depression (Dilsaver 1986), Saricicek et al. performed a 123I-5IA-SPECT study in 
23 non-smoking, medication-free patients with recurrent major depressive disorders 
(MDD) and 23 age- and sex-matched healthy controls (Saricicek et  al. 2012). 
Compared to that in controls, patients with MDD had significantly lower availabil-
ity of α4β2 nAChRs, across all the brain regions that were analyzed. However, there 
was no difference in the density of α4β2 nAChRs between patients with MDD and 
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healthy controls in the human postmortem brain. This discrepancy could be attrib-
uted to the competitive inhibition of excess amount of endogenous ACh, which 
could have resulted from the effect of cholinergic hyperactivity on 123I-5IA 
accumulation.
2.5.5  Smokers
Many studies have demonstrated the upregulation of nAChRs occurred in both 
nicotine- treated animals (Yates et  al. 1995) and postmortem brains of smokers 
(Buisson and Bertrand 2002). This upregulation is transient, however, and the 
nAChR density returns to baseline level after a period of abstinence from nicotine 
treatment (Pietila et al. 1998). Thus, the non-invasive detection of nAChR in smok-
ers is important to monitor the dynamics of nAChR expression, i.e., upregulation 
during smoking and downregulation after smoking cessation.
Staley et al. were the first to noninvasively detect higher levels of α4β2 nAChRs 
in smokers (Staley et al. 2006). They performed 123I-5IA-SPECT imaging and dem-
onstrated an approximate 30% increase in DV values in the cortex and striatum of 
smokers after 7 days of abstinence. A similar upregulation was observed in 18F-2FA- 
PET studies; the amount of increase, however, varied and could be attributed to 
differences in the extent of smoking and/or duration of smoking cessation before the 
imaging studies (Mukhin et al. 2008; Brody et al. 2013). Brody et al. reported an 
interesting finding that the upregulation of nAChRs was more pronounced in men-
thol cigarette smokers compared to non-menthol cigarette smokers (Brody et  al. 
2013). Heavy use of caffeine (i.e., an average of four cups of coffee per day) or 
marijuana (i.e., an average of 22 days of use per month) also affected the α4β2- 
nAChR density in smokers. An approximate 20–40% increase in DV values was 
observed in the prefrontal cortex, thalamus, and brainstem in smokers with heavy 
caffeine or marijuana use compared to smokers who were non-users (Brody et al. 
2016). However, it is possible that the findings were independent of smoking, 
because the changes were not examined in nonsmokers with heavy caffeine or mari-
juana use.
Our research group successfully imaged the dynamic changes of nAChR expres-
sion during smoking cessation. We performed 123I-5IA-SPECT imaging on six non-
smokers and ten smokers who had quit smoking for 4 h, 10 days, and 21 days. Five 
smokers in the 4-h group were included in either the 10-day or 21-day group. 
Compared to the DV values in nonsmokers, those in the brains of smokers decreased 
by approximately 35% in the 4-h group, but increased by approximately 25% in the 
10-day group. The DV values in the 21-day group were comparable to those of 
nonsmokers, indicating that the density of α4β2 nAChRs had returned to the base-
line level (Fig. 2.5) (Mamede et al. 2007). The decrease in the DV values in the 4-h 
M. Ueda et al.
35
group could be attributed to competitive inhibition of nicotine derived from tobacco 
on the binding of 123I-5IA to nAChRs. A 18F-2FA-PET study demonstrated that just 
one to two puffs of smoking resulted in 50% occupancy of α4β2 nAChRs for 3.1 h 
after smoking (Brody et al. 2006). Another study demonstrated the upregulation of 
α4β2-nAChR (approximately 25%) in smokers after 1  week of abstinence. The 
upregulation was maintained up to 4  weeks of abstinence (approximately 15% 
increase), but the DV values then returned to nonsmoker level by 6–12 weeks of 
abstinence (Cosgrove et al. 2009). Differences in the study cohorts could be a pos-
sible reason for discrepancy, since only men were included in the study performed 
by Mamede et al., while both men and women were included the study performed 
by Cosgrove et al.
The degree of upregulation of nAChRs in smokers is sex-dependent. Cosgrove 
et al. performed a 123I-5IA-SPECT study on 26 male and 28 female smokers, and 26 
male and 30 female age-matched nonsmokers. The availability of α4β2 nAChRs 
was significantly higher in the cortex, striatum, and cerebellum of male smokers 
compared to that in male nonsmokers. In contrast, there was no difference in α4β2- 
nAChR availability between female smokers and nonsmokers. The cortical and cer-
ebellar α4β2-nAChR availability showed a significant negative correlation with the 
progesterone level in a SPECT imaging day. Therefore, female sex steroid hor-
mones may have a role in the regulation of α4β2-nAChR availability (Cosgrove 
et al. 2012).
Fig. 2.5 Changes in the distribution volume of 123I-5IA after smoking cessation. Compared to 
nonsmokers, the distribution volumes (DV) of 123I-5IA of smokers at 4 h after ceasing smoking 
were significant lower, while those after 10-day cessation were significantly higher (*P < 0.05 vs. 
nonsmoker). The increased DV values returned to nonsmoker levels 21  days after ceasing 
smoking
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2.6  Nicotinic Acetylcholine Receptor Imaging  
in Mouse Brain
The recent availability of many transgenic mice lines that model human diseases 
have enabled researchers to better elucidate disease mechanisms and drug develop-
ment. However, since many studies on imaging nAChRs have been performed in 
nonhuman primates and humans, technical issues have hampered imaging studies of 
nAChRs in the brain of small animals, especially mice. Mouse brains are too small 
to image clearly using PET and SPECT that are used clinically. However, recent 
advances have improved the sensitivity and spatial resolution of PET and SPECT, 
enabling small animal imaging, which has allowed researchers to clearly visualize 
organs of small rodents. Thus, nuclear medical translational research using trans-
genic mice has become possible and has aided elucidation of human disease pathol-
ogy. We provided the first evaluation of SPECT imaging of α4β2 nAChRs in the 
mouse brain (Matsuura et al. 2016). A 60-min dynamic SPECT imaging session of 
α4β2 nAChRs in the mouse brain was performed using 123I-5IA. For the accurate 
definition of regions of interest (ROIs), each mouse underwent magnetic resonance 
(MR) brain imaging prior to SPECT imaging. The ROIs were then positioned on the 
MR images prior to their application to SPECT images. The mean radioactivity for 
each ROI (i.e., cerebral cortex, striatum, hippocampus, thalamus, and cerebellum) 
was expressed as standardized uptake values (SUVs) and compared to the known 
distribution of α4β2 nAChRs in the mouse brain. 123I-5IA-SPECT allowed clear 
visualization of the mouse brain. A significant positive correlation was observed 
between the SPECT signal intensity and the reported distribution of nAChRs, which 
was measured using [3H]epibatidine (Marks et  al. 1998) (Fig.  2.6, R  =  0.81, 
P < 0.0001 at 30 min; R = 0.72, P < 0.0001 at 60 min). The accumulation of 123I-5IA 
was significantly inhibited by pretreatment with (−)-nicotine. These findings indi-
cated that 123I-5IA SPECT images were α4β2 nAChR-specific, and that the signal 
intensity of the SPECT images can be used as an index of α4β2 nAChR density.
The binding of 123I-5IA decreased after the administration of acetylcholinester-
ase inhibitors in the baboon (Fujita et al. 2003a) and human brain (Esterlis et al. 
2013). Therefore, the sensitivity of 123I-5IA-SPECT to changes in the amount of 
endogenous acetylcholine in the mouse brain was assessed. First, the effect of dif-
ferent concentrations of physostigmine on the cerebral accumulation of 125I-5IA was 
analyzed using the evisceration method. Physostigmine reduced the accumulation 
of 125I-5IA accumulation in all nAChR-rich regions, in a dose-dependent manner. 
Conversely, radioactivity levels in the blood increased in a dose-dependent manner. 
Physostigmine at a concentration of 0.75 mg/kg reduced the uptake of 125I-5IA in 
the thalamus by 51% (Fig. 2.7a, P < 0.01). Next, 123I-5IA-SPECT imaging was per-
formed twice, i.e., before and after physostigmine pretreatment (0.75  mg/kg). 
Compared to the baseline measurements, SUVs in the thalamus was significantly 
reduced (by 38%) with the physostigmine pretreatment (Fig.  2.7b, P  <  0.05). 
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Fig. 2.6 Comparison of in vivo single-photon emission computed tomography (SPECT) analysis 
with the reported α4β2 nAChR density in the mouse brain. Correlation between in vivo radioactiv-
ity determined using SPECT/CT imaging and the reported α4β2 nAChR density in mouse brain. 
The Y-axis indicates the standardized uptake values (SUVs) in each brain region obtained at 
30 min and 60 min after the 123I-5IA injection. The X-axis represents the α4β2 nAChR density 
determined using [3H]epibatidine binding assay (Marks et al. 1998). The correlation coefficient (R) 
was 0.81 and 0.72, at 30 min and 60 min, respectively, indicating a highly significant correlation 
between the two parameters (P < 0.0001)
Fig. 2.7 The effect of physostigmine pretreatment on 123/125I-5IA accumulation. (a) The effect of 
different doses of physostigmine on 125I-5IA accumulation in each brain region, as determined 
using the evisceration method. Each column represents average data from four mice and error bars 
represent the standard deviation (SD) (*P < 0.05, **P < 0.01 vs. vehicle). (b) The effect of physo-
stigmine (0.75 mg/kg) on 123I-5IA accumulation in each brain region was determined using the 
region of interest (ROI) analyses. Each bar represents the average of four mice and error bars 
represent the SD (*P < 0.05 vs. vehicle)
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This suggested that SPECT images were affected by the increase in endogenous 
acetylcholinesterase caused by the administration of physostigmine. Therefore, 
123I-5IA- SPECT imaging may also be useful to evaluate the in vivo efficacy of ace-
tylcholinesterase inhibitors in the mouse brain.
We also successfully detected the changes in nAChR density using 123I-5IA- 
SPECT in the brains of frequently used mouse models of AD, i.e., the Tg2576 and 
APP/PS2 mice. Tg2576 mice overexpress human β-amyloid precursor protein 
(APP) with a familial AD gene mutation (Frautschy et al. 1998), while APP/PS2 
mice are produced by crossbreeding Tg2576 mice with PS2 mice that overexpress 
human presenilin-2 (PS2) proteins carrying the Volga German Kindred mutation 
(N141I). The PS2 mutation reportedly accelerates AD-like phenotypes, such as the 
elevation of Aβ1–40/1–42 levels, presence of amyloid plaques, and memory and learn-
ing defects, by several months, in Tg2576 mice (Toda et al. 2011). Consistent with 
the report by Toda et al. (2011), a novel object recognition (NOR) test demonstrated 
that the levels of cognition of APP/PS2 mice decreased at younger ages than those 
in Tg2576 mice. This test is based on the spontaneous tendency of rodents to spend 
more time exploring a novel object than a familiar one, and allows for the evaluation 
of cognition and recognition memory. The NOR test did not show significant differ-
ences in the cognitive ability between Tg2576 and wild-type mice at 13 months of 
age. Conversely, compared to wild-type mice, 12-month-old APP/PS2 mice exhib-
ited a clear cognitive deficit. At first, 123I-5IA-SPECT imaging was performed in 
Tg2576 and wild-type mice at 13 months of age. A 60-min dynamic SPECT/CT 
imaging was conducted following injection of 123I-5IA into each mouse, via the tail 
vein. The distribution of radioactivity in each brain region was determined by ROI 
analysis and data were compared between Tg2576 and wild-type mice. 123I-5IA- 
SPECT showed a higher signal in brains of Tg2576 mice than that in wild-type mice 
(Fig. 2.8a). SUVs in the thalamus were significantly higher than those in wild-type 
mice (22%, P < 0.05). SUVs in the cortex and hippocampus also tended to increase 
by 15% and 30%, respectively, although these differences were not statistically sig-
nificant. [3H]nicotine binding, which was evaluated in vitro using autoradiographic 
analysis at 7 days after SPECT/CT imaging, was also increased in Tg2576 mice 
compared to that in wild-type mice (Matsuura et al. 2016). These results suggested 
that nAChRs are upregulated in the Tg2576 mice at the age of 13 months.
Next, 123I-5IA-SPECT imaging was performed in APP/PS2 and wild-type mice 
at the age of 12 months. In contrast to Tg2576 mice, the 123I-5IA accumulation in 
APP/PS2 mice decreased in the cortex, hippocampus, and thalamus compared to 
that in wild-type mice (P < 0.05, Fig. 2.8b). The decrease in the nAChR density in 
the brains of APP/PS2 mice was supported by the reduction of α4 nAChRs protein 
levels, which was detected using Western blotting. These findings corroborated with 
a former study, which reported the loss of nAChRs in the cortex and hippocampus 
of patients with advanced AD (Guan et al. 2000). The reason for the discrepancy in 
α4β2 nAChR expression between Tg2576 and APP/PS2 mice, however, is unclear. 
It is possible that the pathology of Tg2576 mice at the age of 13 months represents 
a pre-AD state, while 12-month-old APP/PS2 mice might have the same extent of 
pathology seen in patients with AD. In fact, NOR memory and plaque deposition 
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was not significantly different between Tg2576 and wild-type mice at the age of 
13 months (Jacobsen et al. 2006). APP/PS2 mice, however, exhibited a clear cogni-
tive deficit and severe plaque deposition in the cerebral cortex, at the age of 
12 months. This hypothesis is also supported by the observation of the increase in 
125I-5IA accumulation in the hippocampus of APP/PS2 mouse at 6 months of age 
when the cognitive ability is still normal. These results suggested that the upregula-
tion of α4β2 nAChRs might play a role in the mechanisms underlying neurodegen-
eration in patients with early-stage AD, who show increased Aβ expression. The 
discrepancy in the density of nAChR between several mouse models of AD would 
be an interesting focal point for research on AD pathology.
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Chapter 3
A New Aspect of Cholinergic Transmission 
in the Central Nervous System
Ikunobu Muramatsu, Takayoshi Masuoka, Junsuke Uwada, Hatsumi Yoshiki, 
Takashi Yazama, Kung-Shing Lee, Kiyonao Sada, Matomo Nishio, 
Takaharu Ishibashi, and Takanobu Taniguchi
Abstract In the central nervous system, acetylcholine (ACh) is an important neu-
rotransmitter related to higher brain functions and some neurodegenerative diseases. 
It is released from cholinergic nerve terminals and acts on presynaptic and postsyn-
aptic ACh receptors (AChRs). Following release, ACh is rapidly hydrolyzed and the 
resultant choline is recycled as a substrate for new ACh synthesis. However, this 
classical concept of cholinergic transmission is currently reevaluated due to new 
evidence. In the cholinergic synapse, ACh may be itself taken up into postsynaptic 
neurons by a specific transport system and may act on AChRs at intracellular organ-
elles (Golgi apparatus and mitochondria). Choline for ACh synthesis in cholinergic 
nerve terminals may be mainly supplied from choline at relevant concentration levels 
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present in the extracellular space, rather than recycled from ACh-derived  choline. 
Recent evidence has reopened the issue of classical cholinergic transmission and 
cognition, and may provide a novel approach to rational drug development for the 
treatment of neurodegenerative disorders such as Alzheimer’s disease.
Keywords Cholinergic transmission · Intracellular acetylcholine receptors · 







CHT1 High affinity-choline transporter 1
CNS Central nervous system
DFP Diisopropylfluorophosphate
ERK Extracellular regulated kinase
HC-3 Hemicholinium-3
LTP Long term-potentiation
mAChR Muscarinic acetylcholine receptor
MAPK Mitogen-activated protein kinase







In the central nervous system (CNS), acetylcholine (ACh) is one of the major neu-
rotransmitters involved in higher brain functions, including cognitive processes 
such as learning and memory and extrapyramidal locomotor activity (Everitt and 
Robbins 1997; Terry and Buccafusco 2003; Mesulam 2004; Wess et al. 2007). In 
cholinergic transmission, released ACh acts on ACh receptors (AChRs) located on 
the presynaptic and/or postsynaptic plasma membranes. ACh is also rapidly hydro-
lyzed by ACh esterase (AChE), leading to the termination of synaptic neurotrans-
mission. Then the resultant choline is transported back into the cholinergic nerve 
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terminals by the high-affinity choline transporter 1 (CHT1), and is reutilized as a 
substrate for ACh synthesis (Parsons et al. 1993; Apparsundaram et al. 2000; Okuda 
et al. 2000; Sarter and Parikh 2005). However, this classical tenet of cholinergic 
transmission has recently been challenged by several new findings from recent stud-
ies. The first finding is with regard to the intracellular distribution and function of 
AChRs in postsynaptic neurons and neuroblastoma cells (Yamasaki et  al. 2010: 
Uwada et al. 2011, 2014; Anisuzzaman et al. 2013; Muramatsu et al. 2015); the 
second is the incorporation of ACh itself into postsynaptic neurons (Muramatsu 
et al. 2016); and the third finding is that ACh-derived choline after hydrolysis may 
not be largely reused (Muramatsu et al. 2017). In this chapter, these findings were 
briefly summarized.
3.2  Intracellular Distribution of AChRs
It has been commonly accepted that most neurotransmitter receptors are located on 
the plasma membrane and transduce extracellular to intracellular signals. However, 
recent evidence suggests that several G-protein-coupled receptors including AChRs 
are located, and may also signal from, intracellular sites such as endosomes, Golgi 
apparatus, endoplasmic reticulum, mitochondria, and nuclear membranes (Boivin 
et al. 2008; Jong et al. 2009; Benard et al. 2012; den Boon et al. 2012; Uwada et al. 
2011, 2014; Anisuzzaman et al. 2013).
3.2.1  Muscarinic AChRs
There are five subtypes of muscarinic AChRs (M1–M5 mAChRs), all of which are 
expressed in the CNS (Caulfield and Birdsall 1998; van Koppen and Kaiser 2003; 
Nathanson 2008). In general, the M1 subtype is the most abundant within the CNS, 
M2 and M4 subtypes are moderately expressed, and only low levels of M3 and M5 
subtypes have been found (Volpicelli and Levery 2004). All of the mAChRs are 
generally located and function at the plasma membrane. However, recent studies 
have revealed that M1 mAChRs exist not only at the cell surface but also at intracel-
lular membranes in the hippocampus and other telencephalon regions of rodents 
and humans and in neuroblastoma cells (Uwada et  al. 2011; Anisuzzaman et  al. 
2013). Pharmacologically, the intracellular distribution of mAChRs is evaluated 
from the different binding densities of cell-permeable (hydrophobic) and cell- 
impermeable (hydrophilic) radioligands, [3H]quinuclidinyl benzilate (QNB) and 
[3H]N-methyl-scopolamine (NMS), respectively, in intact segments of brain tissue 
or whole neuronal cells to detect total (QNB binding) and cell surface (NMS bind-
ing) mAChRs (Muramatsu et al. 2005, 2015), and proportions of intracellular and 
surface M1 subtypes are estimated from the competing profiles of M1-selective 
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ligands at the binding sites of both radioligands. Comparable amounts of surface 
and intracellular M1 mAChRs were identified under conditions where brain tissues 
or cultured neurons were not stimulated beforehand. Therefore, it is likely that 
approximately half the amount of M1 mAChR constitutively occurs at intracellular 
sites in the telencephalon and in neuroblastoma cells. Intracellular M1 mAChRs 
were immunohistochemically shown to localize at the Golgi apparatus, and a recent 
molecular biology study revealed that their intracellular localization requires the 
C-terminal tryptophan-based motif of M1 subtype, which does not exist in other 
subtypes (Uwada et al. 2014; Anisuzzaman et al. 2013). The abundant distribution 
of M1 mAChRs in the Golgi apparatus and endoplasmic reticulum of pyramidal 
neurons but not in astroglia was also demonstrated in immunoelectron microscopic 
studies (Yamasaki et al. 2010). A previous immunohistochemical study with a spe-
cific M1 antibody also reported intracellular detection in the cytoplasm of large 
and small dendrites and the dendritic spines of cerebral cortex neurons (Mrzljak 
et al. 1993).
M1 mAChRs cause phosphatidylinositol 4,5-bisphosphate (PIP2) hydrolysis 
leading to calcium (Ca2+) upregulation and activation of the mitogen-activated pro-
tein kinase (MAPK) pathway through the Gαq/11 protein (van Koppen and Kaiser 
2003; Morishima et al. 2013). In rat hippocampal and cortical neurons and neuro-
blastoma cells, the PIP2-Ca2+ response is exclusively mediated by surface M1 
mAChRs on a time scale of seconds. On the other hand, the extracellular signal- 
regulated kinase1/2 (ERK1/2) pathway is activated by intracellular M1 mAChRs on 
a slow time scale of minutes (Uwada et al. 2011; Anisuzzaman et al. 2013). These 
results indicate that M1 mAChRs at each site may be specifically activated and 







Fig. 3.1 Schematic representation of surface and intracellular M1 mAChRs in postsynaptic neu-
rons, and their possible signal transduction pathways and physiological responses
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As aforementioned, M1 mAChRs predominantly exist in the CNS and are 
involved in cognitive enhancement (Everitt and Robbins 1997; Kruse et al. 2014; 
Terry and Buccafusco 2003; Mesulam 2004; Wess et al. 2007). In the hippocampus, 
cholinergic activation induces a theta rhythm of neuronal activity and enhances or 
induces long-term potentiation (LTP) (Huerta and Lisman 1995; Williams and 
Kauer 1997; Fernandez de Sevilla et al. 2008), the primary experimental model for 
investigating the synaptic basis of learning and memory (Bliss and Collingridge 
1993; Seol et al. 2007). M1 mAChR-knockout mice have severe deficits in working 
memory and memory consolidation, as well as impaired hippocampal LTP 
(Anagnostaras et al. 2003; Shinoe et al. 2005; Wess et al. 2007). M1-specific ago-
nists have been shown to facilitate the induction of LTP and improve cognitive func-
tion in several animal models of amnesia (Caccamo et al. 2006; Langmead et al. 
2008; Ma et al. 2009). Thus, the specific distribution of intracellular M1 mAChRs 
in the telencephalon may correlate with synaptic plasticity.
Our electrophysiological study with rat hippocampal slices revealed that cholin-
ergic induction of a theta rhythm and cholinergic facilitation in the early part of 
N-methyl-d-aspartate receptor (NMDAR)-dependent LTP were mainly mediated by 
surface M1 mAChRs, whereas cholinergic facilitation in the late part of NMDAR- 
dependent LTP and the majority of non-NMDAR-dependent LTP were evoked by 
activation of intracellular M1 mAChRs (Anisuzzaman et al. 2013). The induction 
of LTP requires elevation of postsynaptic Ca2+ (Lynch et al. 1983) and activation of 
protein kinases (Soderling and Derkack 2000), whereas the maintenance of late- 
phase LTP depends on the MAPK/ERK cascade, gene transcription, protein synthe-
sis, and posttranslational modification (Davi et al. 2000; Giovannini 2006; Nguyen 
et al. 1994; Frey et al. 1996; Bliss and Collingridge 1993; Routtenberg and Rekart 
2005; Gold 2008). Taking these mechanisms into consideration, it is likely that 
cholinergic stimulation may primarily cause the selective enhancement of respec-
tive signaling processes in the early and late phases of LTP through M1 mAChRs 
located at two distinct sites, leading cholinergic facilitation (Fig. 3.2).
3.2.2  Nicotinic AChRs
The nicotinic AChRs (nAChRs) are widely expressed in the brain, where they main-
tain various neuronal functions including learning and memory (Terry and 
Buccafusco 2003; Dineley et al. 2015; Wu et al. 2016). They also control survival/
death, proliferation/neurite outgrowth, and neurotransmitter release in neuronal 
cells (Akaike et al. 1994; Kihara et al. 2001; Shimohama et al. 1996; 2009; Rosa 
et al. 2006). The major nAChR subtypes in the CNS are heteromeric α4β2, α3β2, 
α7β2 and homomeric α7 assemblies, all of which have high permeability for Ca2+ as 
ionic channels and also transduce signals through the phosphatidylinositol 3-kinase 
(PI3K) signaling pathway (Kihara et al. 2001; Dajas-Bailador and Wonnacott 2004; 
also see other chapters in this book). To date, these responses have been mainly 
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discussed with special reference to nAChRs located on the plasma membrane; how-
ever, the intracellular distribution of nAChRs, especially in the mitochondria, was 
recently reported in immunochemical studies (Lykhmus et al. 2014; Gergalova et al. 
2014). In brain mitochondria, α7β2 nAChRs mainly stimulate the PI3K/AKT path-
way, and α3β2 and α4β2 nAChRs inhibit Src- and Ca2+/calmodulin-dependent 
protein- kinase II pathways. Mitochondrial nAChRs and associated signaling path-
ways are associated with the induction of mitochondrial apoptosis (Lykhmus et al. 
2014). However, more detailed analysis from different approaches is required in 
this issue.
3.3  Incorporation of ACh into Postsynaptic Neurons
To activate intracellular AChRs, the endogenous agonist ACh must cross the post-
synaptic plasma and endosomal membranes. Because ACh is a hydrophilic mole-
cule, the presence of a specific ACh transport system such as the ACh transporter 
(AChT) has been postulated (Muramatsu et al. 2016) (Fig. 3.1). Although detailed 
information on the AChT is lacking, incorporation of ACh into brain slices was 
reported more than four decades ago (Polak and Meeuws 1996; Liang and Quastel 
1969; Katz et al. 1973; Kuhar and Simon 1974). More recently, previous evidence 


























Fig. 3.2 Involvement of surface and intracellular M1 mAChRs in cholinergic facilitation of LTP 
in rat hippocampus. Note that early and late stages of basal LTP are represented to be primarily 
mediated by two distinct signal pathways, which are independently enhanced by surface and intra-
cellular M1 mAChRs. Blue: surface M1 mAChR-mediated. Red: intracellular M1 mAChR- 
mediated. IEGs immediately early genes
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temperature- dependent manners was confirmed (Muramatsu et  al. 2016, 2017). 
The uptake was clearly observed in the presence of irreversible but not reversible 
AChE inhibitors. [3H]ACh uptake was high in the CNS but was negligible or minor 
in the peripheral tissues. The uptake was comparable among brain regions but was 
not related to the density of cholinergic innervation. Hemicholinium-3 (HC-3) and 
tetraethyammonium (TEA) inhibited [3H]ACh uptake in a concentration-dependent 
manner. However, the uptake was little affected by the excitatory or inhibitory 
amino acid neurotransmitters glutamate and gamma-aminobutyric acid, respec-
tively, biogenic amines, tetrodotoxin, and atropine. Therefore, it is likely that ACh 
uptake is facilitated by an intrinsic transport system (AChT), rather than a change 
in neuronal excitability and the involvement of amino acid neurotransmitters. 
Interestingly, [3H]ACh uptake was potently suppressed by AChE inhibitors includ-
ing drugs clinically used to treat the cognitive symptoms of Alzheimer’s disease 
such as donepezil, galantamine and rivastigmine (Muramatsu et al. 2016). These 
results raise the interesting possibility that ACh concentrations released in the syn-
apse may be regulated by both AChE and the postsynaptic uptake of ACh, which 
may be relevant to cholinergic therapy in Alzheimer’s disease. As mentioned above, 
intracellular M1 mAChRs selectively activate ERK in hippocampal neurons and 
participate in the late stage of cholinergic facilitation of LTP.  The intracellular 
M1-mediated responses both were inhibited by TEA and HC-3 at concentrations 
that inhibit ACh uptake. However, PIP2 hydrolysis and the early phase of choliner-
gic facilitation of LTP, which were selectively caused by plasma membrane M1 
AChRs, were not affected by TEA and HC-3 (Uwada and Masuoka unpublished 
observations). These pharmacological results further support the fact that choliner-
gic facilitation of LTP is caused independently by surface and intracellular M1 
mAChRs through distinct signaling pathways (Figs. 3.1 and 3.2). These results also 
indicate that the ACh transport system serves as an intrinsic route for released ACh 
to access intracellular AChRs in postsynaptic neurons.
3.4  Regulation of Synaptic ACh Concentrations 
and the Choline-ACh Cycle
In the CNS, release of ACh from the cholinergic nerve terminals is negatively regu-
lated through presynaptic mAChRs (Raiteri et al. 1989; Starke et al. 1989; Zhang 
et al. 2002; Alquicer et al. 2016). In vitro, this release is monitored with the superfu-
sion technique, where ACh in synaptosomes (Raiteri and Raiteri 2000; Pittaluga 
2016) and brain slices (Richardson and Szerb 1974; Zhang et al. 2002; Alquicer 
et al. 2016) has been synthesized/prelabeled in advance with [3H]choline followed 
by superfusion. Figure 3.3a shows a representative result obtained from a superfu-
sion experiment with rat striatal slices. Atropine dramatically increased [3H]efflux 
evoked by electrical stimulation, indicating that blockade of presynaptic mAChRs 
suppressed autoinhibition of ACh release. Although the presynaptic mAChR 
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subtypes that participate in autoregulation have been the subject of debate, it was 
recently concluded that the M2 subtype has dominant involvement and there is only 
minor participation of the M4 subtype (Dolezal and Tucek 1998; Fadel 2011; Zhang 
et al. 2002; Alquicer et al. 2016).
Released ACh is rapidly hydrolyzed by AChE. Compared with the peripheral 
tissues, AChE activity in the brain (except cerebellum) is extremely high, and ester-
ase activity in the CNS is closely related to the density of cholinergic innervation 
(Muramatsu et al. 2016). The esterase activity in the rat striatum is more than five 
times higher than that in the cerebral cortex and hippocampus, whereas the lowest 
activity is in the cerebellum, on par with that of the heart and colon. Thus, concen-
trations of released ACh appear to be effectively regulated by AChE in the CNS.
Inhibition of AChE would be thought to elicit a dramatic increase in synaptic 
ACh concentration; however, the scenario is not so simple. As mentioned above, 
ACh release is negatively regulated by presynaptic autoreceptors. Thus, it is likely 
that AChE inhibitors suppress hydrolysis of released ACh, which in turn, enhances 
stimulation of presynaptic mAChRs. Figure 3.3b shows a representative result in rat 
striatal slices, where [3H]efflux evoked by electrical stimulation (3 Hz, 30 s) was 
reduced after treatment with an irreversible AChE inhibitor (diisopropyl fluorophos-
phate [DFP]). This inhibitory effect of DFP was abolished by atropine (Muramatsu 
unpublished observations). These results strongly suggest that ACh release and syn-
aptic concentrations of ACh are precisely controlled by the subtle balance between 





































Fig. 3.3 Effects of atropine and diisopropyl phosphorofluoridate in [3H]efflux in superfusion 
experiments. Rat striatal segments were incubated with 0.1 μM [3H]choline for 30 min and then 
superfused. Electrical stimulation (3 Hz, for 30 s) was applied two times (S1 and S2). (a) 0.1 μM 
atropine. (b) 300 μM diisopropyl phosphorofluoridate (DFP). Ordinate: [3H] count (dpm) in super-
fusate collected every minute. Abscissa: time after superfusion
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In addition to presynaptic AChRs and AChE, the postsynaptic uptake of ACh 
itself also regulates synaptic ACh concentrations (Muramatsu et al. 2017). In Sect. 
3.3, it was noted that ACh uptake is inhibited by TEA and HC-3. The concentration 
of both drugs that suppressed ACh uptake significantly increased the evoked [3H]
efflux by electrical stimulation in superfusion experiments. The effects of TEA or 
HC-3 were not related to inhibitory actions on presynaptic mAChRs or AChE 
activity, because the effects of both drugs were observed under conditions which 
mAChRs and AChE were completely inhibited. Therefore, it is possible that a 
portion of released ACh may be incorporated into postsynaptic neurons by AChT, 
participating in the regulation of synaptic ACh concentrations.
After hydrolysis by AChE, it has been classically proposed that ACh-derived 
choline is transported back into cholinergic nerve terminals and recycled for new 
ACh synthesis. In this process, choline uptake is mediated through CHT1, which 
shows high affinity for HC-3 (Ki = 0.001–0.01 μM) and choline (1–5 μM) (Guyenet 
et al. 1973; Haga and Noda 1973; Okuda et al. 2012). In most previous superfusion 
experiments, 10 μM HC-3 had been added into perfusion medium to suppress CHT1 
activity. HC-3 at this concentration might act on presynaptic mAChRs in addition to 
inhibiting choline and ACh uptake. On the other hand, lower concentrations 
(0.1–1 μM) of HC-3, which selectively inhibit CHT1 but do not affect ACh uptake, 
failed to increase [3H]efflux evoked by electrical stimulation in superfusion experi-
ments (Muramatsu et al. 2017). These recent results suggest that the increase in [3H]
efflux by HC-3 is caused by an inhibition of ACh uptake but not choline uptake, 
implying that ACh-derived choline may not be significantly transported back into 
cholinergic terminals. Physiological concentrations of choline are relatively high 
(10–50 μM in plasma and 5–7 μM in cerebrospinal fluid) (Lockman and Allen 2002; 
Sweet et al. 2001), so that endogenous choline can be continuously supplied from 
extracellular spaces as a substrate for ACh synthesis. It is interesting to note that 
perturbations in brain choline homeostasis produce central cholinergic dysfunction 
(Koppen et  al. 1993; Jenden et  al. 1990; Sarter and Parikh 2005). These recent 
results were summarized in this review, and the modified cholinergic transmission 
mechanisms are proposed in Fig. 3.4.
3.5  Perspectives
Cholinergic transmission as well as adrenergic transmission is a prototype of neuro-
transmission, in which the transmitter is synthesized, stored and released from nerve 
terminals, and then acts on postsynaptic membrane receptors. Following release, the 
transmitter undergoes degradation and/or presynaptic reuptake, leading to termina-
tion of synaptic transmission. However, recent studies have revealed that the neuro-
transmission mechanisms may be more complex. In cholinergic transmission in the 
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CNS, released ACh may act both the plasma membrane and intracellular receptors 
in postsynaptic neurons. ACh itself may be taken up into postsynaptic neurons and 
act on intracellular receptors. The proposed model (Fig. 3.4) has reopened the issue 
of classical cholinergic and other neurotransmission mechanisms, and may provide 
a significant impetus for the pharmacological therapy of neurodegenerative disor-
ders such as Alzheimer’s disease.
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Fig. 3.4 A proposed model of cholinergic transmission in CNS. After release from cholinergic 
nerve terminals, ACh acts on plasma membrane and intracellular AChRs (mAChRs and/or 
nAChRs) in postsynaptic pyramidal neurons, in addition to presynaptic mAChRs. Thus, synaptic 
ACh concentrations are regulated by AChE hydrolysis, AChT-mediated postsynaptic uptake and 
presynaptic modulation of release itself. Choline for ACh synthesis may be largely supplied from 
endogenous choline present at relevant concentrations (>5 μM) in the extracellular space, rather 
than from ACh-degraded choline. Red circles: ACh. Green circles: choline
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Chapter 4
Nicotinic Acetylcholine Receptor Signaling: 
Roles in Neuroprotection
Toshiaki Kume and Yuki Takada-Takatori
Abstract Glutamate neurotoxicity is involved in various neurodegenerative disor-
ders including brain ischemic stroke, trauma, and Alzheimer’s and Parkinson’s dis-
eases. In addition to excitatory neuronal death, neuroinflammation accompanied by 
the activation of glial cells has been shown to be induced by these disorders. We 
previously reported the roles of nicotinic acetylcholine receptors (nAChRs) in the 
survival of central nervous system neurons during excitotoxic events and neuroin-
flammation. Nicotine and other nAChR agonists protected cortical neurons against 
glutamate neurotoxicity via α4- and α7-nAChRs in cultures of neurons obtained 
from the cerebral cortex of fetal rats. In addition, donepezil, a therapeutic acetylcho-
linesterase inhibitor currently being used for the treatment of Alzheimer’s disease, 
protected neuronal cells from glutamate neurotoxicity. Moreover, nicotine and 
donepezil induced the upregulation of nAChRs. Thus, we propose that nicotine as 
well as donepezil prevents glutamate neurotoxicity through Α4- and α7-nAChRs 
and the phosphatidylinositol 3-kinase (PI3K)/Akt pathway. In addition to the ben-
eficial effect on neuronal cells, we have reported the responses of astrocytes to bra-
dykinin, an inflammatory mediator, and the effect of nAChR stimulation on these 
responses using cultured cortical astrocytes. Bradykinin induced a transient increase 
of intracellular calcium concentration ([Ca2+]i) in cultured astrocytes. Both nicotine 
and donepezil reduced this bradykinin-induced [Ca2+]i increase. This reduction was 
inhibited not only by mecamylamine, an nAChR antagonist, but also by PI3K and 
Akt inhibitors. These results suggest that nAChR stimulation suppresses the inflam-
matory response induced by bradykinin via the PI3K-Akt pathway in astrocytes.
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4.1  Introduction
Nicotinic acetylcholine receptors (nAChRs) are distributed across various organs, 
such as the central nervous system (CNS), and are involved in changing cell func-
tions and controlling cell survival via several intracellular signal transduction mech-
anisms. Many endogenous compounds such as glutamate are known to trigger 
neuronal death via apoptosis in degenerative diseases of the CNS (Bresnick 1989; 
Choi et al. 1987). To date, we have elucidated that excitatory neurotoxicity triggered 
by excitative glutamate can be inhibited by various endogenous factors. In research 
using cultured rat embryonic cortical neurons, nicotine was shown to exert neuro-
protective effects against glutamate neurotoxicity via neuronal nAChRs (Akaike 
et al. 1994; Kaneko et al. 1997; Shimohama et al. 1998). These studies raised aware-
ness of this issue among many researchers, and numerous groups subsequently 
reported that nAChR agonists inhibit acute glutamate-induced neuronal death.
Alzheimer’s disease (AD) is a common type of dementia. Its pathological char-
acteristics include the formation of senile plaques primarily consisting of amyloid-β 
(Aβ) proteins, neurofibrillary tangles, and neurologic deficit; thus, AD has aspects 
of neurodegenerative disease (Whitehouse et al. 1982; Perry et al. 1995). Various 
disorders related to cholinergic nerves have also been found in the postmortem brain 
of AD patients, such as atrophy of the nucleus of origin of cholinergic nerves, reduc-
tion of acetylcholinergic nerves that project to the cortex from the Meynert nucleus, 
reduced activity of acetylcholine transferase activity in the cortex, and reduced 
expression of ACh and nAChRs (Bartus et al. 1982; Coyle et al. 1983). Since the 
cholinergic nervous system is involved in the functions of cognition and learning, 
attempts have been made to relieve symptoms by supplementing ACh, which led to 
the emergence of treatment drugs that act as acetylcholinesterase (AChE) inhibitors, 
such as donepezil. In addition to the neuronal injury, inflammation in the brain is 
involved in the pathogenesis of AD (Heppner et al. 2015; Heneka et al. 2015; Rogers 
2008; Lee et al. 2010). In inflammatory conditions, it is reported that glial cells, 
such as astrocytes and microglia, are abnormally activated (Morris et al. 2013; Lee 
et al. 1995). This abnormal activation of glial cells contributes to the pathogenesis 
of various neurodegenerative disorders (Heppner et al. 2015; Heneka et al. 2015; 
Rogers 2008; Lee et al. 2010; Yan et al. 2014). Astrocytes are the most abundant 
cells in the CNS and play important roles in the maintenance of neuronal activity 
through the release of neurotrophic factors, the maintenance of ion gradients such 
as extracellular K+, and the construction of the blood–brain barrier (Giaume et al. 
2010). However, a recent study revealed that, in various pathological conditions, 
astrocytes were abnormally activated and could be deleterious to adjacent neurons 
through the release of various inflammatory cytokines (Allan and Rothwell 2001). 
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Therefore, inhibition of the abnormal activation of astrocytes is considered to be a 
therapeutic strategy for several CNS diseases involving inflammation.
As a therapeutic drug of AD, donepezil is an effective AChE inhibitor for slow-
ing the progression of cognitive function disorders. In addition to AChE inhibitory 
activity, several other mechanisms have been noted for their possible relationships 
to the therapeutic effects of these drugs. AD is a neurodegenerative disease, and 
some of the therapeutic effects of donepezil may be attributable to its neuroprotec-
tive action; however, the assessment of its protective action and analysis of its mech-
anism of action have not been fully investigated, and much has yet to be clarified. In 
addition to the effect of donepezil on neurons, another group reported that donepezil 
inhibited the production of inflammatory cytokines induced by the treatment of Aβ 
oligomer in cultured microglia (Kim et al. 2014). However, the effect of donepezil 
on the function of astrocytes has not been elucidated.
This chapter summarizes the effects of nAChR stimulation using nicotine and 
nAChR ligands, including donepezil, on excitatory neuronal death in rat cultured 
neurons and neuroinflammation in astrocytes.
4.2  Neuroprotective Effect via Nicotine Receptors
On the basis of the above findings, we have focused on the neuroprotective action of 
donepezil and found that it exerts its protective effect against glutamate neurotoxic-
ity, as determined through research seeking to reveal its mechanism of action. At the 
same time, we found that donepezil did not exhibit a protective effect when neurons 
were treated simultaneously with glutamate and that it expressed its protective 
action in a manner dependent on the duration and concentration of the pretreatment. 
This strongly suggests that donepezil exerts its protective effect by a mechanism of 
action other than AChE inhibition (Takada et al. 2003).
Thus, we continued our analysis with the objective of elucidating the mechanism 
of the neuroprotective effect of donepezil against glutamate neurotoxicity. It has 
been shown that nicotine exerted a protective effect against glutamate neurotoxicity 
via nAChR in the primary culture of cortical neurons by pretreatment (Akaike et al. 
1994). Since donepezil exerted a neuroprotective effect in a manner dependent on 
the duration of the pretreatment, we examined the possible involvement of acetyl-
choline receptors in the protective action of donepezil. Upon treatment with gluta-
mate after treatment for 24  h with the nAChR antagonist mecamylamine and 
donepezil, we found that mecamylamine treatment significantly prevented the pro-
tective effect of AChE inhibitors. Upon pretreatment with the muscarine acetylcho-
line receptor antagonist scopolamine and donepezil, there was no impact on the 
protective effect of donepezil. These results suggested that the protective effect of 
donepezil against glutamate neurotoxicity involves nAChRs.
Next, we examined nAChR subtypes which are involved in the protective action 
of donepezil. The brain-expressed primary subtypes among the currently known 12 
nAChR subtypes are α4- and α7-nAChR. First, when we verified the expression of 
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primary component subunits of α4- and α7-nAChR in the primary culture of rat 
embryonic cortical neurons used in our laboratory, we detected nAChR mRNA and 
proteins of α4 and α7 subunits, which are the subunits composing α7-nAChR. We 
also used dihydro-β-erythroidine (DHβE) and methyllycaconitine (MLA), which 
are α4- nAChR and α7-nAChR-specific antagonists, to examine the involvement of 
neuronal nAChR subtypes in the neuroprotective action of donepezil. We applied 
glutamate treatment after treatment with donepezil and DHβE or MLA for 24 h and 
found that the protective action of donepezil was significantly inhibited. The above 
results showed that the protective action of donepezil against glutamate neurotoxic-
ity involved nAChRs (Takada et al. 2003).
4.3  Mechanisms of Neuroprotective Effects by Stimulating 
Nicotinic Receptors
Nicotine exerts a neuroprotective effect against neuronal apoptosis via 
α7-nAChR. The phosphatidylinositol 3-kinase (PI3K)/Akt signal pathway has been 
reported to be involved in this protective mechanism (Kihara et al. 2001; Shaw et al. 
2002). In addition to the protective effect of nicotine against glutamate neurotoxic-
ity reportedly being inhibited by various kinase inhibitors through the PI3K path-
way, the phosphorylation of Akt by nicotine treatment and the increase in the 
expression of Bcl-2, an anti-apoptotic protein, have also been reported. Since done-
pezil exerts its protective effect through α7-nAChR, we considered the possibility of 
the involvement of the PI3K-Akt signal pathway in this protective action and inves-
tigated specific inhibitors of kinases that form the PI3K signal pathway. Janus- 
activated kinase 2 (JAK2), a non-receptor tyrosine kinase, and Fyn activate PI3K in 
conjunction with α7-nAChR, so we examined the involvements of AG490 and PP2, 
inhibitors of JAK2 and Fyn. After pretreating cerebral cortical cells with either AG 
490 or PP2 along with donepezil 24 h ahead of time, the application of glutamate 
significantly inhibited the protective action of donepezil. Next, to clarify the involve-
ment of PI3K, we examined the effect of the PI3K inhibitor LY294002 on donepezil 
and found the protective effect of donepezil to be significantly inhibited. After that, 
we examined whether the MAPK pathway might be involved by observing the 
effect of the MAPK inhibitor PD98059 on donepezil; we found that the protective 
effect of donepezil was unaffected. The results of using these different kinase inhib-
itors suggested that the protective effect of donepezil is expressed through the PI3K 
signal pathway.
To further examine the role of donepezil in the PI3K signal transmission path-
way, we observed the phosphorylation of Akt and the change in the amount of Bcl-2 
expression in cerebral cortical cells treated with donepezil. Akt is known to be 
recruited by active PI3K in the vicinity of cell membranes, activated through phos-
phorylation, which in turn activates proteins and caspases of the Bcl-2 family of 
apoptotic control factors to regulate apoptosis. Using western blotting to observe 
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Akt phosphorylation in cerebral cortical neurons treated for 1 h with donepezil, we 
found a marked increase of phosphorylated Akt in the neurons treated with donepe-
zil. Likewise, in assessing change in the amount of Bcl-2 expression in cerebral 
cortical cells treated for 24 h with donepezil, an increase of Bcl-2 expression could 
be seen from the donepezil treatment. By integrating these results, the protective 
effect of donepezil against glutamate neurotoxicity is thought to be linked to the 
activation of PI3K by α7-nAChR via JAK2 and Fyn and, by virtue of activating 
p-Akt, to be expressed through initiation of an apoptosis control program involving 
an increase in Bcl-2 expression (Takada-Takatori et al. 2006).
4.4  Mechanism of the Nicotinic Acetylcholine Receptor 
Upregulation upon Long-Term Nicotine Stimulation
Unlike other receptors, the amount of protein increases in nAChR and its function 
is accelerated—that is, upregulation is provoked—as a result of long-term exposure 
to nicotine and other agonists. However, much remains unknown about the details 
of this mechanism. Thus, further research has been performed on the signals related 
to nAChR upregulation and increased sensitivity of the neuroprotective action in 
order to elucidate the mechanism that promotes the survival of neurons associated 
with nAChR and to understand the changes in cellular and receptor functions that 
are caused by long-term stimulation of nAChR, which has a neuroprotective effect. 
It is assumed that long-term nicotine stimulus is subjected to complex regulation by 
the desensitization of nAChR. Therefore, the study described below investigated 
this mechanism using donepezil, as an nAChR activator, which is currently indi-
cated for long-term clinical use.
When we observed the amounts of nAChR expression in primary cortical neuron 
cultures as a result of long-term treatment with donepezil using western blot analy-
sis, the expression level of α7-nAChR protein was increased. In addition, when we 
observed the immunohistochemical changes in the amount of nAChR expression as 
a result of long-term treatment with donepezil, we observed that the number of 
α7-nAChR-expressing cells increased in the cell membrane, which is important for 
the exertion of nAChR function. These results suggest that long-term stimulation of 
nAChR not only increases the amount of α7-nAChR that is expressed as a protein 
but also promotes a shift of that expression to the cell membrane, which is thought 
to be responsible for the function of α7-nAChR.
Next, to investigate the effect that increased expression of α7-nAChR has on the 
function of nAChR, we investigated the involvement of nicotine in increased intra-
cellular concentrations of calcium ([Ca2+]i). Temporary increases in [Ca2+]i as a 
result of nicotine treatment increased even further as a result of nicotine stimulation 
in cells that were treated with donepezil for 4 days. This indicates that long-term 
treatment with donepezil enhanced the response to nicotine stimulation immedi-
ately after administration and induced upregulation (Kume et al. 2005).
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Since it is clear that nAChR upregulation occurs as a result of long-term stimula-
tion of nAChR receptors in cortical neuron cultures, we continued our investigation 
of the mechanism behind this effect. To investigate the involvement of nAChR stim-
ulation and its downstream signal, we simultaneously carried out both long-term 
donepezil treatment and treatment with MLA, which is an α7-nAChR antagonist. 
The results indicated that the increases in the amount of nAChR proteins caused by 
long-term donepezil treatment were suppressed by simultaneous treatment with 
MLA. Therefore, we simultaneously carried out both long-term donepezil treatment 
and treatment with either LY294002, which is a PI3K inhibitor, or the MAPKK 
inhibitor PD98059 and found that simultaneous treatment with either LY294002 or 
PD98059 suppressed increases in the amount of nAChR proteins. These results 
indicate that the nAChR and the PI3K and MAPK signal pathways are involved in 
nAChR upregulation caused by long-term donepezil treatment. Next, to elucidate 
the mechanism of action of the promotion of nAChR function caused by long-term 
donepezil treatment, we investigated the involvement of the actions of nAChR 
antagonist, PI3K inhibitor, and MAPKK inhibitor on the increases in [Ca2+]i that are 
caused by nicotine. We carried out simultaneous long-term treatment with donepe-
zil and treatment with the α7-nAChR antagonist MLA. This resulted in the suppres-
sion of further increases in [Ca2+]i as a result of nicotine. We then carried out 
simultaneous long-term treatment with donepezil and either the PI3K inhibitor 
LY294002 or the MAPKK inhibitor PD98059. This also resulted in the suppression 
of further increases in [Ca2+]i as a result of nicotine. These results suggest that 
nAChR as well as the PI3K and MAPK pathways are involved in the promotion of 
nAChR function in cell membranes, such as seen when [Ca2+]i increases as a result 
of long-term treatment with donepezil (Takada-Takatori et al. 2008a).
4.5  Mechanism of Increased Sensitivity in the Neuronal 
Protective Effect of Nicotine That Accompanies Receptor 
Upregulation Caused by Long-Term Stimulation 
of Nicotine Receptors
Next, to investigate whether the increased sensitivity to the neuronal protective 
effect results from nAChR causing upregulation, we conducted long-term treatment 
with donepezil and investigated its effect on donepezil against glutamate neurotox-
icity during a state of increased nAChR function. The concentrations of donepezil 
that are sufficiently low that they do not lead to expression of the normal protective 
action (1 nM) in the treatment of neurons that have been subjected to long-term 
treatment with donepezil resulted in the marked suppression of glutamate neurotox-
icity. This indicates that the protective effect that is induced by long-term treatment 
with donepezil is dependent on both the treatment duration and the concentration. 
Therefore, to elucidate the mechanism of neuroprotection that occurs under the con-
ditions of long-term treatment, we investigated the effect of simultaneous long-term 
T. Kume and Y. Takada-Takatori
65
treatment with donepezil, nAChR antagonist, and either PI3K or MAPK pathway 
inhibitor on increased sensitivity to the neuroprotective action of donepezil. First, 
when we examined simultaneous long-term treatment with donepezil and treatment 
with the α7-nAChR antagonist MLA, we observed that the neuroprotective action 
caused by low concentrations of donepezil administered after long-term treatment 
with donepezil was suppressed by the simultaneous treatment with MLA.  Next, 
when we examined simultaneous long-term treatment with donepezil and treatment 
with either the PI3K inhibitor LY294002 or the MAPKK inhibitor PD98059, we 
found that both had the same suppressive effect. Finally, to elucidate the mechanism 
by which the survival signal is enhanced by the phosphorylation of Akt in the down-
stream PI3K pathway, we observed the phosphorylation of Akt in cortical neurons 
with long-term donepezil treatment and pretreatment using western blotting. The 
results indicated that, although the amount of phosphorylated Akt in neurons with 
long-term donepezil treatment and pretreatment increased markedly, when we car-
ried out treatment with nAChR inhibitor and PI3K inhibitor simultaneously with 
donepezil pretreatment, increases in the amount of phosphorylated Akt were sup-
pressed. These results indicate that when receptors are in a state of upregulation as 
a result of long-term nAChR stimulation, the promotive function of nAChR in cell 
membranes increases sensitivity to the neuroprotective effect of donepezil, which in 
turn indicates that the nAChR and either the PI3K or the MAPK signal pathways are 
involved in that action. When nAChR is in an upregulated state, the survival signal 
via the nAChR, PI3K-Akt, and MAPK pathways is more efficiently transmitted, 
and thus, we assume that this is why even lower concentrations of donepezil exerted 
the protective effect (Takada-Takatori et al. 2008b).
The mechanism of the neuroprotective effect of donepezil via nAChR that we 
assume is at work as a result of the above results is shown in Fig. 4.1. We hypothe-
size the following: As a result of the stimulation of α4- and α7-nAChR, donepezil 
exerts its neuroprotective effect via the PI3K-Akt signal pathway. Long-term 
nAChR stimulation induces the upregulation of nAChR in cell membranes, and the 
resulting promotion of nAChR function causes increased sensitivity to the neuro-
protective effect (Takada-Takatori et al. 2009).
4.6  Effect of the Stimulation of Nicotinic Acetylcholine 
Receptor in Astrocytes on Inflammatory Response 
in the Brain
Not only direct nAChR receptor stimulation on neuronal cells but also an indirect 
effect through glial cells is considered to mediate the neuroprotective effect. 
Therefore, we investigated the effect of nAChR stimulation on the inflammatory 
responses of astrocytes, which play a crucial role in brain inflammation. As an 
inflammatory mediator in the brain, bradykinin is produced in the early stage of 
inflammation and induces the expression of several inflammatory genes (Lin et al. 
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2012; Hsieh et al. 2007; Schwaninger et al. 1999). In particular, bradykinin induces 
a variety of responses, such as a transient increase of intracellular calcium concen-
tration ([Ca2+]i) (Akita and Okada 2011), the expression of matrix metalloprotease-9 
(Lin et al. 2012) and cyclooxygenase-2 (COX-2) (Hsieh et al. 2007), and the release 
of interleukin-6 (IL-6) (Schwaninger et al. 1999) and glutamate (Liu et al. 2009) in 
astrocytes. In addition, it was previously reported that the cleavage of high- 
molecular- weight kininogen, the precursor of bradykinin, was increased in the cere-
brospinal fluid of AD patients (Iores-Marçal et al. 2006; Bergamaschini et al. 1998) 
and that bradykinin receptor antagonists ameliorated the cognitive deficits in AD 
model mice (Bicca et al. 2015; Prediger et al. 2008; Lacoste et al. 2013). Accordingly, 
it can be speculated that inflammation induced by bradykinin in astrocytes is 
involved in the pathogenesis of AD. On the basis of these findings, to elucidate the 
effect of nAChR stimulation using nicotine and donepezil on the function in astro-
cytes, we investigated the responses of astrocytes to bradykinin and the effects of 
donepezil on these responses using cultured cortical astrocytes.
Fig. 4.1 The mechanism of the neuroprotective effects of donepezil via nicotinic acetylcholine 
receptors
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We first examined the effect of bradykinin on [Ca2+]i in cultured cortical astro-
cytes. Bradykinin induced a transient increase in [Ca2+]i in a concentration- dependent 
manner. Next, we verified the gene expression of B1 and B2 receptors in cultured 
cortical astrocytes. Both B1 and B2 receptors were expressed in our cultured astro-
cytes. We investigated the involvement of B1 and B2 receptors in the increase in 
[Ca2+]i induced by bradykinin using subtype-specific antagonists. Des-Arg9-[Leu8]-
bradykinin, an antagonist of B1 receptors, did not affect the increase in [Ca2+]i 
induced by bradykinin, but HOE140, an antagonist of B2 receptors, almost com-
pletely inhibited the Ca2+ response induced by bradykinin. We further determined 
whether the [Ca2+]i increase induced by bradykinin was due to Ca2+ influx from the 
extracellular space or Ca2+ release from the intracellular Ca2+ store. Bradykinin- 
induced [Ca2+]i increase did not change upon excluding extracellular Ca2+. In con-
trast, depletion of Ca2+ stored in the endoplasmic reticulum (ER) by treating cells 
with thapsigargin, a blocker of Ca2+-ATPase on the ER, significantly reduced the 
Ca2+ response. These results suggest that bradykinin-induced [Ca2+]i response is 
attributable not to Ca2+ influx from the extracellular space but to Ca2+ release from 
the ER. Next, we examined the effect of nicotine and donepezil on the increase in 
[Ca2+]i induced by bradykinin. Simultaneous treatment of nicotine and donepezil 
did not affect the increase of [Ca2+]i. However, 24 h pretreatment of these drugs 
significantly reduced the Ca2+ response in a concentration-dependent manner, while 
these drugs did not affect the cell morphology and cell proliferation in astrocytes. 
These results suggest that nicotinic receptor stimulation suppressed the increase of 
[Ca2+]i induced by bradykinin and that pretreatment is required for this inhibitory 
effect.
We attempted to elucidate the mechanism of the inhibitory effect of nicotinic 
receptor stimulation on the increase of [Ca2+]i induced by bradykinin. We previously 
reported that donepezil exerted a neuroprotective effect on glutamate neurotoxicity 
via nAChRs in cultured cortical neurons (Takada-Takatori et al. 2006). Thus, we 
herein investigated the involvement of nAChRs in this effect of donepezil using 
nAChR antagonists. When cortical astrocytes were treated with a nAChR antago-
nist, mecamylamine, for 24 h before Ca2+ imaging, the inhibitory effect of donepezil 
was significantly antagonized. Previous studies reported that the most abundant 
nAChR subtypes in the brain are the α7- and α4- nAChRs (Paterson and Nordberg 
2000) and that both of the receptor subtypes were also expressed in astrocytes 
(Oikawa et al. 2005). Thus, we examined the effects of MLA, an α7- nAChR antag-
onist, and DHβE, an α4- nAChR antagonist, on the inhibition by donepezil of the 
[Ca2+]i increase induced by bradykinin. When cortical astrocytes were pretreated 
with either MLA or DHβE for 24 h, the inhibitory effect of donepezil did not change. 
However, the effect of donepezil was significantly suppressed by treating cortical 
astrocytes with both MLA and DHβE for 24 h prior to bradykinin. These results 
suggested that both α7- and α4- nAChRs were involved in the inhibitory effect of 
donepezil on the increase of [Ca2+]i induced by bradykinin.
Previous studies demonstrated that JAK2 was activated in the downstream sig-
naling of nAChRs (Razani-Boroujerdi et al. 2007; Marrero and Bencherif 2009). 
Therefore, we used AG490, a JAK2 inhibitor, to investigate the involvement of 
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JAK2 in the inhibitory effect of donepezil. Treatment with AG490 significantly sup-
pressed the inhibitory effect of donepezil on the increase in [Ca2+]i induced by 
bradykinin.
We previously reported that the stimulation of nAChRs activated PI3K and that 
the phosphorylation and activation of Akt downstream of PI3K were induced 
(Kihara et al. 2001). Thus, we examined the involvement of the PI3K-Akt pathway 
in the inhibitory effect of donepezil on the Ca2+ response induced by bradykinin. 
LY294002, a PI3K inhibitor, and Akt inhibitor significantly suppressed the effect of 
donepezil. In addition, we investigated the effect of donepezil on the phosphoryla-
tion state of Akt in cultured cortical astrocytes. The phosphorylation level of Akt 
was significantly elevated by treating cells with donepezil for 6 h.
Taking the obtained findings together, nAChR stimulation using donepezil 
induced the activation of the PI3K-Akt pathway in both cultured astrocytes and 
cultured neurons. However, there are some differences between astrocytes and neu-
rons with respect to the signaling pathway mediated by nAChRs. For example, we 
previously showed that Akt phosphorylation was induced 1 h after the treatment of 
donepezil in cultured neurons, although donepezil induced Akt phosphorylation 6 h 
after the treatment in cultured astrocytes. Moreover, treatment of MLA or DHβE 
alone did not inhibit the effect of donepezil, and the combination of MLA and 
DHβE significantly reduced this effect. Thus, further studies are needed to elucidate 
the differences of the time course of Akt phosphorylation and the involvement of 
nAChR subtypes between neurons and astrocytes. Here we demonstrated that the 
Akt inhibitor suppressed the effect of donepezil on the increase in [Ca2+]i induced 
by bradykinin. Other researchers reported that, as the downstream signaling of the 
PI3K-Akt pathway, the activated Akt induced the phosphorylation of inositol tri-
sphosphate (IP3) receptors and lowered the function of IP3 receptors (Khan et al. 
2006; Szado et al. 2008). Taken together, these findings suggest that the phosphory-
lation and hypofunction of IP3 receptors by Akt could be involved in the effect of 
donepezil.
A previous study showed that bradykinin induced the production of intracellular 
reactive oxygen species (ROS) after the [Ca2+]i increase in cultured astrocytes (Akita 
and Okada 2011). To elucidate the effect of donepezil on ROS production, we 
examined ROS production induced by bradykinin using a fluorescent ROS indica-
tor, H2DCF-DA. Bradykinin induced ROS production in a time-dependent manner. 
Donepezil significantly inhibited the increase of intracellular ROS level induced by 
bradykinin. Previous studies reported that an increase in intracellular ROS level 
activated transcription factors, such as nuclear factor-kappa B (NF-κB) and activa-
tor protein 1, and this activation led to inflammatory responses in astrocytes (Yang 
et al. 2012; Park et al. 2004). In fact, bradykinin induced the expression of IL-6 and 
COX-2 downstream of ROS production and activation of NF-κB in cultured astro-
cytes (Hsieh et al. 2007; Schwaninger et al. 1999). We here demonstrated that done-
pezil inhibited ROS production induced by bradykinin. Taking these results and 
reports into account, we suggest that nAChR stimulation using donepezil decreases 
the inflammatory response induced by bradykinin by regulating the increase of 
intracellular ROS level.
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4.7  Conclusion and Future Prospects
It was previously reported that nAChR is involved in AD and many neurodegenera-
tive diseases. We investigated the involvement of nAChRs in the neuroprotective 
action that is induced through the use of AD drugs and found that PI3K-Akt and 
other intracellular information transmission systems play an important role in the 
neuroprotective effect and nAChR upregulation. In addition, we found that nAChR 
stimulation exerted an inhibitory effect on the [Ca2+]i increase induced by bradyki-
nin via the PI3K-Akt pathway and also inhibited the increase of the ROS level in 
cultured cortical astrocytes. The cholinergic hypothesis was first proposed in the 
1970s, but interesting new discoveries relating to the mechanism of action of AD 
drugs based on this hypothesis continue to be made. Research into the molecular 
mechanism that targets the signals that are related to nAChR, which is still only 
slightly understood, should make major contributions to the development of new 
drugs for neurodegenerative disorders including AD.
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Chapter 5
Regulation by Nicotinic Acetylcholine 
Receptors of Microglial Glutamate 
Transporters: Role of Microglia 
in Neuroprotection
Norimitsu Morioka, Kazue Hisaoka-Nakashima, and Yoshihiro Nakata
Abstract Accumulated evidence shows that activation of microglia is associated 
with a change in morphology, from ramified to globular, which also represents a 
transition to M1 microglia. M1 microglia contribute to the induction and develop-
ment of various neuroinflammatory disorders, including stroke, spinal cord injury, 
multiple sclerosis, Parkinson’s disease, Alzheimer’s disease psychiatric disorders, 
neuropathic pain and epilepsy. Thus, inhibition of microglial activation would be 
crucial in treating neurological disorders. Recent studies suggest a number of attrac-
tive molecular targets for blocking microglial activation. Among them, the nicotinic 
ACh receptor (nAChR), which especially contains the α7 subunit, contributes to the 
regulation of microglial activity through the inhibition of the synthesis of proinflam-
matory molecules. In addition, the glutamate transporter GLAST expressed in 
microglia is upregulated by α7 nAChR stimulation, which is mediated through both 
inositol triphosphate-Ca2+/calmodulin-dependent protein kinase II and fibroblast 
growth factor-2 pathways. It is possible, then, that activation of microglial α7 
nAChR could be neuroprotective through inhibition of the production of proinflam-
matory molecules and enhancement of glutamate clearance from the synapse. This 
chapter will give an overview of the role of the α7 nAChR in microglial functioning 
and its potential as a therapeutic target for neurological disorders.
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Neuroinflammation is involved in the induction of various neurodegenerative and 
neuropsychiatric disorders including stroke, spinal cord injury, multiple sclerosis, 
Parkinson’s disease, Alzheimer’s disease, depressive disorders, schizophrenia, neu-
ropathic pain and epilepsy (Blank and Prinz 2013; Frank-Cannon et  al. 2009; 
Yrjänheikki et al. 1998). Neuroinflammation is mainly mediated by CNS glial cells 
such as microglia and astrocytes. Microglia, originally derived from the reticuloen-
dothelial system, have a pivotal role as the main effector cells of the immune system 
(Kettenmann and Verkhratsky 2008). Although present in all region of the CNS, 
microglia are not uniformly distributed, representing between 0.5 and 16.6% of all 
cells in human and mouse brain (Lawson et  al. 1990; Mittelbronn et  al. 2001). 
Microglia act as a type of macrophage in peripheral tissues. Microglia are highly 
ramified, with long processes and small cell bodies, under the normal physiological 
state (Kettenmann et al. 2011). The recent emergence of live cell imaging technol-
ogy reveals that microglia have highly motile processes that continuously survey the 
surrounding environment (Nimmerjahn et al. 2005; Davalos et al. 2005). This state 
represents the “resting” phenotype, which is involved in maintaining homeostasis 
(Kettenmann et al. 2011). Therefore, changes in microglial activity and functional-
ity are indicative of pathological conditions.
5.2  Neuroinflammatory and Neuroprotective Roles 
of Microglia
It is widely known that activation of microglia, in response to illness, infection and 
injury, lead to morphological changes, from the highly ramified configuration to a 
globular, amoeboid shape (Kitamura et al. 1978; Stence et al. 2001; Thomas 1992). 
Activated microglia demonstrate increased proliferation, migration to the site of 
injury, scavenging of exogenous substances, cellular debris and pathogens, and pro-
duction of proinflammatory molecules, including cytokines, chemokines, prosta-
glandins, nitric oxide and reactive oxygen species (Suzuki et al. 2004; Hide et al. 
2000; Koizumi et al. 2007; Stence et al. 2001; Nolte et al. 1996; Morioka et al. 2013; 
Garrido-Gil et al. 2013; Fernandes et al. 2014). Cells that exhibit this phenotype are 
identified as “M1 microglia” (Kigerl et al. 2009). In fact, it has been demonstrated 
that hyper- or chronic activation of microglia could lead to the initiation of neurode-
generative disorders (Moehle and West 2015; Henkel et al. 2009). In addition, treat-
ment with the microglial inhibitor minocycline, a tetracycline antibiotic, reduces 
inflammation in animal models of neurodegeneration (Wu et al. 2002; Hou et al. 
2016).
At the same time, microglia also contribute to tissue recovery. Microglia produce 
anti-inflammatory and neuroprotective molecules, such as brain-derived neuro-
trophic factor (BDNF), glial cell-derived neurotrophic factor (GDNF), transforming 
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growth factor-β (TGF-β), tumor necrosis factor (TNF), interleukin-4 (IL-4) and 
interleukin-10 (IL-10) (Suzuki et al. 2004; Lai and Todd 2008; Polazzi and Monti 
2010; Amantea et al. 2015). Microglia showing anti-inflammatory and neuroprotec-
tive properties are called “M2 microglia”. Stimulation of microglia with IL-4 and 
interleukin-13 (IL-13), which are secreted by Th2 lymphocytes (Freilich et  al. 
2013), induces the M2 phenotype. M2 microglia express markers such as heparin- 
binding lectin, cysteine-rich protein FIZZ-1 and arginase-1 (Freilich et al. 2013). 
Transient middle cerebral artery occlusion induces brain tissue infraction and cell 
apoptosis. The number of apoptotic cells in infarcted tissue in transgenic mice in 
which microglia were selectively ablated was significantly more than that of wild- 
type mice (Lalancette-Hébert et al. 2007). Microglial phenotype is altered depend-
ing on environmental conditions―thus, microglial functioning show apparently 
opposing properties, either pro-inflammatory or anti-inflammatory (Ponomarev 
et  al. 2007). Previous findings also indicate that blockade of microglial activity 
alone may not be sufficient as a treatment for neuroinflammatory disorders, so fur-
ther elucidating changes in microglial phenotypes and properties under specific 
pathological conditions is crucial. Although there are a number of studies on the 
role of M1 microglia in proinflammatory responses and their involvement in neuro-
logical disorders, their roles in neuroprotection and their function in neuroinflam-
matory and neurodegenerative diseases have yet to be fully elaborated. In this vein, 
more research is necessary on identifying the neuroprotective molecules released by 
microglia under pathological conditions.
5.3  Nicotinic Acetylcholine Receptors and Microglia
Nicotinic acetylcholine receptors (nAChRs) are ligand-gated ion channels, consist-
ing of hetero- or homo-pentameric subunits. These receptors have important roles in 
neurobiological processes such as memory, learning, locomotion, attention and 
anxiety (Dajas-Bailador and Wonnacott 2004; Dani and Bertrand 2007; Zoli et al. 
2015). In the mammalian brain, 12 genes each encode a subunit, and nine different 
nAChR subunits have been identified (α2-α10 and β2-β4) (Dani and Bertrand 2007). 
The homomeric α7 nAChR is one of the most abundantly expressed and widely 
distributed subtype in the brain (Gotti and Clementi 2004; Sargent 1993). The α7 
nAChR is expressed not only in neurons, but also in non-neuronal cells such as 
astrocytes, microglia, oligodendrocyte precursor cells and brain endothelial cells 
(Liu et al. 2015; Kihara et al. 2001; Suzuki et al. 2006; Hawkins et al. 2005; Rogers 
et al. 2001). Human microglia express the α3, α5, α7 and β4 subunits (Rock et al. 
2008), whereas the α7 nAChR is the only functional nAChR subtype in rat cortical 
microglia (Morioka et al. 2014). The rat cortical microglia, then, makes an ideal 
system to study the neurobiological role of the α7 nAChR.
The α7 nAChR appears to have a critical role in neuroprotection. Peripheral mac-
rophages express α7 nAChR, which regulate the systemic response to inflammation 
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(Wang et al. 2003). Microglial α7 nAChR could be responsible for modulating the 
response to inflammation in the mouse brain. Prevention of lipopolysaccharide 
(LPS)-induced TNF release from murine microglia is mediated through activation 
of the α7 nAChR (Shytle et  al. 2004). Activation of microglial α7 nAChR sup-
presses the production of a number of proinflammatory molecules (Suzuki et  al. 
2006; Giunta et al. 2004; De Simone et al. 2005; Rock et al. 2008; Zhang et al. 
2017). Furthermore, stimulation of the α7 nAChR suppresses the production of 
reactive oxygen species (ROS) in microglia stimulated with fibrillar β-amyloid pep-
tide (Moon et  al. 2008), in addition, treatment of cultured microglia with galan-
tamine, a nAChR allosteric ligand, induces phagocytosis of β-amyloid in an α7 
nAChR-dependent manner (Takata et al. 2010), suggesting a potential role of the α7 
nAChR in the pathophysiology of Alzheimer’s disease. Stimulation of the α7 
nAChR also increases expression of anti-inflammatory and neuroprotective mole-
cules such as TGF-β1, IL-4, IL-10 and heme oxygenase-1 (De Simone et al. 2005; 
Parada et al. 2013; Rock et al. 2008; Zhang et al. 2017). Treatment of a microglial 
cell line BV2 with an α7 nAChR agonist increases autophagy, an anti-inflammatory 
response (Shao et  al. 2017). Furthermore, treatment with nicotine inhibits LPS- 
induced H+ currents through α7 nAChR (Noda and Kobayashi 2017). It is known 
that H+ channel-mediated currents are required for NAPDH oxidase-dependent 
ROS generation in brain microglia, a key step in the neuroinflammatory pathway 
(Wu et  al. 2012). While it is currently unknown whether the stimulation of α7 
nAChR induces the switching of microglial phenotype from M1 to M2, studies 
clearly indicate the importance of microglia-expressed α7 nAChR in reducing neu-
roinflammation, and suggest that microglial α7 nAChR could be utilized as a thera-
peutic target for the treatment of neuropathological disorders (Table 5.1).
5.4  Glutamate Transporters and Microglia
Glutamate is not only one of the major excitatory neurotransmitters mediating 
memory, learning and acute pain perception, but is excitotoxic at high concentra-
tions in the synapse. Therefore, the regulation of synaptic glutamate concentration, 
to prevent the overstimulation of post-synaptic neurons, is important in preventing 
excitotoxicity, and is mainly conducted through Na+/K+-dependent glutamate trans-
porters located in glial cells and neurons (Robinson and Dowd 1997). Thus far, five 
glutamate transporters have been cloned and pharmacologically characterized: 
excitatory amino acid transporter (EAAT) 1 (glutamate/aspartate transporter; 
GLAST) and EAAT2 (glutamate transporter 1; GLT-1), which are mainly expressed 
in glial cells, and EAAT3 (excitatory amino acid carrier 1; EAAC1), EAAT4 and 
EAAT5, which are mainly expressed in neurons (Arriza et al. 1997; Fairman et al. 
1995; Kanai and Hediger 1992; Pines et al. 1992). In general, astrocytic GLAST 
and GLT-1 are important for maintaining low concentration of glutamate (Shibata 
et al. 1997), and astrocytic glutamate uptake at synapses account for about 90% of 
total clearance under physiological conditions (Tanaka et al. 1997).
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Microglia express functional glutamate transporters, which are involved in regu-
lating glutamate homeostasis in synapses (Morioka et al. 2008). It has been shown 
that activated microglia express GLAST and GLT-1 both in vivo and in vitro (Noda 
et al. 1999). Microglial glutamate uptake at synapses is about 10% of that of astro-
cytes under physiological conditions (Persson et  al. 2005; Shaked et  al. 2005). 
Under excitotoxic conditions induced by high concentrations of glutamate,  however, 
activity and expression of microglial glutamate transporters are enhanced by exclud-
Table 5.1 Effect of α7 nAChR stimulation on microglial function
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Nicotine Increased TGF-β1, IL-4, 
CX3CL1, CCR2, CXCR6 
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Mouse BV2 ACh Inhibition of LPS-induced IL-1β 
and IL-6 expression, p38 
phosphorylation increased IL-4, 
and IL-10 expression rescue of 
LPS-suppressed JAK/STAT3 




Mouse BV2 PNU282987 Increased autophagy
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ing excess glutamate. For example, GLT-1 expression is increased in activated 
microglia following nerve injury (López-Redondo et al. 2000). Furthermore, stimu-
lation of cultured microglia with LPS increases GLT-1 expression and glutamate 
transport capacity (Persson et al. 2005). A clinical study demonstrated that microg-
lial glutamate transporters are involved in the control of neuronal damage in trau-
matic brain injury. Upregulation of GLAST expression in microglia is observed in 
brain white matter 1 week after ischemia (Beschorner et al. 2007). In addition, the 
expression of glutamate transporters (GLAST, GLT-1 and EAAC1) is observed in 
microglia/macrophages within the infract region at 7 and 28 days after ischemia 
(Arranz et  al. 2010). Thus, these observations indicate that microglial glutamate 
transporters could be crucial in reducing glutamate-mediated excitotoxicity. 
Although astrocytes generally have a crucial role in clearing glutamate from the 
synapses, the activity of glutamate transport in astrocytes is in fact downregulated 
under pathological conditions (Fine et al. 1996; Xin et al. 2009). Therefore, microg-
lial glutamate transporters, which are upregulated under pathological conditions, 
serve as a back-up to astrocytic glutamate uptake (López-Redondo et al. 2000; Xin 
et al. 2009). However, microglial glutamate transporter function and the functional 
relationship between α7 nAChR and glutamate transporters in microglia, have yet 
to be elaborated.
5.5  Nicotinic Acetylcholine Receptor and Glutamate 
Transporters
A number of studies have described significant interactions between nAChR and 
monoamine transporters, which comprise of noradrenaline, dopamine and serotonin 
transporters. For example, treatment with nicotine induced increased expression 
and functioning of these transporters in frontal cortical neurons and other cell types 
(Danielson et al. 2011; Itoh et al. 2010; Awtry and Werling 2003; Middleton et al. 
2004). By contrast, few studies have demonstrated a positive functional interaction 
between the nAChR and glutamate transporters. Basal glutamate uptake in cultured 
glial cells derived from rat pups prenatally exposed to nicotine is higher than normal 
(Lim and Kim 2001). Furthermore, increased activity of astrocytic glutamate trans-
porters (GLAST and GLT-1) is observed following neuronal nAChR stimulation, 
which increases synaptic levels of glutamate (Poitry-Yamate et al. 2002). Chronic 
treatment of Xenopus oocytes overexpressing EAAC1 with nicotine reduces 
EAAC1 activity (Yoon et al. 2014). Stimulation of cultured cerebellar astrocytes 
with nicotine modulates glutamate uptake, which is probably mediated through 
either a cAMP-independent or cAMP-dependent mechanism (Lim and Kim 2003).
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5.6  Alpha7 Nicotinic Acetylcholine Receptors and Microglial 
Glutamate Transporters
Although nicotine modulates activity and expression of glutamate transporters in 
the CNS, the actual nAChR subtype involved and the intracellular signal cascade 
mediating the transporter’s response to nAChR stimulation are not clear. 
Furthermore, a potential role of α7 nAChR modulating microglial glutamate trans-
porters has yet to be elaborated. A recent study showed that activation of the microg-
lial α7 nAChR system is crucial in the regulation of glutamate transporters (Morioka 
et al. 2014, 2015). Cultured rat cortical microglia mainly express GLAST and not 
GLT-1, as shown by RT-PCR and pharmacological analysis using selective inhibi-
tors for GLAST and GLT-1. Treatment with nicotine increases GLAST mRNA 
expression and glutamate transport activity and the effect of nicotine is blocked by 
pretreatment with a selective α7 nAChR antagonist, indicating that α7 nAChR 
mediates nicotine-induced GLAST expression. Understanding the role of the α7 
subtype, this is the only nAChR subtype expressed in the cortical microglia.
The concentration of nicotine needed to induce GLAST expression is relatively 
high (300–1000 μM) compared to concentrations utilized in other in vitro assays. It 
is possible that, compared to α7 nAChR expressed in other cell types, cortical 
microglial α7 nAChR has unique properties. Microglial α7 nAChR demonstrates a 
different pattern of electrical current compared with that demonstrated by neurons, in 
which stimulation of cortical microglia with nicotine does not evoke current, although 
ATP treatment evokes current (Suzuki et al. 2006). Furthermore, the α7 nAChR has 
two isoforms with different pharmacological properties: a low and a high affinity 
nicotinic binding site (Severance et al. 2004). In fact, high concentrations of nicotine 
(>1000 μM) is used to stimulate microglia/macrophage α7 nAChR (Takata et  al. 
2010; Sun et al. 2013). Thus, in the case of microglial α7 nAChR, high concentra-
tions of nicotine may be needed to activate microglia. Further investigation is neces-
sary to elucidate precise pharmacological and functional properties of α7 nAChR.
Various intracellular signal molecules are involved following stimulation of α7 
nAChR in vitro (Kihara et al. 2001; Arredondo et al. 2006; Maouche et al. 2013). In 
rat cortical microglia, stimulation of the α7 nAChR induced a rapid and transient 
increase in the concentration of cytosolic Ca2+ through the activation of phospholi-
pase C (PLC) and the release of Ca2+ from inositol triphosphate (IP3)-sensitive intra-
cellular stores, but not through the influx of extracellular Ca2+ (Suzuki et al. 2006). 
Increased cytosolic Ca2+ concentration through an IP3 receptor-dependent mecha-
nism is one of the key events underlying nicotine-α7 nAChR-mediated GLAST 
expression, block of the IP3 receptor, but not removal of extracellular Ca2+, inhibits 
nicotine’s effect. Likewise, Mashimo et  al. previously demonstrated that an IP3 
receptor signaling cascade is crucial in the regulation of GLAST expression in 
Bergmann glial cells, which are a type of astrocyte found in the cerebellum 
(Mashimo et al. 2010).
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A number of studies have indicated that several signaling molecules are activated 
following increased cytosolic Ca2+ concentration in microglia (Takata et al. 2010; 
Suzuki et al. 2006; Hide et al. 2000). The calmodulin-Ca2+/calmodulin-dependent 
protein kinase ΙΙ (CaMKII) pathway is activated following an α7 nAChR-mediated 
Ca2+ influx, eventually leading to microglia phagocytosis of amyloid β (Takata et al. 
2010). CaMKII activation is crucial since inhibiting CaMKII blocks nicotine- 
induced GLAST expression and glutamate transport in cortical microglia. Others 
have confirmed that CaMKII activity has an important role in glutamate uptake in 
cortical astrocytes induced through other pharmacological stimuli (Smith and 
Navratilova 1999). By contrast, other signal molecules, including protein kinase A, 
protein kinase C, phosphatidylinositol 3-kinase, janus-activated kinase, Src tyrosine 
kinase and extracellular signal-regulated protein kinase, do not appear to have a 
major role in nicotine-mediated GLAST expression in microglia.
Increased cytosolic Ca2+ concentration is observed within 1–2  min following 
nicotine treatment (Suzuki et al. 2006). Thus, it is speculated that CaMKII is rapidly 
activated in parallel with increased intracellular Ca2+. However, upregulation of 
GLAST mRNA expression is observed only after 18  h of nicotine treatment. 
Therefore, this delay between increased cytosolic Ca2+ concentration and GLAST 
expression suggests the induction of intermediary molecules which could have a 
role in GLAST expression. In fact, the protein synthesis inhibitor cycloheximide 
blocks nicotine-induced GLAST mRNA expression, indicating the presence of a 
protein intermediary between increased Ca2+ concentration and GLAST 
expression.
Stimulation of nAChRs contributes to the production of several molecules such 
as cytokines, chemokines, and neurotrophic factors (Hawkins et al. 2015; Maggio 
et al. 1998; Son and Winzer-Serhan 2009; Takarada et al. 2012). These substances 
in turn could enhance clearance of glutamate from the synapse by increasing 
GLAST expression. A number of studies have demonstrated that growth factors, 
including epidermal growth factor (EGF), fibroblast growth factor (FGF), insulin- 
like growth factor-1 (IGF-1) and TGF-β1, modulate GLAST expression in astro-
cytes (Figiel et al. 2003; Lee et al. 2009; Suzuki et al. 2001). In addition, treatment 
of cultured microglia with nicotine increases FGF-2 mRNA, but not EGF, IGF-1 
and TGF-β1 mRNAs, via the stimulation of the α7 nAChR. FGF-2 protein is also 
increased after treatment with nicotine. Thus, these findings indicate that FGF-2 
could be the crucial intermediary between α7 nAChR and GLAST upregulation.
In fact, treatment of cultured microglia with recombinant FGF-2 increases 
expression of GLAST and increases glutamate transport. In addition, pretreatment 
with a selective inhibitor of FGF receptor (FGFR) tyrosine kinase blocks the stimu-
latory effect of nicotine on GLAST expression and glutamate transport. The FGFR 
has four subtypes (FGFR1-FGFR4). Cultured cortical microglia express FGFR1 
mRNA, but not FGFR2 mRNA, FGFR3 mRNA, and FGFR4 mRNA. In neurons, 
FGF2 exerts neuroprotection by activating FGFR1, thereby decreasing glutamate- 
induced damage of hippocampal neurons through the production of GDNF (Lenhard 
et  al. 2002). Thus, the microglial α7 nAChR-FGF-2-FGFR1 pathway elicited by 
nicotine could be neuroprotective through the enhancement of glutamate clearance 
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by GLAST upregulation. FGF-2 has a neuroprotective role in preclinical animal 
models of neuroinflammation and neurodegenerative disorders. FGF-2 secreted 
from injured neurons could lead to microglia transformation and neuroprotective 
activities such as migration and phagocytosis (Noda et al. 2014). Enhancing brain 
FGF-2 expression restores hippocampal functioning in a preclinical model of 
Alzheimer’s disease (Kiyota et al. 2011).
Although further investigation is needed to elaborate the relationship between 
transformed M2 microglia and neuroprotection, the findings so far indicate that the 
nicotine-α7 nAChR system modulates microglial GLAST function and regulates 
the clearance of synaptic glutamate (Fig. 5.1).
5.7  Drug Development Targeting α7 nAChR for Neurological 
Disorders
Targeting the α7 nAChR is a potential strategy to treat neurological disorders which 
currently have no effective treatments. In fact, a selective α7 nAChR agonist reduces 
6-hydroxydopamine-induced dopaminergic neuronal damage in a rat model of 
Parkinson’s disease (Suzuki et al. 2013; Bordia et al. 2015). Furthermore, the α7 
nAChR is a potential target for the treatment of cognitive dysfunction associated 
with Alzheimer’s disease. Systemic treatment with selective α7 nAChR agonists, 









Fig. 5.1 Schematic representation of nicotine-α7 nAChR mediating GLAST expression in 
microglia. Long-term treatment (more than 18  h) of microglia with nicotine (300–1000  μM) 
upregulates the expression of GLAST (mRNA and protein) through the stimulation of the α7 
nAChR. The stimulation of α7 nAChR increases transient Ca2+ concentration through phospholi-
pase C and inositol triphosphate (IP3)-dependent pathways, and subsequent activation of Ca2+/
calmodulin-dependent protein kinase II (CaMKII). The treatment of microglia with nicotine 
induces expression of fibroblast growth factor-2 (FGF-2) mRNA and protein. FGF-2 produced 
stimulates FGFR1 expressed in microglia in an autocrine and paracrine manner, and increases both 
GLAST expression and glutamate transport. Thus, clearance of synaptic glutamate is achieved via 
activation of a nicotine-α7 nAChR system, through regulation of GLAST expression and gluta-
mate transport in microglia through IP3-Ca2+- CaMKII and FGF-2 pathways
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β-amyloid-treated mice (Sadigh-Eteghad et al. 2015). In addition, the α7 nAChR 
may be involved in regulating nociceptive transduction, as α7 nAChR agonists ame-
liorate experimental painful peripheral neuropathies (Di Cesare Mannelli et  al. 
2014; Freitas et al. 2013). Studies uncovering the relationship between α7 nAChR 
and microglial function in particular suggest the possibility that α7 nAChR expressed 
by microglia are a novel therapeutic target for the treatment of neurological disor-
ders. For example, stimulation of the α7 nAChR enhances microglial β-amyloid 
clearance (Takata et al. 2010). Direct activation of microglial α7 nAChR is neuro-
protective, through upregulation of heme oxtgenase-1, against oxygen and glucose 
deprivation in organotrophic hippocampal culture (Parada et al. 2013). Recent find-
ings also demonstrate that stimulation of α7 nAChR enhances GLAST expression 
and glutamate transport in microglia, suggesting that enhancing glutamate reuptake 
at the synapse is crucial in maintaining normal functioning of the glutamatergic 
system. Furthermore, it is also possible that downregulation of the α7 nAChR itself 
is associated with the induction of neurological disorders. Thus, direct stimulation 
of α7 nAChR or gene therapy to enhance α7 nAChR expression, especially in 
microglia, could be useful for treatment of various neurological disorders.
5.8  Conclusions
Hyperactivation of microglia, especially transitioning to the M1 phenotype, contrib-
utes to the induction of neuropathology in the CNS, suggesting that targeting M1 
microglia could be an appropriate treatment for neurological disorders. Although 
mechanisms regulating the switching of microglial phenotypes have yet to be fully 
elaborated, inducing the transitioning of microglia from the M1 phenotype to the 
M2 phenotype could be an alternate therapeutic approach. As described above, the 
α7 nAChR contributes to the regulation of a number of microglial functions, espe-
cially in the reduction of neuroinflammatory responses and the clearance of poten-
tially excitotoxic levels of synaptic glutamate. Therefore, further understanding of 
the molecular and cellular mechanisms underlying α7 nAChR expressed in microg-
lia could aid in the development of therapeutic strategies for neuroinflammatory and 
neurodegenerative diseases, which in general, are lacking in effective treatments.
Acknowledgement This work was supported in part by grants from Smoking Research 
Foundation. We also thank Dr. Aldric T. Hama for his careful editing of the manuscript.
References
Amantea D, Micieli G, Tassorelli C, Cuartero MI, Ballesteros I, Certo M, Moro MA, Lizasoain 
I, Bagetta G (2015) Rational modulation of the innate immune system for neuroprotection in 
ischemic stroke. Front Neurosci 9:147. https://doi.org/10.3389/fnins.2015.00147
Arranz AM, Gottlieb M, Pérez-Cerdá F, Matute C (2010) Increased expression of glutamate 
transporters in subcortical white matter after transient focal cerebral ischemia. Neurobiol Dis 
37(1):156–165. https://doi.org/10.1016/j.nbd.2009.09.019
N. Morioka et al.
83
Arredondo J, Chernyavsky AI, Jolkovsky DL, Pinkerton KE, Grando SA (2006) Receptor-mediated 
tobacco toxicity: cooperation of the Ras/Raf-1/MEK1/ERK and JAK-2/STAT-3 pathways 
downstream of alpha7 nicotinic receptor in oral keratinocytes. FASEB J 20(12):2093–2101. 
https://doi.org/10.1096/fj.06-6191com
Arriza JL, Eliasof S, Kavanaugh MP, Amara SG (1997) Excitatory amino acid transporter 5, a 
retinal glutamate transporter coupled to a chloride conductance. Proc Natl Acad Sci U S A 
94(8):4155–4160
Awtry TL, Werling LL (2003) Acute and chronic effects of nicotine on serotonin uptake in prefron-
tal cortex and hippocampus of rats. Synapse 50(3):206–211. https://doi.org/10.1002/syn.10259
Beschorner R, Simon P, Schauer N, Mittelbronn M, Schluesener HJ, Trautmann K, Dietz K, 
Meyermann R (2007) Reactive astrocytes and activated microglial cells express EAAT1, 
but not EAAT2, reflecting a neuroprotective potential following ischaemia. Histopathology 
50(7):897–910. https://doi.org/10.1111/j.1365-2559.2007.02703.x
Blank T, Prinz M (2013) Microglia as modulators of cognition and neuropsychiatric disorders. 
Glia 61(1):62–70. https://doi.org/10.1002/glia.22372
Bordia T, McGregor M, Papke RL, Decker MW, McIntosh JM, Quik M (2015) The α7 nico-
tinic receptor agonist ABT-107 protects against nigrostriatal damage in rats with unilat-
eral 6- hydroxydopamine lesions. Exp Neurol 263:277–284. https://doi.org/10.1016/j.
expneurol.2014.09.015
Dajas-Bailador F, Wonnacott S (2004) Nicotinic acetylcholine receptors and the regulation 
of neuronal signalling. Trends Pharmacol Sci 25(6):317–324. https://doi.org/10.1016/j.
tips.2004.04.006
Dani JA, Bertrand D (2007) Nicotinic acetylcholine receptors and nicotinic cholinergic mecha-
nisms of the central nervous system. Annu Rev Pharmacol Toxicol 47:699–729. https://doi.
org/10.1146/annurev.pharmtox.47.120505.105214
Danielson K, Truman P, Kivell BM (2011) The effects of nicotine and cigarette smoke on the 
monoamine transporters. Synapse 65(9):866–879. https://doi.org/10.1002/syn.20914
Davalos D, Grutzendler J, Yang G, Kim JV, Zuo Y, Jung S, Littman DR, Dustin ML, Gan WB 
(2005) ATP mediates rapid microglial response to local brain injury in  vivo. Nat Neurosci 
8(6):752–758. https://doi.org/10.1038/nn1472
De Simone R, Ajmone-Cat MA, Carnevale D, Minghetti L (2005) Activation of alpha7 nico-
tinic acetylcholine receptor by nicotine selectively up-regulates cyclooxygenase-2 and 
prostaglandin E2  in rat microglial cultures. J  Neuroinflammation 2(1):4. https://doi.
org/10.1186/1742-2094-2-4
Di Cesare Mannelli L, Pacini A, Matera C, Zanardelli M, Mello T, De Amici M, Dallanoce C, 
Ghelardini C (2014) Involvement of α7 nAChR subtype in rat oxaliplatin-induced neuropa-
thy: effects of selective activation. Neuropharmacology 79:37–48. https://doi.org/10.1016/j.
neuropharm.2013.10.034
Fairman WA, Vandenberg RJ, Arriza JL, Kavanaugh MP, Amara SG (1995) An excitatory amino- 
acid transporter with properties of a ligand-gated chloride channel. Nature 375(6532):599–603. 
https://doi.org/10.1038/375599a0
Fernandes A, Miller-Fleming L, Pais TF (2014) Microglia and inflammation: conspiracy, 
controversy or control? Cell Mol Life Sci 71(20):3969–3985. https://doi.org/10.1007/
s00018-014-1670-8
Figiel M, Maucher T, Rozyczka J, Bayatti N, Engele J (2003) Regulation of glial glutamate trans-
porter expression by growth factors. Exp Neurol 183(1):124–135
Fine SM, Angel RA, Perry SW, Epstein LG, Rothstein JD, Dewhurst S, Gelbard HA (1996) Tumor 
necrosis factor alpha inhibits glutamate uptake by primary human astrocytes. Implications for 
pathogenesis of HIV-1 dementia. J Biol Chem 271(26):15303–15306
Frank-Cannon TC, Alto LT, McAlpine FE, Tansey MG (2009) Does neuroinflamma-
tion fan the flame in neurodegenerative diseases? Mol Neurodegener 4:47. https://doi.
org/10.1186/1750-1326-4-47
Freilich RW, Woodbury ME, Ikezu T (2013) Integrated expression profiles of mRNA and miRNA 
in polarized primary murine microglia. PLoS One 8(11):e79416. https://doi.org/10.1371/jour-
nal.pone.0079416
5 Regulation by Nicotinic Acetylcholine Receptors of Microglial Glutamate…
84
Freitas K, Ghosh S, Ivy Carroll F, Lichtman AH, Imad Damaj M (2013) Effects of α7 posi-
tive allosteric modulators in murine inflammatory and chronic neuropathic pain models. 
Neuropharmacology 65:156–164. https://doi.org/10.1016/j.neuropharm.2012.08.022
Garrido-Gil P, Rodriguez-Pallares J, Dominguez-Meijide A, Guerra MJ, Labandeira-Garcia JL 
(2013) Brain angiotensin regulates iron homeostasis in dopaminergic neurons and microglial 
cells. Exp Neurol 250:384–396. https://doi.org/10.1016/j.expneurol.2013.10.013
Giunta B, Ehrhart J, Townsend K, Sun N, Vendrame M, Shytle D, Tan J, Fernandez F (2004) 
Galantamine and nicotine have a synergistic effect on inhibition of microglial activa-
tion induced by HIV-1 gp120. Brain Res Bull 64(2):165–170. https://doi.org/10.1016/j.
brainresbull.2004.06.008
Gotti C, Clementi F (2004) Neuronal nicotinic receptors: from structure to pathology. Prog 
Neurobiol 74(6):363–396. https://doi.org/10.1016/j.pneurobio.2004.09.006
Hawkins BT, Egleton RD, Davis TP (2005) Modulation of cerebral microvascular permeability by 
endothelial nicotinic acetylcholine receptors. Am J Physiol Heart Circ Physiol 289(1):H212–
H219. https://doi.org/10.1152/ajpheart.01210.2004
Hawkins JL, Denson JE, Miley DR, Durham PL (2015) Nicotine stimulates expression of proteins 
implicated in peripheral and central sensitization. Neuroscience 290C:115–125. https://doi.
org/10.1016/j.neuroscience.2015.01.034
Henkel JS, Beers DR, Zhao W, Appel SH (2009) Microglia in ALS: the good, the bad, and the 
resting. J NeuroImmune Pharmacol 4(4):389–398. https://doi.org/10.1007/s11481-009-9171-5
Hide I, Tanaka M, Inoue A, Nakajima K, Kohsaka S, Inoue K, Nakata Y (2000) Extracellular ATP 
triggers tumor necrosis factor-alpha release from rat microglia. J Neurochem 75(3):965–972
Hou Y, Xie G, Liu X, Li G, Jia C, Xu J, Wang B (2016) Minocycline protects against 
lipopolysaccharide- induced cognitive impairment in mice. Psychopharmacology (Berl) 
233(5):905–916. https://doi.org/10.1007/s00213-015-4169-6
Itoh H, Toyohira Y, Ueno S, Saeki S, Zhang H, Furuno Y, Takahashi K, Tsutsui M, Hachisuka 
K, Yanagihara N (2010) Upregulation of norepinephrine transporter function by prolonged 
exposure to nicotine in cultured bovine adrenal medullary cells. Naunyn Schmiedeberg’s Arch 
Pharmacol 382(3):235–243. https://doi.org/10.1007/s00210-010-0540-7
Kanai Y, Hediger MA (1992) Primary structure and functional characterization of a high-affinity 
glutamate transporter. Nature 360(6403):467–471. https://doi.org/10.1038/360467a0
Kettenmann H, Verkhratsky A (2008) Neuroglia: the 150 years after. Trends Neurosci 31(12):653–
659. https://doi.org/10.1016/j.tins.2008.09.003
Kettenmann H, Hanisch UK, Noda M, Verkhratsky A (2011) Physiology of microglia. Physiol Rev 
91(2):461–553. https://doi.org/10.1152/physrev.00011.2010
Kigerl KA, Gensel JC, Ankeny DP, Alexander JK, Donnelly DJ, Popovich PG (2009) Identification 
of two distinct macrophage subsets with divergent effects causing either neurotoxicity or 
regeneration in the injured mouse spinal cord. J  Neurosci 29(43):13435–13444. https://doi.
org/10.1523/JNEUROSCI.3257-09.2009
Kihara T, Shimohama S, Sawada H, Honda K, Nakamizo T, Shibasaki H, Kume T, Akaike A (2001) 
alpha 7 nicotinic receptor transduces signals to phosphatidylinositol 3-kinase to block A beta- 
amyloid- induced neurotoxicity. J Biol Chem 276(17):13541–13546. https://doi.org/10.1074/
jbc.M008035200
Kitamura T, Tsuchihashi Y, Fujita S (1978) Initial response of silver-impregnated “resting microg-
lia” to stab wounding in rabbit hippocampus. Acta Neuropathol 44(1):31–39
Kiyota T, Ingraham KL, Jacobsen MT, Xiong H, Ikezu T (2011) FGF2 gene transfer restores hip-
pocampal functions in mouse models of Alzheimer’s disease and has therapeutic implications 
for neurocognitive disorders. Proc Natl Acad Sci U S A 108(49):E1339–E1348. https://doi.
org/10.1073/pnas.1102349108
Koizumi S, Shigemoto-Mogami Y, Nasu-Tada K, Shinozaki Y, Ohsawa K, Tsuda M, Joshi BV, 
Jacobson KA, Kohsaka S, Inoue K (2007) UDP acting at P2Y6 receptors is a mediator of 
microglial phagocytosis. Nature 446(7139):1091–1095. nature05704 [pii] 391038/nature05704
N. Morioka et al.
85
Lai AY, Todd KG (2008) Differential regulation of trophic and proinflammatory microglial effec-
tors is dependent on severity of neuronal injury. Glia 56(3):259–270. https://doi.org/10.1002/
glia.20610
Lalancette-Hébert M, Gowing G, Simard A, Weng YC, Kriz J (2007) Selective ablation of prolifer-
ating microglial cells exacerbates ischemic injury in the brain. J Neurosci 27(10):2596–2605. 
https://doi.org/10.1523/JNEUROSCI.5360-06.2007
Lawson LJ, Perry VH, Dri P, Gordon S (1990) Heterogeneity in the distribution and morphology 
of microglia in the normal adult mouse brain. Neuroscience 39(1):151–170
Lee ES, Sidoryk M, Jiang H, Yin Z, Aschner M (2009) Estrogen and tamoxifen reverse manganese- 
induced glutamate transporter impairment in astrocytes. J Neurochem 110(2):530–544. https://
doi.org/10.1111/j.1471-4159.2009.06105.x
Lenhard T, Schober A, Suter-Crazzolara C, Unsicker K (2002) Fibroblast growth factor-2 requires 
glial-cell-line-derived neurotrophic factor for exerting its neuroprotective actions on glutamate- 
lesioned hippocampal neurons. Mol Cell Neurosci 20(2):181–197
Lim DK, Kim HS (2001) Changes in the glutamate release and uptake of cerebellar cells in peri-
natally nicotine-exposed rat pups. Neurochem Res 26(10):1119–1125
Lim DK, Kim HS (2003) Opposite modulation of glutamate uptake by nicotine in cultured astro-
cytes with/without cAMP treatment. Eur J Pharmacol 476(3):179–184
Liu Y, Zeng X, Hui Y, Zhu C, Wu J, Taylor DH, Ji J, Fan W, Huang Z, Hu J (2015) Activation of α7 
nicotinic acetylcholine receptors protects astrocytes against oxidative stress-induced apoptosis: 
implications for Parkinson’s disease. Neuropharmacology 91:87–96. https://doi.org/10.1016/j.
neuropharm.2014.11.028
López-Redondo F, Nakajima K, Honda S, Kohsaka S (2000) Glutamate transporter GLT-1 is 
highly expressed in activated microglia following facial nerve axotomy. Brain Res Mol Brain 
Res 76(2):429–435
Maggio R, Riva M, Vaglini F, Fornai F, Molteni R, Armogida M, Racagni G, Corsini GU (1998) 
Nicotine prevents experimental parkinsonism in rodents and induces striatal increase of neuro-
trophic factors. J Neurochem 71(6):2439–2446
Maouche K, Medjber K, Zahm JM, Delavoie F, Terryn C, Coraux C, Pons S, Cloëz-Tayarani I, 
Maskos U, Birembaut P, Tournier JM (2013) Contribution of α7 nicotinic receptor to airway 
epithelium dysfunction under nicotine exposure. Proc Natl Acad Sci U S A 110(10):4099–
4104. https://doi.org/10.1073/pnas.1216939110
Mashimo M, Okubo Y, Yamazawa T, Yamasaki M, Watanabe M, Murayama T, Iino M (2010) 
Inositol 1,4,5-trisphosphate signaling maintains the activity of glutamate uptake in Bergmann 
glia. Eur J Neurosci 32(10):1668–1677. https://doi.org/10.1111/j.1460-9568.2010.07452.x
Middleton LS, Cass WA, Dwoskin LP (2004) Nicotinic receptor modulation of dopamine trans-
porter function in rat striatum and medial prefrontal cortex. J Pharmacol Exp Ther 308(1):367–
377. https://doi.org/10.1124/jpet.103.055335
Mittelbronn M, Dietz K, Schluesener HJ, Meyermann R (2001) Local distribution of microglia in 
the normal adult human central nervous system differs by up to one order of magnitude. Acta 
Neuropathol 101(3):249–255
Moehle MS, West AB (2015) M1 and M2 immune activation in Parkinson’s disease: foe and ally? 
Neuroscience 302:59–73. https://doi.org/10.1016/j.neuroscience.2014.11.018
Moon JH, Kim SY, Lee HG, Kim SU, Lee YB (2008) Activation of nicotinic acetylcholine receptor 
prevents the production of reactive oxygen species in fibrillar beta amyloid peptide (1-42)-stim-
ulated microglia. Exp Mol Med 40(1):11–18. https://doi.org/10.3858/emm.2008.40.1.11
Morioka N, Abdin MJ, Kitayama T, Morita K, Nakata Y, Dohi T (2008) P2X(7) receptor stimu-
lation in primary cultures of rat spinal microglia induces downregulation of the activity for 
glutamate transport. Glia 56(5):528–538. https://doi.org/10.1002/glia.20634
Morioka N, Tokuhara M, Harano S, Nakamura Y, Hisaoka-Nakashima K, Nakata Y (2013) The 
activation of P2Y6 receptor in cultured spinal microglia induces the production of CCL2 
through the MAP kinases-NF-κB pathway. Neuropharmacology 75C:116–125. https://doi.
org/10.1016/j.neuropharm.2013.07.017
5 Regulation by Nicotinic Acetylcholine Receptors of Microglial Glutamate…
86
Morioka N, Tokuhara M, Nakamura Y, Idenoshita Y, Harano S, Zhang FF, Hisaoka-Nakashima 
K, Nakata Y (2014) Primary cultures of rat cortical microglia treated with nicotine increases 
in the expression of excitatory amino acid transporter 1 (GLAST) via the activation of the 
α7 nicotinic acetylcholine receptor. Neuroscience 258:374–384. https://doi.org/10.1016/j.
neuroscience.2013.11.044
Morioka N, Harano S, Tokuhara M, Idenoshita Y, Zhang FF, Hisaoka-Nakashima K, Nakata Y 
(2015) Stimulation of α7 nicotinic acetylcholine receptor regulates glutamate transporter 
GLAST via basic fibroblast growth factor production in cultured cortical microglia. Brain Res 
1625:111–120. https://doi.org/10.1016/j.brainres.2015.08.029
Nimmerjahn A, Kirchhoff F, Helmchen F (2005) Resting microglial cells are highly dynamic sur-
veillants of brain parenchyma in vivo. Science 308(5726):1314–1318. https://doi.org/10.1126/
science.1110647
Noda M, Kobayashi AI (2017) Nicotine inhibits activation of microglial proton currents via inter-
actions with α7 acetylcholine receptors. J Physiol Sci 67(1):235–245. https://doi.org/10.1007/
s12576-016-0460-5
Noda M, Nakanishi H, Akaike N (1999) Glutamate release from microglia via glutamate trans-
porter is enhanced by amyloid-beta peptide. Neuroscience 92(4):1465–1474
Noda M, Takii K, Parajuli B, Kawanokuchi J, Sonobe Y, Takeuchi H, Mizuno T, Suzumura 
A (2014) FGF-2 released from degenerating neurons exerts microglial-induced neuro-
protection via FGFR3-ERK signaling pathway. J  Neuroinflammation 11:76. https://doi.
org/10.1186/1742-2094-11-76
Nolte C, Möller T, Walter T, Kettenmann H (1996) Complement 5a controls motility of murine 
microglial cells in vitro via activation of an inhibitory G-protein and the rearrangement of the 
actin cytoskeleton. Neuroscience 73(4):1091–1107
Parada E, Egea J, Buendia I, Negredo P, Cunha AC, Cardoso S, Soares MP, López MG (2013) The 
microglial α7-acetylcholine nicotinic receptor is a key element in promoting neuroprotection 
by inducing heme oxygenase-1 via nuclear factor erythroid-2-related factor 2. Antioxid Redox 
Signal 19(11):1135–1148. https://doi.org/10.1089/ars.2012.4671
Persson M, Brantefjord M, Hansson E, Rönnbäck L (2005) Lipopolysaccharide increases microg-
lial GLT-1 expression and glutamate uptake capacity in vitro by a mechanism dependent on 
TNF-alpha. Glia 51(2):111–120. https://doi.org/10.1002/glia.20191
Pines G, Danbolt NC, Bjørås M, Zhang Y, Bendahan A, Eide L, Koepsell H, Storm-Mathisen J, 
Seeberg E, Kanner BI (1992) Cloning and expression of a rat brain L-glutamate transporter. 
Nature 360(6403):464–467. https://doi.org/10.1038/360464a0
Poitry-Yamate CL, Vutskits L, Rauen T (2002) Neuronal-induced and glutamate-dependent activa-
tion of glial glutamate transporter function. J Neurochem 82(4):987–997
Polazzi E, Monti B (2010) Microglia and neuroprotection: from in vitro studies to therapeutic 
applications. Prog Neurobiol 92(3):293–315. https://doi.org/10.1016/j.pneurobio.2010.06.009
Ponomarev ED, Maresz K, Tan Y, Dittel BN (2007) CNS-derived interleukin-4 is essential for the 
regulation of autoimmune inflammation and induces a state of alternative activation in microg-
lial cells. J Neurosci 27(40):10714–10721. https://doi.org/10.1523/JNEUROSCI.1922-07.2007
Robinson MB, Dowd LA (1997) Heterogeneity and functional properties of subtypes of sodium- 
dependent glutamate transporters in the mammalian central nervous system. Adv Pharmacol 
37:69–115
Rock RB, Gekker G, Aravalli RN, Hu S, Sheng WS, Peterson PK (2008) Potentiation of HIV-1 
expression in microglial cells by nicotine: involvement of transforming growth factor-beta 1. 
J NeuroImmune Pharmacol 3(3):143–149. https://doi.org/10.1007/s11481-007-9098-7
Rogers SW, Gregori NZ, Carlson N, Gahring LC, Noble M (2001) Neuronal nicotinic acetylcho-
line receptor expression by O2A/oligodendrocyte progenitor cells. Glia 33(4):306–313
Sadigh-Eteghad S, Talebi M, Mahmoudi J, Babri S, Shanehbandi D (2015) Selective activation 
of α7 nicotinic acetylcholine receptor by PHA-543613 improves Aβ25-35-mediated cognitive 
deficits in mice. Neuroscience 298:81–93. https://doi.org/10.1016/j.neuroscience.2015.04.017
Sargent PB (1993) The diversity of neuronal nicotinic acetylcholine receptors. Annu Rev Neurosci 
16:403–443. https://doi.org/10.1146/annurev.ne.16.030193.002155
N. Morioka et al.
87
Severance EG, Zhang H, Cruz Y, Pakhlevaniants S, Hadley SH, Amin J, Wecker L, Reed C, Cuevas 
J (2004) The alpha7 nicotinic acetylcholine receptor subunit exists in two isoforms that con-
tribute to functional ligand-gated ion channels. Mol Pharmacol 66(3):420–429. https://doi.
org/10.1124/mol.104.000059
Shaked I, Tchoresh D, Gersner R, Meiri G, Mordechai S, Xiao X, Hart RP, Schwartz M 
(2005) Protective autoimmunity: interferon-gamma enables microglia to remove gluta-
mate without evoking inflammatory mediators. J  Neurochem 92(5):997–1009. https://doi.
org/10.1111/j.1471-4159.2004.02954.x
Shao BZ, Ke P, Xu ZQ, Wei W, Cheng MH, Han BZ, Chen XW, Su DF, Liu C (2017) Autophagy 
plays an important role in anti-inflammatory mechanisms stimulated by Alpha7 nicotinic ace-
tylcholine receptor. Front Immunol 8:553. https://doi.org/10.3389/fimmu.2017.00553
Shibata T, Yamada K, Watanabe M, Ikenaka K, Wada K, Tanaka K, Inoue Y (1997) Glutamate 
transporter GLAST is expressed in the radial glia-astrocyte lineage of developing mouse spinal 
cord. J Neurosci 17(23):9212–9219
Shytle RD, Mori T, Townsend K, Vendrame M, Sun N, Zeng J, Ehrhart J, Silver AA, Sanberg PR, 
Tan J (2004) Cholinergic modulation of microglial activation by alpha 7 nicotinic receptors. 
J Neurochem 89(2):337–343. https://doi.org/10.1046/j.1471-4159.2004.02347.x
Smith TL, Navratilova E (1999) Increased calcium/calmodulin protein kinase activity in astro-
cytes chronically exposed to ethanol: influences on glutamate transport. Neurosci Lett 
269(3):145–148
Son JH, Winzer-Serhan UH (2009) Chronic neonatal nicotine exposure increases mRNA expres-
sion of neurotrophic factors in the postnatal rat hippocampus. Brain Res 1278:1–14. https://doi.
org/10.1016/j.brainres.2009.04.046
Stence N, Waite M, Dailey ME (2001) Dynamics of microglial activation: a confocal time-lapse 
analysis in hippocampal slices. Glia 33(3):256–266
Sun Y, Li Q, Gui H, Xu DP, Yang YL, Su DF, Liu X (2013) MicroRNA-124 mediates the choliner-
gic anti-inflammatory action through inhibiting the production of pro-inflammatory cytokines. 
Cell Res 23(11):1270–1283. https://doi.org/10.1038/cr.2013.116
Suzuki K, Ikegaya Y, Matsuura S, Kanai Y, Endou H, Matsuki N (2001) Transient upregulation 
of the glial glutamate transporter GLAST in response to fibroblast growth factor, insulin- 
like growth factor and epidermal growth factor in cultured astrocytes. J  Cell Sci 114(Pt 
20):3717–3725
Suzuki T, Hide I, Ido K, Kohsaka S, Inoue K, Nakata Y (2004) Production and release of neuro-
protective tumor necrosis factor by P2X7 receptor-activated microglia. J Neurosci 24(1):1–7. 
24/1/1 [pii] 10.1523/JNEUROSCI.3792-03.2004
Suzuki T, Hide I, Matsubara A, Hama C, Harada K, Miyano K, Andrä M, Matsubayashi H, Sakai 
N, Kohsaka S, Inoue K, Nakata Y (2006) Microglial alpha7 nicotinic acetylcholine receptors 
drive a phospholipase C/IP3 pathway and modulate the cell activation toward a neuroprotective 
role. J Neurosci Res 83(8):1461–1470. https://doi.org/10.1002/jnr.20850
Suzuki S, Kawamata J, Matsushita T, Matsumura A, Hisahara S, Takata K, Kitamura Y, Kem 
W, Shimohama S (2013) 3-[(2,4-Dimethoxy)benzylidene]-anabaseine dihydrochloride pro-
tects against 6-hydroxydopamine-induced parkinsonian neurodegeneration through α7 nico-
tinic acetylcholine receptor stimulation in rats. J  Neurosci Res 91(3):462–471. https://doi.
org/10.1002/jnr.23160
Takarada T, Nakamichi N, Kawagoe H, Ogura M, Fukumori R, Nakazato R, Fujikawa K, Kou 
M, Yoneda Y (2012) Possible neuroprotective property of nicotinic acetylcholine receptors 
in association with predominant upregulation of glial cell line-derived neurotrophic factor in 
astrocytes. J Neurosci Res 90(11):2074–2085. https://doi.org/10.1002/jnr.23101
Takata K, Kitamura Y, Saeki M, Terada M, Kagitani S, Kitamura R, Fujikawa Y, Maelicke A, 
Tomimoto H, Taniguchi T, Shimohama S (2010) Galantamine-induced amyloid-{beta} clear-
ance mediated via stimulation of microglial nicotinic acetylcholine receptors. J  Biol Chem 
285(51):40180–40191. https://doi.org/10.1074/jbc.M110.142356
5 Regulation by Nicotinic Acetylcholine Receptors of Microglial Glutamate…
88
Tanaka K, Watase K, Manabe T, Yamada K, Watanabe M, Takahashi K, Iwama H, Nishikawa 
T, Ichihara N, Kikuchi T, Okuyama S, Kawashima N, Hori S, Takimoto M, Wada K (1997) 
Epilepsy and exacerbation of brain injury in mice lacking the glutamate transporter GLT-1. 
Science 276(5319):1699–1702
Thomas WE (1992) Brain macrophages: evaluation of microglia and their functions. Brain Res 
Brain Res Rev 17(1):61–74
Wang H, Yu M, Ochani M, Amella CA, Tanovic M, Susarla S, Li JH, Yang H, Ulloa L, Al-Abed 
Y, Czura CJ, Tracey KJ (2003) Nicotinic acetylcholine receptor alpha7 subunit is an essential 
regulator of inflammation. Nature 421(6921):384–388. https://doi.org/10.1038/nature01339
Wu DC, Jackson-Lewis V, Vila M, Tieu K, Teismann P, Vadseth C, Choi DK, Ischiropoulos H, 
Przedborski S (2002) Blockade of microglial activation is neuroprotective in the 1-methyl- 
4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson disease. J  Neurosci 
22(5):1763–1771
Wu LJ, Wu G, Akhavan Sharif MR, Baker A, Jia Y, Fahey FH, Luo HR, Feener EP, Clapham DE 
(2012) The voltage-gated proton channel Hv1 enhances brain damage from ischemic stroke. 
Nat Neurosci 15(4):565–573. https://doi.org/10.1038/nn.3059
Xin WJ, Weng HR, Dougherty PM (2009) Plasticity in expression of the glutamate transporters 
GLT-1 and GLAST in spinal dorsal horn glial cells following partial sciatic nerve ligation. Mol 
Pain 5:15. https://doi.org/10.1186/1744-8069-5-15
Yoon HJ, Lim YJ, Zuo Z, Hur W, Do SH (2014) Nicotine decreases the activity of glutamate 
transporter type 3. Toxicol Lett 225(1):147–152. https://doi.org/10.1016/j.toxlet.2013.12.002
Yrjänheikki J, Keinänen R, Pellikka M, Hökfelt T, Koistinaho J  (1998) Tetracyclines inhibit 
microglial activation and are neuroprotective in global brain ischemia. Proc Natl Acad Sci U S 
A 95(26):15769–15774
Zhang Q, Lu Y, Bian H, Guo L, Zhu H (2017) Activation of the α7 nicotinic receptor promotes 
lipopolysaccharide-induced conversion of M1 microglia to M2. Am J Transl Res 9(3):971–985
Zoli M, Pistillo F, Gotti C (2015) Diversity of native nicotinic receptor subtypes in mammalian brain. 
Neuropharmacology 96(Pt B):302–311. https://doi.org/10.1016/j.neuropharm.2014.11.003
Open Access This chapter is licensed under the terms of the Creative Commons Attribution 4.0 
International License (http://creativecommons.org/licenses/by/4.0/), which permits use, sharing, 
adaptation, distribution and reproduction in any medium or format, as long as you give appropriate 
credit to the original author(s) and the source, provide a link to the Creative Commons license and 
indicate if changes were made.
The images or other third party material in this chapter are included in the chapter’s Creative 
Commons license, unless indicated otherwise in a credit line to the material. If material is not 
included in the chapter’s Creative Commons license and your intended use is not permitted by 
statutory regulation or exceeds the permitted use, you will need to obtain permission directly from 
the copyright holder.
N. Morioka et al.
89© The Author(s) 2018 
A. Akaike et al. (eds.), Nicotinic Acetylcholine Receptor Signaling  
in Neuroprotection, https://doi.org/10.1007/978-981-10-8488-1_6
Chapter 6
Shati/Nat8l and N-acetylaspartate (NAA) 
Have Important Roles in Regulating 
Nicotinic Acetylcholine Receptors 
in Neuronal and Psychiatric Diseases 
in Animal Models and Humans
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Abstract Shati/Nat8l was originally isolated as a methamphetamine-related- 
molecule from the nucleus accumbens of mice. Since then, Shati/Nat8l has been 
characterized as an N-acetyltransferase-8-like protein (Nat8l) that catalyzes 
N-acetylaspartate (NAA) synthesis from aspartate and acetyl-coenzyme A.  It has 
been shown that elevated NAA levels detected by proton magnetic resonance spec-
troscopy (1H-MRS) brain imaging indicates increased neuronal activity. Our group 
produced Shati/Nat8l knock out mice (Shati/Nat8l KO mice), which exhibit hyper 
locomotion, anxiety behaviors, and social dysfunction. These mice have a high sen-
sitivity to methamphetamine, as evidenced by their results in assessments of loco-
motor activity and conditioned place preference, as well as their elevated dopamine 
levels. We used an adeno-associated virus (AAV) vector containing Shati/Nat8l 
(AAV-Shati/Nat8l) to overexpress the protein in different brain regions such as the 
striatum and the nucleus accumbens, in order to investigate their involvement in 
methamphetamine-induced behavioral and pharmacological changes. We showed 
that overexpression of accumbal Shati/Nat8l attenuates methamphetamine-induced 
behaviors.
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Recent clinical studies have revealed further novel roles of Shati/Nat8l in psychi-
atric and neuronal diseases. We are just beginning to appreciate the various actions 
of this intriguing, recently discovered molecule in the central nervous system.
Keywords Shati/Nat8l · Methamphetamine · Addiction · Depression · Alzheimer’s 
disease · ATP
6.1  Introduction
Shati is a molecule originally isolated from the nucleus accumbens of mice that had 
received repeated administration of methamphetamine (Niwa et  al. 2007, 2008). 
Shati was later identified as an N-acetyltransferase-8-like protein (Nat8l) and was 
found to catalyze N-acetylaspartate (NAA) synthesis from aspartate and acetyl- 
coenzyme A (Ariyannur et  al. 2010) (Fig. 6.1). We renamed the novel molecule 
from Shati to Shati/Nat8l following this finding. NAA is present at high concentra-
tions in the central nervous system and is combined with glutamate and converted 
into N-acetylaspartylglutamate (NAAG) by NAAG synthetase (NAAGS) (Becker 
et al. 2010). NAAG is widely distributed in the brains of mammals (Neale et al. 
2000) and acts as a highly selective neurotransmitter for group II metabotropic glu-
tamate receptor 3 (mGluR3) (Neale et al. 2011). Following the release of NAAG 
into the synaptic cleft, NAAG binds mGluR3 and is metabolized to NAA and gluta-
mate by glutamate carboxypeptidase II (GCPII) (Bzdega et al. 1997; Fig. 6.1). A 
postmortem study showed that the levels of NAA and NAAG are significantly lower 
in the brains of subjects with major depressive disorder, schizophrenia and bipolar 
disorder (Reynolds and Reynolds 2011). In patients with pre-Alzheimer’s disease, 
NAA levels are significantly reduced in the cingulate gyrus. A clinical study using 
magnetic resonance spectroscopy (MRS) showed that NAA was significantly 
increased in adult patients with autism spectrum disorder when compared with a 
control group (Aoki et al. 2012). Together, these observations suggest that the NAA 
synthetase, Shati/Nat8l, may play important roles in psychiatric, neurodegenerative, 
and neurodevelopmental disorders.
Furthermore, treatment of a neuroblastoma-derived cell line with a physiological 
level of NAA resulted in apoptosis of cancerous cells and enhanced neuronal differ-
entiation (Mazzoccoli et al. 2016). NAA is of unique clinical significance and hence 
is exploited in MRS.  Treatment of an SH-SY5Y neuroblastoma-derived cell line 
with sub-cytotoxic physiological concentrations of NAA has been shown to inhibits 
cell growth (Mazzoccoli et al. 2016). This effect is partly due to enhanced apoptosis, 
which is indicated by a decrease in the anti-apoptotic factors survivin and Bcl-xL, 
and partly due to the arrest of the cell-cycle progression, linked to enhanced expres-
sion of the cyclin-inhibitors p53, p21Cip1/Waf1, and p27Kip1 (Mazzoccoli et  al. 
2016). NAA-pre-treated SH-SY5Y cells were more sensitive to the cytotoxic effect 
of the chemotherapeutic drugs cisplatin and 5-fluorouracil (Mazzoccoli et al. 2016).






































Fig. 6.1 Schematic overview of Shati/Nat8l function. Shati/Nat8l catalyzes the N-acetylation of 
aspartate, forming N-acetylaspartate (NAA). The condensation of NAA and glutamate is catalyzed 
by N-acetylaspartylglutamate (NAAG) synthetase (NAAGS). NAAG is released from nerve termi-
nals most likely via synaptic vesicles. The transporter responsible for the translocation of NAAG 
into synaptic vesicles is unknown. Released NAAG can be degraded by glutamate carboxypepti-
dase II (GCP-II), membrane-bound enzymes mainly expressed by astrocytes, liberating NAA and 
glutamate (Moffett et  al. 2007). NAAG may also bind to metabotropic glutamate receptor 3 
(mGluR3) on presynaptic membranes and astrocytes. mGluR3 is coupled to a Gi protein and nega-
tively coupled to adenylyl cyclase (Conn and Pin 1997). The NAA transporter, sodium-dependent 
dicarboxylate (NaDC3), is expressed by astrocytes and oligodendrocytes (Huang et al. 2000). In 
oligodendrocytes, NAA can be degraded by aspartoacylase II (ASPA-II, liberating aspartate and 
acetate (Moffett et al. 2007). The released acetate may be used for lipid synthesis by myelinating 
oligodendrocytes (Burri et al. 1991; Namboodiri et al. 2006). To what extent NAA is taken up by 
astrocytes in vivo or its metabolic fate in these cells is unclear
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In this review, we will introduce the various functions of Shati/Nat8l and NAA 
in psychiatric behaviors, especially addictive behaviors, and summarize their roles 
in neuronal and psychiatric diseases.
6.2  Shati/Nat8l and Drug Reward
6.2.1  Function of Accumbal Shati/Nat8l in Nicotinic Effects
We previously reported that overexpression of Shati/Nat8l in the nucleus accum-
bens (NAc) of mice depressed the pharmacological effects of methamphetamine, 
especially addiction-related behaviors, hyperactivity, and place preference. In an 
in  vivo microdialysis experiment, the extracellular dopamine (DA) level was 
increased by 200–300% of the base line by peripheral methamphetamine injection. 
In the NAc of these mice, NAA and NAAG levels were significantly reduced 
(Miyamoto et al. 2014). The mGluR3 antagonist, LY341495, cancelled the Shati- 
Nat8l- indeuced reduction of hyperlocomotion and conditioned place preference 
after methamphetamine treatment. Furthermore, LY341495 also cancelled the 
Shati/Nat8l-associated increase in extracellular DA levels in the NAc of 
methamphetamine- treated mice. These results indicate that the overexpression of 
Shati/Nat8l in the NAc suppresses the increase in dopamine release caused by meth-
amphetamine via mGluR3 (Miyamoto et al. 2014).
We also investigated the effects of Shati/Nat8l on nicotine preference using a 
three-bottle paradigm. Experiments were performed as follows: I. Both NAc-Mock 
and NAc-Shati/Nat8l overexpressing mice were habituated to an experimental 
chamber which contained three water bottles on days 1–3. II. The tap water in all 
three bottles was changed to 2% saccharin to habituate animals to saccharin on days 
4–6. III. The contents of all three bottles were replaced with a mixture of 75 μg/mL 
and 2% saccharin on days 8–14 (Fig. 6.2). During the subsequent test phase, three 
bottles containing either 0 μg/mL nicotine +2% saccharin, 75 μg/mL nicotine +2% 
saccharin or 150 μg/mL nicotine +2% saccharin, were presented to each mouse, and 
the total intake of nicotine was measured in each mouse on days 15–21 (Fig. 6.2). 
The daily amounts of nicotine intake are shown in Fig. 6.3a. On the first day of the 
test phase, an average of 300 μg of nicotine was consumed by both groups. In the 
NAc-Mock mice, the amount of nicotine consumed increased each day during days 
15–17 (Fig. 6.3a). In contrast, the Shati/Nat8l mice showed a lower intake of nico-
tine enriched solution during this period (Fig. 6.3a). These results suggest that over-
expression of Shati/Nat8l in NAc lowers nicotine intake and preference. The 2% of 
saccharin were essential for the experimental protocol, since nicotine also has aver-
sive effects due to its bitter taste. While overexpression of Shati/Nat8l in NAc low-
ered nicotine preference during days 16–17 (Fig.  6.3a), total intake (water and 
nicotine solution) was not changed (Fig. 6.3c, d).
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Next, we performed in vivo microdialysis experiments to measure the amount of 
extracellular DA induced by nicotine in the system (Fig. 6.4a). Basal levels of extra-
cellular DA in the NAc of Shati/Nat8l-overexpressing mice were significantly lower 
than those of NAc-Mock mice (Fig. 6.4b). In the NAc-Mock mice group, the extra-
cellular DA level was significantly increased 60–120 min after nicotine injection, up 
to a level of approximately 170% of that of the saline injection. Nicotine-injected 
NAc-Shati/Nat8l mice showed low levels of extracellular DA at the 60–120 min 
time point similar to saline-injected groups (Fig. 6.5). Furthermore, the suppressive 
(day)
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Fig. 6.2 Procedure for the three bottle test to evaluate nicotine preference. I. Both NAc-Mock and 
NAc-Shati/Nat8l mice were habituated to an experimental chamber which contained three water 
bottles on days 1–3. II. The tap water in all three bottles was changed to 2% saccharin to habituate 
animals to saccharin on days 4–6. III. The contents of all three bottles were replaced with a mixture 
of 75 μg/mL nicotine and 2% saccharin on days 8–14. During the test phase, three bottles contain-
ing either 0 μg/ mL nicotine +2% saccharin, 75 μg/mL + 2% saccharin or 150 μg/mL + 2% sac-
charin were presented to each mouse, and the total intake of nicotine was measured in each mouse 
on days 15–21
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Fig. 6.3 Effects on nicotine preference of overexpression of Shati/Nat8l in NAc of mice. (a) Daily 
nicotine consumption in the test phase from days 15–21. (b) Total nicotine consumption during the 
test phase. (c) Daily solution intake in the test phase. (d) Total solution intake during the test phase
A. Nitta et al.
95
effects of Shati/Nat8l on nicotine-induced DA elevation were partially reversed by 
LY341495, an mGluR2/3 antagonist (Fig. 6.6). These results indicate that the func-
tion of Shati/Nat8l to suppress the effect of nicotine-induced extracellular DA in the 
NAc is partially dependent on mGluR3. These results are similar to those showing 
Fig. 6.4 Apparatus for in vivo microdialysis and quantification of basal DA levels. (a) Apparatus 
for in vivo microdialysis to measure dopamine (DA). (b) Effects of Shati/Nat8l overexpression in 
the basal levels of extracellular DA. Each column represents the mean ± S.E.M. n = 10, *P < 0.05 




















Fig. 6.5 Effect of Shati/Nat8l overexpression on nicotine (NIC)-induced dopamine (DA) release 
in the NAc. At 0 min, NAc-Shati/Nat8l and NAc-Mock mice were injected with either nicotine 
(0.4 mg/kg as free base) or saline (sal) subcutaneously. Each value represents the mean ± S.E.M. 
(n = 5, ****P < 0.001 vs. Mock-sal group, #P < 0.05 vs. Mock-NIC group, two- way repeated 
measure ANOVA with Bonferroni’s post hoc test)
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the action of Shati/Nat8l against the pharmacological effects of methamphetamine. 
One difference is the complete or partial contribution of mGluR3 in methamphet-
amine and nicotine use, respectively. Both nicotine and methamphetamine regulate 
the DA reward system in the brain. Methamphetamine directly alters dopamine 
uptake and release, while nicotine first binds to the nicotinic acetylcholine receptor 
(nAChR) and, following signal transduction contributes to the potentiation of DA 
release. The suppressive effects of Shati/Nat8l on the DA release might happen 
downstream of the mGluR3 pathway. Further studies are required to discern whether 
there is a mechanistic crossover between the pharmacological actions of nicotine 
and methamphetamine. We attempted to investigate Shati/Nat8l mRNA changes in 
the NAc, the hippocampus and the frontal cortex, related to reward pathways fol-
lowing single or repeated treatments with nicotine. Unfortunately, we could not 
reproduce the results of the mRNA measurements, potentially because the levels of 
Shati/Nat8l or NAAG do not change based on the activation of nAChR. In relation 
to Shati/Nat8l production, methamphetamine and nicotine most likely act through 
different pathways.
Taken together, our results show that Shati/Nat8l in the NAc has a protective 
effect against the deleterious physiological changes associated with nicotine or 
methamphetamine administration.
6.2.2  Striatal Shati/Nat8l and the Reward System
We produced Shati/Nat8l transgenic mice (Shati/Nat8l-Tg) to investigate global 
overexpression in the brain. A targeting vector was used to produce the Shati/Nat8l-Tg 





























Fig. 6.6 The suppressant effect of Shati/Nat8l overexpression on nicotine-induced dopamine 
(DA) elevation was partially blocked by the mGluR2/3 antagonist, LY341495. At −30 min, NAc- 
Shati/Nat8l and NAc-Mock mice were injected with the mGluR2/3 antagonist, LY341495 (LY, 
0.1 mg/kg, i.p.). Mice were injected with nicotine (NIC) (0.4 mg/kg, s.c.) 30 min after LY341495 
injection. Each value represents the mean ± SEM. (n = 5, *P < 0.05 vs. Shati/Nat8l-Saline group, 
two-way repeated measures ANOVA with Bonferroni post hoc test)
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cassette including the CAG promoter followed by the his-Shati/Nat8l sequence was 
obtained from a CAG promoter the his-Shati/Nat8l expression plasmid (Fig. 6.7a). 
The transgene cassette was microinjected into fertilized eggs from C57BL/6  J 
females mated with males. Genotyping confirmation of Shati/Nat8l-Tg mice using 
a wild type mouse as a control is shown in Fig. 6.7b. Shati/Nat8l mRNA levels were 
measured by quantitative real-time reverse transcriptase (RT)-PCR in the brain and 
are presented relative to the expression of the housekeeping gene, 36B4. Shati/Nat8l 
mRNA was highly expressed in the whole brain of 8-week-old transgenic mice 
(Fig. 6.8). However, Shati/Nat8l mRNA levels were increased in relation to wild 
type expression in the striatum only, not in other brain regions, such as the olfactory 
bulb, the prefrontal cortex or the NAc (Fig. 6.9). These Shati/Nat8l-Tg mice were 
therefore used for striatal Shati/Nat8l-overexpression mice. The mice showed no 
differences in basal locomotor activity compared to wild-type mice when observed 
in a novel environment (Fig. 6.10). These mice also performed a Y maze task as well 
as novel object recognition tests, to assess their learning abilities (Fig. 6.11). In the 
Y maze task, neither the number of total entries nor spontaneous alternation behav-
iors were different between Shati/Nat8l-Tg and wild type mice (Fig. 6.12). In the 
novel recognition test, both time and trial exploratory preference (in %) were simi-
lar between wild type and Shati/Nat8l-Tg mice (Fig. 6.12). Next, anxiety-like emo-
tional behaviors in Shati/Nat8l-Tg mice were investigated using the light/dark box 
test, and no difference in the time spent on the light side was observed between 
Shati/Nat8l-Tg mice and wild type mice (Fig. 6.13). Results from both the light/
dark box and elevated plus maze tests indicated no effect of increased levels of stria-
tal Shati/Nat8l on anxiety-like behaviors. We also investigated the social abilities of 
the Shati/Nat8l-Tg mice. The experimental schedule of the three-chamber social 
interaction test is shown in Fig. 6.13a. In trial 1, the test mouse was placed in the 
Fig. 6.7 Genetic scheme of Shati/Nat8l-Tg mice. (a) Targeting vector used to produce 
Shati/Nat8l-Tg mice. Transgenic mice ubiquitously expressing the His-tagged Shati/Nat8l gene 
were produced by Unitech (Chiba, Japan). Briefly, the transgene cassette including the CAG pro-
moter followed by the his-Shati/Nat8l sequence was obtained from the CAG promoter his-Shati/
Nat8l expression plasmid. The transgene cassette was microinjected into fertilized eggs from 
C57BL/6J females mated with males. (b) Genotyping results of Shati/Nat8l-Tg mice using a wild 
type mouse
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center of the chamber, while the other side of the chamber remained empty and no 
wire cage was placed. Both Shati/Nat8l-Tg and wild type mice were more interested 
in the novel object (Fig. 6.13b, left). In trial 2, another novel object was placed in 
the wire cage on one side, and an unfamiliar mouse (C57BL/6J) was placed in a 
wire cage on the opposite side. The Shati/Nat8l-Tg mice and wild type mice showed 
a similar level of interest in the unfamiliar mouse (Fig. 6.13b, right). In a prepulse 
inhibition (PPI) test, auditory startle response (Fig. 6.14a) and sensory motor con-
trol function (Fig. 6.14b) were not changed in Shati/Nat8l-Tg mice. Furthermore, in 
forced swimming and tail suspension tests, the immobility times of Shati/Nat8l-Tg 
































Fig. 6.9 Expression of Shati/Nat8l mRNA in various brain regions of Shati/Nat8l-Tg mice. Shati/
Nat8l mRNA levels were measured by quantitative real-time RT-PCR in the brain and are pre-






























Fig. 6.8 Expression of 
Shati/Nat8l mRNA in the 
whole brain of Shati/
Nat8l-Tg mice. Shati/Nat8l 
mRNA levels were 
measured by quantitative 
real-time RT-PCR in the 
brain and are presented as 
relative to the expression 
of the housekeeping gene, 
36B4. Values are mean ± 
SEM (n = 5 mice/group, 
**P < 0.01 vs. wild type 
group, Student’s t-test)
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results indicate Shati/Nat8l-Tg mice do not demonstrate schizophrenia or 
depression- like behaviors. 
Shati/Nat8l-Tg mice were not stable for the overexpression of Shati/Nat8l in the 
striatum, depending on their generation. In general, mouse lines generated with 
transgenes are often not stable, since transecting genes is a process that does not 
happen naturally. Therefore, to measure the effect of increased striatal Shati/Nat8l 
on the reward system, we injected an EGFP-tagged AAV containing Shati/Nat8l 
into the striatum of mice (Str-Shati/Nat8l) and confirmed localized overexpression 
by in situ hybridization and EGFP immunohistochemistry in the dorsal striatum 

















































Fig. 6.10 Locomotor activity in Shati/Nat8l-Tg mice. No difference in basal locomotor activity 
was observed in a novel environment between Shati/Nat8l-Tg mice and wild type mice. Values are 
mean ± SEM (n = 10 or 14 mice/group)
Fig. 6.11 Spontaneous alternation behavior in Shati/Nat8l-Tg mice. There was no difference in 
(a) total arm entries or (b) spontaneous alternation behavior in the Y-maze test observed between 
Shati/Nat8l-Tg mice and wild type mice. Values are mean ± SEM (n = 10 or 14 mice/group)
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Fig. 6.13 Social interaction in Shati/Nat8l-Tg mice. (a) Experimental schedule of three chamber 
social interaction test. (b), left A novel object was placed in a wire cage on one side of the chamber, 
and no wire cage was placed on the other side of the chamber. Both Shati/Nat8l-Tg mice and wild 
type mice were more interested in the novel object. Values are mean ± SEM (n = 10 or 14 mice/
group, ***P < 0.001 vs. empty side for each group, Student’s t-test). WT: wild type, Tg: transgenic. 
(b), right Another novel object was placed in a wire cage on one side of the chamber, and an unfa-
miliar mouse (C57BL/6 J) was placed in a wire cage on the other side of the chamber. Shati/
Nat8l-Tg mice were not more interested in the unfamiliar mouse than the wild type group. Values 
are mean ± SEM (n = 10 or 14 mice/group, ***P < 0.001 vs. unfamiliar mouse, ♯♯P < 0.01 vs. wild 
type group, Student’s t-test)


















Habituation (30min/day) Training (10min) Trail (10min)
(A)
(B) WT Shati/Nat8l-Tg
Fig. 6.12 Novel object recognition in Shati/Nat8l-Tg mice. (a) Experimental schedule of the 
novel object recognition test. (b) No difference in exploratory preference in the novel object rec-
ognition test was observed between Shati/Nat8l-Tg mice and wild type mice. Values are mean ± 
SEM (n = 10 or 14 mice/group, **P < 0.001 vs. training phase for each group, Student’s t-test)
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Fig. 6.14 Startle response and PPI in Shati/Nat8l-Tg mice. a Startle response was measured for 
70, 80, 90, 100, 110 and 120 dB (background noise: 70 dB). Values are mean ± SEM. b PPI was 
measured with 4, 8 and 16 dB of prepulse intensity (background noise: 70 dB). Values are mean ± 










































Fig. 6.15 Depressive behavior in Shati/Nat8l-Tg mice in the tail suspension test. No difference in 
immobility time was observed during the tail suspension test between Shati/Nat8l-Tg mice and 
wild type mice. Values are mean ± SEM (n = 10 or 14 mice/group)
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area. Str-Shati/Nat8l mice showed no difference in methamphetamine-induced 
hyperactivity compared to mock-injected mice (Fig.  6.17a). Methamphetamine- 
induced conditioned place preference was also not changed in Str-Shati/Nat8l mice 
(Fig. 6.17b). Therefore, we conclude that Shati/Nat8l in the striatum does not con-
tribute to reward effects in mice.
6.3  Shati/Nat8l in Learning and Memory
6.3.1  Hippocampal Shati/Nat8l in Learning and Memory
Shati/Nat8l produces NAA from acetyl-coA and aspartic acid, and represents one of 
the amino acids with the highest-concentration amino acids in the brain. Recently, a 
change in NAA concentration measured by MRS was proposed as a biomarker for 
early-stage Alzheimer’s (Murray et al. 2014). This suggests that Shati/Nat8l and/or 
NAA are related in some way to the onset of Alzheimer’s disease. However, learn-
ing ability was not changed in Y maze and novel object tests conducted in Shati/
Nat8l KO mice (Furukawa-Hibi et al. 2012). We overexpressed Shati/Nat8l in the 
hippocampus via AAV injection (Hip-Shati/Nat8l), and conducted learning and 
memory tests. In the novel object trial session, Hip-Shati/Nat8l mice preferred to 
explore the novel object for a significantly prolonged time compared to mock injec-
tion mice (Fig. 6.18). This result suggests that cognitive ability might be potentiated 















































Fig. 6.16 Depressive behavior in Shati/Nat8l-Tg mice in the forced swimming test. No difference 
in immobility time was observed in the forced swimming test between Shati/Nat8l-Tg mice and 
wild type mice. Values are mean ± SEM (n = 10 or 14 mice/group)
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demonstrated that a change in NAA level is a clinical marker for Alzheimer’s dis-
ease, although these authors looked at only the posterior cingulate gyri, the inferior 
precunei and the posterior cingulate cortex. Proton magnetic resonance spectros-
copy (1H-MRS) showed low NAA/creatine ratios in the posterior cingulate cortices 
of patients with Alzheimer’s disease, which is a typical region for the accumulation 
of amyloid beta. Vulnerability to shifts in NAA is not the same in all brain regions 
in patients with Alzheimer’s disease. Our results using Hip-Shati/Nat8l mice are 
partly in agreement with these clinical observations. There are also other clinical 
studies that measure NAA levels in relation to Alzheimer’s disease using the MRS 




























































Fig. 6.17 Pharmacological 
changes to locomotor 




difference was seen in (a) 
the locomotor activity after 
treatment with 
methamphetamine (1 mg/
kg) or (b) conditioned 
place preference with 
methamphetamine (1 mg/
kg) between Str-Mock and 
Str-Shati/Nat8l
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investigate changes in Shati/Nat8l itself in the brain of patients with Alzheimer’s 
disease, since Shati/Nat8l has also functions, apart from being synthetase for NAA.
6.3.2  Function of Accumbal Shati/Nat8l on Learning Memory 
and Emotional Behaviors
We have shown that nicotine reversed scopolamine-induced impairment in the pas-
sive avoidance task in rats through its action on the dopaminergic neuronal system 
(Nitta et al. 1994). The study did not mention which brain areas are important for 
the nicotine-potentiated learning ability. If altered DA levels triggered by Shati/
Nat8l overexpression had any effect on cognitive function, Shati/Nat8l-Tg mice 
would show potentiated cognitive function over normal mice. However, their cogni-
tive functions were not changed in Y maze or novel object tests (Figs. 6.8 and 6.9).
6.3.3  Function of Shati/Nat8l in Axon Outgrowth
In vitro studies were performed to evaluate the function of Shati/Nat8l in neuronal 
cells, since Shati/Nat8l mRNA signals were observed in all brain regions of mice 





















Fig. 6.18 Enhanced approach preference to novel object in Hip-Shati/Nat8l mice in the novel 
object recognition test. Hip-Shati/Nat8l mice significantly preferred to approach the novel object 
compared to Hip-mock mice. (**P < 0.01 vs. trial for each group, ##P < 0.01 vs Hip-Mock group, 
Student’s t-test)
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dentate granule cells, hippocampal pyramidal cells, and cerebellar granule cells. 
Neuronal cells of all brain regions showed positive Shati/Nat8l mRNA signals. 
Hippocampal neurons were selected for their easy evaluation and high cell density. 
Shati/Nat8l mRNA positive cells colocalized with NeuN (a marker for neurons)- 
positive cells but not with GFAP (a marker for astrocytes)- or Iba1 (a marker for 
microglia)-positive cells. These results show that Shati/Nat8l mRNA is only 
expressed in neuronal cells of the mouse hippocampus. An AAV vector containing 
Shati/Nat8l was transfected into primary cultured mouse neurons. Overexpression 
of Shati/Nat8l in primary cultured neurons induced axonal growth but not dendrite 
elongation. Treatment with a selective group II mGluR antagonist did not eliminate 
Shati/Nat8l-induced axon outgrowth, and NAAG itself did not induce axon out-
growth. Overexpression of Shati/Nat8l also increased the ATP content in the cul-
tured hippocampal neurons. These results suggest that neuronal Shati/Nat8l induces 
axon outgrowth via ATP synthesis independently of the mGluR3 signaling pathway. 
Shati/Nat8l is associated with microtubule structure when overexpressed in COS7 
cells and primary mouse cultured neurons (Toriumi et al. 2013). On the other hand, 
it was also reported that Shati/Nat8l co-localizes with a mitochondrial marker in 
SH-SH5Y cells (Ariyannur et  al. 2010), and that Shati/Nat8l is localized in the 
endoplasmic reticulum (Wiame et al. 2009). Shati/Nat8l may have novel functions 
in neuronal cells. NAA is produced in the mitochondria because it is associated with 
the tricarboxylic acid cycle (TCA) related to cell metabolism (Madhavarao et al. 
2003). The levels of NAA and ATP were increased in primary cultured neurons 
overexpressed with Shati/Nat8l. The TCA cycle produces ATP molecules at the 
highest rate in terms of cell metabolism, and ATP in the growth cone is known to 
promote neurite elongation in cultured neurons (Höpker et al. 1996). Neuronal den-
drite length in Shati/Nat8l KO mice was significantly shorter than in wildtype mice 
(Berent-Spillson et  al. 2004). Shati/Nat8l appears to play a major role in ATP- 
induced neurite elongation. Shati/Nat8l is an indicator of the stimulation of mGluR3. 
However, neither NAAG nor LY341495, the endogenous agonist of mGluR3 and an 
antagonist of mGluR3, respectively, affected axon outgrowth. Shati/Nat8l is thus 
associated with neurite elongation and the ATP synthesis pathway during NAA 
synthesis.
6.4  Shati/Nat8l and Psychiatric Disease
6.4.1  Patients with Depression and NAA
NAA is used as a biomarker of depression in specific regions of the human brain as 
it is an indicator of neuronal activity in 1H–MRS. NAA is significantly decreased in 
the anterior cingulate gyrus of patients with depression. Brain-derived neurotrophic 
factor (BDNF) has been reported to be one of the biomarkers for patients with 
depressive (Rogóż et al. 2017; Zhao et al. 2016). Anti-depressant drugs rescue the 
reduction in NAA, in addition to BDNF. Interestingly, BDNF mRNA is increased in 
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the prefrontal cortex, the NAc and the hippocampus in the brains of Shati/Nat8l KO 
mice (Furukawa-Hibi et al. 2012). Therefore, the changes in Shati/Nat8l and BDNF 
are not parallel, but independent. Although detailed mechanisms for the roles of 
Shati/Nat8l and/or BDNF in depression have not been clarified, they may neverthe-
less serve as reliable clinical markers.
6.4.2  Shati/Nat8l and Depressive Behaviors in Mice
Miyamoto et al. (2017) also demonstrated that striatal Shati/Nat8l induces depres-
sive behaviors. We produced mice overexpressing Shati/Nat8l in the striatum (Str- 
Shati/Nat8l mice) using an AAV vector, as described earlier. The Str-Shati/Nat8l 
mice showed depression-like behaviors in forced swimming and tail suspension 
tests (Miyamoto et al. 2017) as measured by prolonged immobility, indicating that 
Shati/Nat8l is an inducer of depression. These dysfunctions are cancelled by the 
anti-depressant drug, fluvoxamine, and the mGluR3 antagonist, LY341495. Shati/
Nat8l levels may be a factor in the vulnerability to stress. In the psychiatric field, 
mental diseases are often caused by two factors, genetic background and circum-
stance, and striatal Shati/Nat8l might thus represent one of the genetic factors.
6.4.3  Shati/Nat8l and Postpartum Depression
Postpartum depression is observed in about 13% of postpartum women, and is 
defined as a depressive disorder leading to a substantial impairment of daily life. It 
also has large impacts on the patients’ families, including the promotion of depres-
sive tendencies in the husband, the abuse or neglect of the child and/or delayed 
cognitive development or increased psychopathological issues in the child (Stumbo 
et al. 2015).
The occurrence of postpartum depression has been related to fluctuations in the 
levels of steroid hormones and glucocorticoids (cortisol in humans, corticosterone 
in animals) occurring during pregnancy and after delivery. Mice that received 
chronic ultra-mild stress (CUMS, procedure described in Fig. 6.19) demonstrated 
similar symptoms to the depression symptoms related to pregnancy in humans. 
Pregnant female mice subjected to CUMS could be a model for human postpartum 
depression, since the mice show prolonged immobility in forced swimming and tail 
suspension tests and anhedonia against sucrose (Shang et  al. 2016). The dams 
exposed to CUMS during gestation showed depression-like behavior during their 
postpartum period. Shati/Nat8l mRNA expression was increased in the striatum of 
the dams, but not in the NAc or the frontal cortex (Fig.  6.20). The relationship 
between Shati/Nat8l in the striatum and postpartum depression-like behavior 
induced by CUMS was investigated. The dams that overexpressed Shati/Nat8l spe-
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cifically in the bilateral striatum showed increased sensitivity to stress, and exacer-
bated depression-like symptoms such as despair behaviors.
We also carried out a clinical study among pregnant women. Serum concentra-
tions of Shati/Nat8l were measured in pregnant womean during late pregnancy and 
at 5 days and 1 month after delivery, respectively. The women were divided into two 
groups, a non-depressive and a depressive group, based on their score on the 
Edinburgh Postnatal Depression Scale (EPDS). Serum concentrations of Shati/
Nat8l were higher in the depressive group than in the non-depressive group at the 
time point before delivery (Nitta et al. unpublished data). Serum concentrations of 
Shati/Nat8l at the late pregnancy stage could be one predictive biomarker for post-
natal depression, and the appropriate preventive and early interventions might thus 
be undertaken for pregnant and postpartum women. We also measured serum con-
centrations of Shati/Nat8l in these women after delivery, but observed no significant 
differences.
Fig. 6.19 Chronic ultramild stress protocol. The chronic ultramild stress (CUMS) regimen con-
sisted of five ultramild stressors: period of cage tilt (30°), confinement in a small box (11 × 8 × 
8 cm), paired housing, one overnight period with soiled cage (50 ml water on 1 L paper pellet) and 
permanent light. The animals were also placed on a reversed light/dark cycle from Friday evening 
through the next Monday. This procedure was scheduled over a 1-week period and repeated 
throughout the period from the time of separation from the male until parturition
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6.5  Conclusions
Shati/Nat8l and NAA have various functions in the central nervous system. In addi-
tion to the neuronal system, Shati/Nat8l is also highly expressed in the adipose tis-
sue, and NAA pathway could similarly serve as an acetyl-CoA metabolizing 
mechanism in adipocytes (Pessentheiner et al. 2013). An increase in lipolysis fol-
lowed by an activation of β-oxidation can restore acetyl-CoA back to the mitochon-
dria. Lipid turnover can raise the oxidative potential of the brown fat cells and 
thereby boost the brown adipogenic phenotype. However, the physiological stimuli 
contributing to the regulation of the NAA pathway are unknown (Pessentheiner 
et al. 2013). These results suggest the possibility that Shati/Nat8l also plays a role 
in lifestyle diseases such as diabetes.
Because of their widespread occurrence in the human body, Shati/Nat8l and 
NAA have the potential to be used as treatment tools for a variety of diseases in the 
near future.
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Abstract Cerebrovascular disorders including ischemic stroke, intracerebral hem-
orrhage and subarachnoid hemorrhage are among the major clinical concerns for 
which effective therapies are poorly available. Accumulating lines of evidence indi-
cate that drugs acting on nicotinic acetylcholine receptors (nAChRs) may provide 
therapeutic effects on these disorders, based on their neuroprotective and anti- 
inflammatory actions. For example, the cholinergic neurotransmission in the central 
nervous system via nAChRs may function as an endogenous neuroprotective sys-
tem that prevents pathogenic events associated with ischemic stroke. On the other 
hand, exogenous administration of nicotine or nAChR agonists to experimental 
models of ischemic stroke has been reported to produce conflicting results (either 
protective or deleterious), which may be largely dependent on the different regi-
ments of drug treatments. With regard to intracerebral hemorrhage, preclinical find-
ings suggest that post-treatment with nAChR agonists is effective in alleviating 
brain tissue damage and neurological outcome. The beneficial actions of nAChR 
agonist have also been reported for an experimental model of subarachnoid hemor-
rhage, which should be confirmed by further investigations. Although smoking has 
been considered as an important risk factor for stroke episodes, specific targeting of 
the central nAChRs may prove to be an effective and novel strategy for the treat-
ment of diverse types of cerebrovascular disorders.
Keywords Nicotine · Cerebral infarction · Hemorrhagic stroke · Neuroprotection · 
Neuroinflammation · Acethylcholinesterase inhibitor
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Acetylcholine (ACh) has a long history of biomedical research as it is the first com-
pound that has been identified as a chemical neurotransmitter. In the periphery, 
motor neurons release ACh from their nerve terminals that innervate skeletal mus-
cles and transmit signals via activation of muscle type nicotinic acetylcholine recep-
tors (nAChRs) that are heteropentamers consisting of subunits named α1, β1, δ and 
ε. The cell bodies of sympathetic and parasympathetic postganglionic neurons 
express neuronal type of nAChRs composed of subunits distinct from those con-
tained in muscle nAChRs, such as α3α5β4 and α3α5β2β4. These nAChRs expressed 
in autonomic ganglia receive cholinergic inputs from preganglionic neurons. 
Postganglionic neurons of the parasympathetic nervous system also utilize ACh as 
a neurotransmitter, and various peripheral tissues receive the signals from these 
neurons mainly via muscarinic ACh receptors.
Cholinergic neurotransmitter system is also present in the brain, and nAChRs as 
well as muscarinic receptors are widely distributed throughout the central nervous 
system (Taly et al. 2009). A notable feature of nAChR-mediated signal transmission 
in the central nervous system is that it may mediate various functions in addition to 
the role in fast neurotransmission. That is, stimulation of nAChRs in central neurons 
affords cytoprotective and survival-promoting effects, as discussed in other chapters 
as well as in the literatures elsewhere (Akaike et al. 2010; Mudo et al. 2007). In 
addition, nAChR stimulation may be able to limit inflammation in the brain under 
pathological conditions, by directly regulating the cells involved in inflammatory 
reactions such as brain-resident microglia and infiltrating monocytes/macrophages 
(Shytle et al. 2004; Wang et al. 2003). The principal nAChR subtypes expressed in 
the central nervous system are homopentamers consisting of α7 subunits and het-
eropentamers consisting of α4 and β2 subunits, although nAChRs containing other 
types of subunits such as α3, α6, β3 and β4 are also expressed in a brain region- 
specific manner (Taly et al. 2009; Zoli et al. 2015). Differences in subunit composi-
tions between the peripheral nAChRs (either muscle type or neuronal type) and the 
central nAChRs may enable drug development specifically targeted for nAChRs in 
the brain, thereby avoiding adverse peripheral actions.
One of the major reasons for the central nAChRs being expected to serve as drug 
targets is that effective pharmacotherapies are not available at present for various 
kinds of central nervous system disorders associated with neurodegeneration. 
Among these disorders are cerebrovascular diseases resulting from the disruption of 
circulatory system that supplies blood flow to the brain. This chapter summarizes 
various preclinical and clinical findings related to the functions of nAChRs in regu-
lating pathological events associated with cerebrovascular disorders, and discusses 
the potentials of nAChR-related drugs as novel therapeutics combating these 
disorders.
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7.2  Overviews on Stroke Disorders
The term “stroke” represents diverse sets of disorders associated with disrupted 
cerebrovascular functions, which are classified into two major categories such as 
ischemic stroke and hemorrhagic stroke. Ischemic stroke is featured by interception 
of the blood flow in the brain tissues and, depending on the causes of interception, 
is further categorized into several different types including atherothrombotic brain 
infarction, cardiogenic embolism and lacunar stroke. In either case, the conse-
quences of hypoperfusion are shortage of supplies of oxygen and glucose to the 
brain parenchymal cells. Because energy demands of neurons are met almost 
entirely by the aerobic metabolism of glucose, even short periods of ischemic epi-
sodes may result in severe and irreversible brain tissue damage accompanied by 
neuron loss. Rescuing neurons from cell death is extremely difficult in the ischemic 
core region where oxygen/glucose supply is almost totally abolished. In contrast, in 
the peri-infarct or “penumbra” region where oxygen/glucose supply is decreased 
but not abolished, neuronal cell death displays at least in part the features of pro-
grammed cell death that occurs with a certain delay from the onset of the insults. 
Therefore, neuroprotection in the penumbra after ischemic insults may be possible 
if appropriate treatment strategies are established (Catanese et al. 2017). Practically, 
however, only a few drugs effective in brain tissue preservation are available at pres-
ent for the treatment of ischemic stroke (Table 7.1). A powerful approach is the 
reestablishment of blood flow by removal of the blood clot, and for this purpose, 
tissue plasminogen activator that promotes fibrinolysis is administered within 4.5 h 
after ischemic attack. Otherwise, edaravone is the sole choice of drugs in Japan 
intended for neuroprotection via its free radical-scavenging action.
The major types of hemorrhagic stroke are characterized by extravasation of 
blood into either brain parenchyma (intracerebral hemorrhage; ICH) or subarach-
noid space (subarachnoid hemorrhage; SAH), and both cases are accompanied by 
poor prognosis. Hemorrhagic stroke has pathological features quite distinct from 
those of ischemic stroke. In ICH, tissue damage is caused primarily by the blood 
flowing out of ruptured vessels into the brain parenchyma. Biological actions of 
blood constituents (particularly, proteases involved in the coagulation cascade), in 
addition to the physical damage of blood mass (so called the “mass effect”) are the 
main contributors of pathogenic events in ICH (Qureshi et  al. 2009). Currently, 
there are no established pharmacotherapies that are applicable after the occurrence 
of ICH events and are effective in neuroprotection (Katsuki 2010). Drugs such as 
glycerol and mannitol that manipulate plasma osmotic pressure and suppress brain 
edema formation may be available, but they still lack solid clinical evidence that 
justifies their application to ICH cases (Table 7.1). Clinical practice for SAH is in a 
similar situation to that for ICH, in the sense that direct neuroprotective pharmaco-
therapies are yet unavailable. Representative drugs used for the current treatment of 
SAH include fasudil, a Rho kinase inhibitor that prevents post-SAH vasospasm and 
ozagrel, an inhibitor of thromboxane A2 synthase that prevents platelet 
aggregation.
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Overall, although cerebrovascular disorders such as ischemic stroke, ICH and 
SAH are among the major issues of clinical concerns in the modern world, effective 
drug treatment strategies are, for the most part, far from established. With these situ-
ations under consideration, the following sections summarize the findings obtained 
from various kinds of efforts addressing the possibility of nAChRs as drug targets 
for the therapies of these disorders.
7.3  Ischemic Stroke and nAChRs
7.3.1  Roles of Endogenous Cholinergic System in Regulation 
of Ischemic Injury
7.3.1.1  Effects of nAChR Antagonists and Allosteric Modulators
Potential involvement of endogenous ACh in regulation of the pathogenic events in 
ischemic brain injury has been suggested by a study addressing the effects of nAChR 
antagonists in neonatal rats. In 7-day-old rats that underwent permanent occlusion 
of left common carotid artery, subcutaneous administration of subtype non-selective 
Table 7.1 Current drug therapies applicable after cerebrovascular events
Actions Drug name Grade Time window
For ischemic stroke
Thrombolytic Tissue plasminogen activator A Within 4.5 h
Urokinase B Within 6 h
Anticoagulant Argatroban B Within 48 h
Heparin C1 Within 48 h
Anti-platelet Aspirin A Within 48 h
Ozagrel B Within 5 days
Radical scavenger Edaravone B Within 24 h
Edema regulator Glycerol or mannitol C1
For ICH
Anti-hypertensive Calcium blockers and others B or C1
Edema regulator Glycerol or mannitol C1
Anti-fibrinolysis Tranexamic acid C1




Edema regulator Glycerol or mannitol C1
Anti-hypertensive Calcium blockers and others C1
According to the Japanese Guidelines for the Management of Stroke 2015 by the Japan Stroke 
Society. Grade A, strongly recommended; Grade B, recommended; Grade C1, may be considered 
for application but scientific evidence is insufficient
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nAChR antagonist mecamylamine or specific α7 nAChR antagonist methyllycacon-
itine just before induction of 1-h hypoxia aggravated neural damage in the hippo-
campus. Mecamylamine also aggravated neural damage in the cerebral cortex 
(Furukawa et  al. 2013). On the other hand, daily treatment with mecamylamine 
from 24 h after induction of 45-min transient global ischemia did not clearly affect 
the degree of cell death-related events such as the number of dead CA1 neurons and 
caspase-3 activity in the hippocampus in young adult mice (Ray et al. 2014).
PNU-120596 is a positive allosteric modulator of α7 nAChRs. The drug does not 
activate nAChRs by itself but inhibits desensitization and enhances activation of α7 
nAChRs by orthosteric agonists. In addition, the ACh degradation product choline 
may produce agonistic activity at nAChRs in the presence of positive allosteric 
modulators. Indeed, Kalappa et al. (2013) demonstrated that choline delayed oxy-
gen/glucose deprivation-induced injury of hippocampal CA1 neurons in vitro in the 
presence of PNU-120596, and PNU-120596 alone was not effective in the absence 
of choline in these experimental settings. The combined neuroprotective effect of 
choline and PNU-120596 was abolished by α7 nAChR antagonist methyllycaconi-
tine. The neuroprotective potential of PNU-120596 was also confirmed in 90-min 
transient focal ischemia in rats, where 3-h pretreatment or 30-min posttreatment 
with the drug significantly reduced the infarct volume (Kalappa et al. 2013). A com-
panion study by the same group reported that the effective time window of PNU- 
120596 administered intravenously was extended to 6 h after induction of middle 
cerebral artery occlusion (MCAO; Sun et al. 2013). These results strongly suggest 
that cholinergic neurotransmission functions as an endogenous neuroprotective sys-
tem against ischemic brain injury.
7.3.1.2  Effects of Acetylcholinesterase Inhibitors
The concentration of ACh in the synaptic cleft is tightly regulated by acetylcholin-
esterase (AChE), as ACh released from the nerve terminals is promptly degraded by 
this hydrolyzing enzyme. Accordingly, application of AChE inhibitors is a conven-
tional procedure to augment cholinergic neurotransmission. Several studies have 
addressed the effect of AChE inhibitors in rodent models of ischemic stroke. The 
earliest example is a study on donepezil, a centrally acting reversible inhibitor of 
AChE that is prescribed for amelioration of cognitive deficits in Alzheimer disease. 
An oral dose of donepezil (12 mg/kg) administered 2 h before or 1 h after induction 
of permanent MCAO in rats significantly reduced the infarct volume. The protective 
effect of donepezil was abolished by mecamylamine, suggesting the involvement of 
nAChR activation (Fujiki et al. 2005).
Another AChE inhibitor galantamine has also been reported to exhibit neuropro-
tective effects where the first administration was performed 24 h before or 3 h after 
induction of transient global ischemia in Mongolian gerbils by occlusion of the 
common carotid artery. The effects included an increase in surviving neurons, a 
decrease in terminal deoxynucleotidyl transferase-mediated dUTP nick end  labeling 
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(TUNEL)-positive cells/caspase-3-positive cells in hippocampal CA1 region and 
amelioration of spatial memory deficit, and these effects were attenuated by concur-
rent treatment with mecamylamine (Lorrio et al. 2007). A later examination using 
rat hippocampal slices subject to oxygen/glucose deprivation followed by reoxy-
genation revealed that a tyrosine kinase Janus kinase (Jak) 2 mediated the protective 
effect of galantamine by suppressing activation of nuclear factor (NF) -κB and 
induction of inducible nitric oxide synthase (iNOS) expression (Egea et al. 2012). 
Under similar experimental conditions in mouse hippocampal slices, 30-min pre-
treatment with nicotine (10–100 μM) reduced the extent of oxygen/glucose depriva-
tion-induced cell injury via activation of α7 nAChRs (Egea et al. 2007).
Wang et al. (2008) reported the effect of huperzine A, yet another AChE inhibi-
tor, in a rat model of transient focal cerebral ischemia. When administered at the 
onset or 6 h after transient MCAO, huperzine A restored regional cerebral blood 
flow, reduced infarct size and decreased neurological deficit score. Similar to the 
cases with galantamine, huperzine A inhibited NF-κB activation and decreased 
expression of proinflammatory factors such as tumor necrosis factor (TNF) -α, 
interleukin (IL) -1β, iNOS and cyclooxygenase (COX) -2. In addition, mecamyla-
mine abolished the inhibitory effect of huperzine A on glial cell activation and par-
tially reversed the reduction of infarct size by huperzine A.
Overall, these results obtained from the examinations on three different kinds of 
AChE inhibitors are consistent with the idea that endogenous ACh affords neuro-
protective effects against ischemia and ischemia-reperfusion injury, by activating 
nAChRs (Fig. 7.1).
7.3.1.3  Effect of Cholinergic Neuronal Activity
Vagus nerve stimulation is known to produce several therapeutic effects, and in the 
case of ischemia/reperfusion injury in rats, a brief episode of vagus nerve stimula-
tion ameliorates neurological deficits and reduces infarct volume (Sun et al. 2012). 
Jiang et al. (2014) addressed the mechanisms of the neuroprotective effects of vagus 
nerve stimulation. They confirmed that vagus nerve stimulation given at 30  min 
after transient focal ischemia was able to ameliorate neurological deficit and reduced 
the infarct volume at 24 h after reperfusion. They additionally found that the increase 
in the levels of several cytokines such as TNF-α, IL-1β and IL-6 in the peri-infarct 
region was significantly prevented by vagus nerve stimulation. Notably, vagus nerve 
stimulation prevented ischemia/reperfusion-induced loss of α7 nAChR expression 
in microglia in the penumbra region, and also reversed ischemia-induced decrease 
in the level of phosphorylated Akt. Although the evidence is at most indirect, these 
results imply the involvement of cholinergic neurotransmission pathway in the neu-
roprotective effect of vagus nerve stimulation.
As for microglial nAChRs, another line of findings in a positron emission tomog-
raphy imaging study implicates α4β2 nAChRs in the pathology of cerebral  ischemia. 





















Fig. 7.1 Enhancement of endogenous cholinergic signaling suppresses ischemia-induced patho-
logical events. Stimulation of nicotinic acetylcholine receptor (nAChR) by endogenous acetylcho-
line (ACh) can be enhanced either by inhibitors of acetylcholinesterase (AChE) such as donepezil 
that promote accumulation of extracellular ACh, or by positive allosteric modulators (PAMs) of 
nAChRs such as PNU-120596 that increase the affinity and/or efficacy of ACh on nAChRs. PAMs 
may also allow choline to exert agonistic activity on nAChRs. Stimulation of nAChRs, particularly 
of α7 subtype, by these drugs leads to phosphorylation/activation of a tyrosine kinase Janus kinase 
2 (Jak2). Although detailed mechanisms are yet to be identified, activated Jak2 may inhibit phos-
phorylation of inhibitor of κB (IκB) α, prevent ischemia-induced recruitment of nuclear factor κB 
(NF-κB; illustrated as subunits p65 and p50), and consequently, suppress NF-κB-dependent 
expression of pro-inflammatory factors (See Sects. 7.3.1.1 and 7.3.1.2 for details)
That is, α4β2 nAChR binding probed by 2[18F]-fluoro-A85380 and [11C]PK11195 in 
rat brains showed a transient increase that peaked at 7 days after MCAO (Martin 
et al. 2015). Increased expression of α4β2 nAChRs in microglia/macrophages and 
astrocytes was confirmed by immunohistochemical examinations. Although the 
functional significance of these changes in the expression of α4β2 nAChRs is 
unclear, this nAChR subtype in addition to α7 nAChRs may serve as a target for 
regulation of pathogenic events, particularly those involving inflammatory reac-
tions, in ischemic brain injury.
7 Nicotinic Acetylcholine Receptors in Regulation of Pathology of Cerebrovascular…
120
7.3.2  Effects of nAChR Agonists on Ischemic Injury
7.3.2.1  Positive Findings
As discussed in the previous section (Sect. 7.3.1), stimulation of nAChRs appears to 
provide neuroprotective effects against ischemia-reperfusion injury. Indeed, many 
lines of evidence indicate that nicotine and other compounds with direct agonistic 
activity on nAChRs can provide beneficial effects on experimental model of isch-
emic stroke (Table 7.2). Kagitani et  al. (2000) reported the effect of intravenous 
injection of nicotine in an intermittent transient ischemia model in rats. When rats 
with permanent ligation of bilateral vertebral arteries received transient and inter-
mittent occlusion (two to three times for 2 min at 2-min intervals) of bilateral carotid 
arteries, the blood flow in the hippocampus was substantially and reversibly 
decreased, and delayed death of hippocampal CA1 neurons was induced. 
Administration of nicotine (30–100 μg/kg) at 5 min before occlusion slightly but 
significantly improved hippocampal blood flow during occlusion and increased the 
number of surviving CA1 neurons. Kagitani et al. (2000) assume that the neuropro-
tecive effect of nicotine under these conditions is attributable to the vasodilative 
response induced by nAChR stimulation and resultant increase in regional blood 
flow in the hippocampus. On the other hand, the presence of nicotine during 
Table 7.2 Studies reporting beneficial effects of nicotine and nAChR agonists in experimental 
models of ischemia
Conditions of drug treatment References
Nicotine (30–100 μg/kg, i.v.) 5 min before transient ischemia in rats Kagitani et al. 
(2000)








Nicotine (0.5 mg/kg, i.p.) 2, 6 or 12 h after transient ischemia followed by 
three times administration per day for 7 days
Guan et al. 
(2015)
Nicotine hydrogen tartrate (0.3 mg/kg, s.c.) twice daily for 12 days, from 
2 days after focal devasularization
Gonzalez et al. 
(2006)
GTS-21 (1–5 mg/kg, i.p.) 30 min before, or GTS-21 (10 mg/kg, p.o.) twice 
daily for 2 weeks before, transient ischemia in Mongolian gerbils
Nanri et al. 
(1998b)




PNU-282987 (10 mg/kg, i.p.) 60 min after thrombotic stroke in mice Parada et al. 
(2013)
PHA-568487 (doses are not described, i.p.) immediately and 24 h after 
permanent ischemia in mice
Han et al. 
(2014b)
PHA-568487 (0.8 mg/kg, i.p.) 1 and 2 days after permanent ischemia in mice Han et al. 
(2014a)
See Sect. (7.3.2.1) in the main text for details of the findings in each study
i.p. intraperitoneal, i.v. intravenous, p.o. per oral, s.c. subcutaneous
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ischemic episodes may produce direct protective effects on neuronal cells. For 
example, in rat primary cortical cultures, 4-h hypoxia induced neuronal cell death 
with features of apoptosis. Application of nicotine (10–100 μM) during hypoxia 
prevented cell death probably via activation of both α7 nAChRs and α4β2 nAChRs, 
as methyllycaconitine (α7 nAChR antagonist) and dihydro-β-erythroidine (α4β2 
nAChR antagonist) blocked the effect of nicotine (Hejmadi et al. 2003).
GTS-21 is a synthetic nAChR agonist with fourfold higher affinity than nicotine 
for α7 nAChRs. The effect of GTS-21 and nicotine was tested on an ischemia- 
reperfusion model of Mongolian gerbils. When the drugs were injected intraperito-
neally at 30 min before 3-min forebrain ischemia, both GTS-21 (1–5 mg/kg) and 
nicotine (0.3–1.5 mg/kg) improved performance of animals in passive avoidance 
and attenuated cell death in the hippocampal CA1 region. GTS-21 (10 mg/kg) was 
effective also when orally administered twice daily for 2 weeks prior to ischemia 
(Nanri et al. 1998b). Moreover, the same group examined the effect of GTS-21 in 
rats with permanent occlusion of bilateral common carotid arteries (Nanri et  al. 
1998a). In this study, GTS-21 (1 or 10 mg/kg) was administered orally 24 h and 
30 min before induction of ischemia and then once daily for 2 months. GTS-21 
significantly prevented ischemia-induced histopathological changes in the cerebral 
cortex and in the white matter, and improved the cognitive function of rats as 
assessed by radial maze learning performance.
Potential involvement of endocannabinoid system in the neuroprotective effect 
of nicotine has been proposed by a study by Chen et  al. (2013). Intraperitoneal 
administration of nicotine hydrogen tartrate (1.2 mg/kg) transiently increased the 
tissue content of endocannabinoids 2-arachidonoylglycerol and anandamide in rats, 
which peaked at 2 h after administration. Nicotine also increased the protein expres-
sion level of cannabinoid CB1 receptor. Moreover, 2-h pretreatment with nicotine 
reduced the infarct volume and neurological deficit induced by 120-min MCAO, 
and these effects were significantly reversed by AM251, a CB1 receptor antagonist.
All of these findings mentioned above were obtained by pretreatment of nicotine 
or nAChR agonist. However, the pretreatment regimens of drugs are not very useful 
for combating stroke disorders, because in almost all clinical situations the drug 
therapy is available only after certain delay from the onset of acute stroke episodes. 
With these concerns, several studies have examined the effect of therapeutic treat-
ment with nAChR agonists on ischemic injury and indeed reported positive results. 
In a study by Guan et al. (2015), transient forebrain ischemia was induced in rats by 
four-vessel occlusion. Nicotine (0.5 mg/kg) was administered intraperitoneally at 2, 
6 or 12 h after induction of 15-min ischemia, and thereafter, three times per day for 
7 days. Under these conditions, nicotine significantly increased the number of sur-
viving CA1 neurons in the hippocampus. At the same time, nicotine was found to 
decrease the number of microglia and to prevent ischemia-induced up-regulation of 
mRNAs encoding TNF-α and IL-1β in the hippocampal CA1 region. In addition, 
nicotine inhibited proliferation of primary cultured microglia, and this effect was 
blocked by α7 nAChR antagonist α-bungarotoxin. These results suggest that attenu-
ation of proliferation and activation of microglia contribute to the neuroprotective 
effect of the therapeutic treatment with nicotine.























Fig. 7.2 Specific α7 nAChR agonist may afford anti-inflammatory effects via expression of heme 
oxygenase-1 (HO-1) in the brains after ischemic insults. According to Parada et al. (2010, 2013), 
application of α7 nAChR agonist such as PNU-282987 activates Jak2 in microglia/macrophages, 
which leads to activation of PI3-kinase (PI3K)/Akt pathway. By the action of Akt, a transcription 
factor Nrf2 is liberated from Keap1, escapes from degradation and binds to antioxidant response 
element (ARE) of the promoter regions of genes encoding phase II detoxifying enzymes such as 
HO-1 and the catalytic subunit of glutamate cysteine ligase (GCL-c). HO-1 induced by these sig-
naling pathways plays a critical role in inhibiting ischemia-associated pro-inflammatory responses 
such as the production of reactive oxygen species (ROS) and tumor necrosis factor-α (TNF-α)
Involvement of regulation of microglia in the therapeutic effect of α7 nAChR 
agonist has also been demonstrated in a photothrombotic ischemia model in mice 
(Parada et al. 2013). That is, intraperitoneal administration of PNU-282987 (10 mg/
kg) at 60 min after induction of thrombotic stroke using Rose Bengal decreased the 
volume of cortical infarct and diminished neurological deficits. Notably, the protec-
tive effect of PNU-282987 was abolished by concomitant treatment with heme oxy-
genase (HO) inhibitor or by deletion of HO-1 gene. In hippocampal slice culture 
preparation, PNU-282987 induced HO-1 expression, prevented cell death and atten-
uated production of reactive oxygen species and TNF-α resulting from oxygen/glu-
cose deprivation and reoxygenation. The protective effect of PNU-282987 in slice 
cultures was abolished by application of HO inhibitor or by depletion of microglia 
from the slices. These results propose HO-1 as a key mediator of the neuroprotec-
tive and anti-inflammatory effect of microglial α7 nAChR stimulation (Fig. 7.2).
Using another α7 nAChR agonist PHA-568487, Han et al. (2014b) examined the 
role of microglia/macrophage phenotypes. Mice were treated with PHA-568487 
immediately and 24 h after permanent MCAO. The treatment significantly reduced 
the infarct volume and partially ameliorated behavioral performance. The peri- 
H. Katsuki and K. Matsumoto
123
infarct region of PHA-568487-treated mice contained a smaller number of 
 pro- inflammatory microglia/macrophages (so called “M1” phenotype identified as 
CD11b+Iba-1+) and a larger number of anti-inflammatory microglia/macrophages 
(so called “M2” phenotype identified as CD206+Iba-1+), than that of saline-treated 
mice (Han et al. 2014b). Similar protective effect on neuron survival and regulatory 
effect on microglia/macrophage phenotypes were obtained when administration of 
PHA-568487 (0.8 mg/kg) was initiated at 1 day after permanent MCAO (Han et al. 
2014a). These results suggest that the regulation of microglia/macrophage pheno-
types underlies the neuroprotective effect of α7 nAChR agonist against ischemic 
injury.
The effect of repeated administration (twice daily for 12 days) of low dose nico-
tine (0.3 mg/kg as nicotine hydrogen tartrate) has been reported in a rat focal isch-
emia model prepared by unilateral devascularization in the motor cortex. The 
findings are notable in the sense that post-treatment started as late as 48 h after 
ischemic surgery was proven to be effective in promoting the recovery of motor 
performance. Interestingly, nicotine treatment increased the morphological com-
plexity of dendritic processes of layer V pyramidal neurons of the cingulate cortex, 
both in control rats and ischemia-induced rats (Gonzalez et al. 2006). Therefore, 
nicotine-induced enhancement of dendritic growth of cortical neurons might facili-
tate the recovery of motor functions.
7.3.2.2  Negative Findings
Under several experimental conditions, nicotine has been reported to produce no 
effect or even worsen the outcome of ischemic events. For example, Lim et  al. 
(2009) examined the effect of nicotine on rehabilitation following devascularization 
in the forelimb area of the motor cortex in rats. Oral administration of nicotine 
(0.3 mg/kg, twice daily for 3 weeks starting from 1 week before stroke induction) 
did not improve motor function recovery.
It should be noted that virtually all studies reporting the deleterious effect of 
nicotine on ischemic brain injury were aimed to reveal potential adverse effects of 
smoking on cerebrovascular disorders, and therefore that these studies generally 
employ long-term and/or continuous pretreatment regimen for nicotine administra-
tion (Table 7.3). An early study by Wang et al. (1997) examined the effect of nico-
tine (4.5  mg/kg/day) administered subcutaneously for 14  days by osmotic 
minipumps, prior to induction of ischemic insults in rats. Nicotine decreased the 
blood flow in the penumbra region during reperfusion after transient MCAO, wors-
ened neurological deficit, and increased the injury and edema volume. Interestingly, 
nicotine-treated rats exhibited depletion of tissue plasminogen activator in cerebral 
capillaries, which might be causally relevant to the poor recovery of the blood flow 
after reperfusion and to the resultant exacerbation of brain tissue injury. In a more 
recent study, the effect of 4-week continuous treatment with nicotine (2 or 4 mg/kg/
day, subcutaneously by osmotic pumps) prior to 2-h transient MCAO was examined 
(Li et  al. 2016). Nicotine at both doses significantly increased the infarct size, 
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although the neurological deficit seems to be ameliorated by the treatments. Authors 
attributed the exacerbation of pathological changes by nicotine to enhanced oxida-
tive stress, as the cerebral cortex and the cerebral arteries in nicotine-treated rats 
exhibited decreased expression levels of Mn superoxide dismutase and mitochon-
drial uncoupling protein-2, as compared to those in control rats.
Bradford et  al. (2011) examined the effect of chronic nicotine treatment with 
special reference to inflammatory responses. In their study, 14-day pretreatment 
with nicotine (0.5–2  mg/kg/day, subcutaneously by osmotic pumps) dose- 
dependently increased the infarct volume and brain water content at 3 days after 
30-min MCAO. In addition, nicotine given at 2 mg/kg/day worsened neurological 
outcome and decreased the survival rate of mice. They also demonstrated that 
14-day treatment with nicotine (2 mg/kg/day), either alone or in combination with 
ischemia/reperfusion insults, markedly increased the expression of various cyto-
kines (including TNF-α and IL-1β) and chemokines (including CCL2 and CXCL5) 
in brain tissue and isolated brain microvessels. Consistent with these observations, 
ischemia/reperfusion-induced infiltration of neutrophils and monocytes was aug-
mented by 14-day pretreatment with nicotine.
In a study on permanent MCAO in mice, subcutaneous delivery of 4.5 mg/kg/
day for 3 weeks has been shown to exacerbate brain edema (Paulson et al. 2010). 
Exacerbation of brain edema was also observed when nicotine was intraperitoneally 
administered 1  h before MCAO.  Although the precise mechanisms of action of 
nicotine in these experimental settings have not been addressed, the effect might be 
relevant to nicotine-induced altered functions of Na+, K+, 2Cl− cotransporters in the 
blood-brain barrier (Paulson et al. 2006).
Table 7.3 Studies reporting deleterious effects of nicotine in experimental models of ischemia
Conditions of drug treatment References
Nicotine (4.5 mg/kg/day, s.c.) continuous infusion for 14 days prior to 
transient ischemia in rats
Wang et al. 
(1997)
Nicotine (2 and 4 mg/kg/day, s.c.) continuous infusion for 4 weeks prior to 
transient ischemia in rats
Li et al. (2016)
Nicotine (2 mg/kg/day, s.c.) continuous infusion for 14 days prior to 
transient ischemia in mice
Bradford et al. 
(2011)
Nicotine (187.5, 562.5 or 1125 μg/kg, i.p.) 1, 3 or 6 h, respectively, before 
permanent ischemia in mice
Paulson et al. 
(2010)
Nicotine (4.5 mg/kg/day, s.c.) continuous infusion for 1 or 3 weeks prior to 
permanent ischemia in mice
Paulson et al. 
(2010)
Nicotine (1 mg/kg, i.p.) daily injection for 15 days prior to transient 
ischemia in female rats
Raval et al. 
(2009)
Nicotine (4.5 mg/kg/day, s.c.) continuous infusion for 16 days prior to 
transient ischemia in female rats
Raval et al. 
(2011)
Nicotine (4 μg/kg/min, s.c. To dams) continuous infusion from day 4 of 
gestation to day 10 after birth in rats
Li et al. (2012)
See Sect. 7.3.2.2 in the main text for details of the findings in each study
i.p. intraperitoneal, s.c. subcutaneous
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Fig. 7.3 Nicotine may produce harmful influences on ischemia-related pathological events. Long- 
term pretreatment with nicotine by continuous infusion is generally shown to aggravate the pathol-
ogy of ischemic stroke in experimental animals. Multiple mechanisms are postulated to play 
important roles in these harmful consequences as summarized here (See Sect. 7.3.2.2 for details. 
SOD superoxide dismutase, t-PA tissue plasminogen activator, UCP-2 uncoupling protein-2)
Potential interaction of the effect of nicotine with that of estrogen has been pro-
posed by studies using ovariectomized rats. Daily intraperitoneal injection of 1  mg/
kg nicotine for 15 days to female rats with normal menstrual cycle accelerated neu-
ron loss in the hippocampal CA1 region at 7 days after 10-min ligation of carotid 
artery. In addition, ovariectomy per se exacerbated ischemia-induced loss of CA1 
neurons and occluded the effect of repeated nicotine treatment (Ravel et al. 2009). 
These results suggest that the neuroprotective effect of endogenous estrogen is can-
celled by nicotine. Indeed, oral contraceptives that lowered the plasma level of 
17β-estradiol exacerbated ischemia-induced loss of hippocampal CA1 neurons, 
synergistically with 16-day treatment of nicotine. Abolishment by nicotine of the 
neuroprotective effect of 17β-estradiol on oxygen/glucose deprivation-induced 
injury, as well as attenuation by nicotine of estrogen receptor-mediated recruitment 
of cyclic AMP response element binding protein, was also demonstrated in rat hip-
pocampal slice cultures (Ravel et al. 2011).
Finally, neonatal male rats continuously exposed to nicotine during the perinatal 
period (from day 4 of gestation to day 10 after birth) exhibited larger infarct size 
after hypoxic-ischemic injury than control rats. The augmented pathology may be 
attributable to altered angiotensin II signaling resulting from decreased expression 
of angiotensin II AT2 receptors (Li et al. 2012).
Taken together, long-term continuous exposure to nicotine may aggravate the 
consequences of ischemic stroke, by altering expression and function of various 
cytoprotective proteins, pro-inflammatory factors, transporters and receptors in the 
brain (Fig. 7.3).
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7.4  Hemorrhagic Stroke and nAChRs
7.4.1  Effects of nAChR Agonists on Intracerebral Hemorrhage 
(ICH)
ICH is initiated by the rupture of blood vessels within the brain parenchyma and 
bleeding from ruptured vessels. The mechanisms involved in brain tissue injury 
after ICH include several distinct features from those involved in ischemic brain 
injury. A notable feature of ICH is that blood constituents may exert specific bio-
logical actions on neurons and glial cells in the brain and make substantial contribu-
tion to the complicated pathogenic events. Thrombin, a serine protease that normally 
functions in the coagulation cascade, is a remarkable example because it can stimu-
late several members of protease-activated receptors (PARs) that are expressed in 
various cell types including neurons, astrocytes and microglia. Indeed, several lines 
of evidence indicate that thrombin may contribute to the pathogenesis of experi-
mental ICH models. For example, a thrombin inhibitor argatroban reduces edema 
and inflammation associated with ICH in rats (Kitaoka et al. 2002; Nagatsuna et al. 
2005).
To facilitate investigations on the pathogenic mechanisms of ICH and explora-
tion of therapeutic drug candidates, we developed an in  vitro neurodegeneration 
model of ICH, using organotypic brain slice cultures (Fujimoto et al. 2006). Coronal 
slices containing the cerebral cortex and the striatum were prepared from neonatal 
rats, and after cultivation for 9–11 days, they were treated with thrombin. Thrombin 
induced delayed neuronal cell death in the cerebral cortex and tissue shrinkage 
accompanied by cell death in the striatum. Results of various pharmacological inter-
ventions revealed the mechanisms involved in cell and tissue injuries in the cerebral 
cortex and the striatum. With regard to the tissue injury in the striatum, stimulation 
of PAR-1 and recruitment of mitogen-activated kinase (MAPK) families plays a 
critical role. In addition, thrombin-induced striatal tissue injury was abrogated by 
deletion of tissue microglia prior to thrombin treatment. Importantly, potential 
involvement of microglial MAPK activation in tissue injury was confirmed in a rat 
model of ICH induced in the striatum by collagenase injection (Ohnishi et al. 2007), 
which substantiates the validity of slice culture experiments as a model of ICH 
pathogenesis.
Then we examined the effect of nicotine on thrombin neurotoxicity in cortico- 
striatal slice cultures (Ohnishi et al. 2009). In this set of experiments, cortico-striatal 
slices were prepared and cultured for 11 days in serum-containing medium, main-
tained for 1 day in serum-free medium, and then treated with 100 U/ml thrombin in 
serum-free medium for 3 days. When applied to slice cultures for the entire culture 
period of 15 days, nicotine (3–30 μM) attenuated thrombin-induced shrinkage of 
striatal tissue and prevented thrombin-induced neuron loss in the cerebral cortex. 
Thrombin-induced increase in the number of microglia in the cortex was also atten-
uated by nicotine in a concentration-dependent manner. The cytoprotective effect 
and anti-inflammatory effect of nicotine were largely abrogated by mecamylamine 
H. Katsuki and K. Matsumoto
127
(non-selective nAChR antagonist), methyllycaconitine (α7 nAChR antagonist) and 
dihydro-β-erythroidine (α4β2 nAChR antagonist), suggesting the involvement of 
both of the major central nAChR subtypes.
With these lines of evidence in vitro, we moved onto investigations in vivo to 
address the effect of nicotine in a mouse model of ICH prepared by injection of col-
lagenase (that disrupts vascular basement membrane) into the striatum. Based on 
the findings in slice culture preparations, we initially examined the effect of long- 
term pretreatment of nicotine (1 mg/kg, intraperitoneally once per day for 1 week) 
and obtained cytoprotective effect of nicotine on striatal neurons within the hema-
toma assessed at 3  days after induction of ICH (our unpublished observations). 
However, the long-term pretreatment regimen is unrealistic for ICH pharmacother-
apy in clinical practice, so we next examined the effect of nicotine in a post- treatment 
regimen. ICH was induced by collagenase injection into the striatum, and nicotine 
tartrate dehydrate (1 and 2 mg/kg as nicotine free base) was first administered intra-
peritoneally 3 h after ICH induction. Nicotine treatment was repeated three times in 
total, at 24  h intervals. Under these conditions, nicotine (2  mg/kg) partially but 
significantly attenuated the decrease in the number of striatal neurons in the central 
region of hematoma at 3 days after ICH. ICH-induced increase in TUNEL-positive 
cells that may represent apoptotic cell death was also inhibited by nicotine treat-
ment. Interestingly, nicotine decreased expression of a pro-apoptotic protein Bax in 
the striatum and consequently increased the relative expression level of Bcl-2, an 
anti-apoptotic protein. Therefore, counteraction of the apoptotic cell death events 
may underlie the neuroprotective effect of nicotine in ICH (Fig. 7.4). In the peri- 
hematoma region, the pathological features were accumulation of activated microg-
lia/macrophages and increase in oxidative stress (as revealed by nitrotyrosine 
immunoreactivity), both of which were significantly attenuated by nicotine treat-
ment. Moreover, nicotine at 2 mg/kg alleviated neurological deficits observed after 
ICH (Hijioka et al. 2011). When the effect of α7 nAChR agonist PNU-282987 (3 
and 10  mg/kg) was tested in the same treatment regimen as nicotine, the drug 
showed neuroprotective and anti-inflammatory effects, whereas α4β2 nAChR ago-
nist RJR-2403 showed no significant therapeutic effect (Hijioka et al. 2012). These 
results suggest that α7 nAChR is the major nAChR subtype responsible for the 
therapeutic effect of nicotine in ICH.
Consistent with our findings, Krafft et al. (2012) reported the therapeutic effect 
of PNU-282987 (12  mg/kg) and another α7 nAChR agonist PHA-543613 (4 or 
12 mg/kg) in a mouse model of ICH based on autologous blood infusion into the 
striatum. In their study, agonists were administered intraperitoneally at 1 h after 
ICH surgery. These drug treatments improved behavioral outcome and prevented 
brain edema formation at 24 h after surgery. The effect of PHA-543613 was coun-
teracted by a phosphoinositide 3-kinase (PI3K) inhibitor wortmannin. In addition, 
PHA-543613 increased the level of phosphorylated Akt and prevented ICH-induced 
activation of glycogen synthase kinase (GSK) -3β and caspase-3, which was also 
cancelled by wortmannin. These results indicate that the therapeutic effect of α7 
nAChR stimulation is mediated by PI3K/Akt pathway leading to inactivation of 


























Fig. 7.4 nAChRs expressed in distinct types of cells may contribute to the therapeutic effects of 
nAChR agonists against brain tissue damage associated with intracerebral hemorrhage (ICH). 
Stimulation of nAChRs (probably α7 nAChRs) by nicotine in neurons results in decreased expres-
sion of a pro-apoptotic protein Bax, thereby inhibits ICH-induced apoptotic neuronal cell death 
(Hijioka et al. 2011, 2012). On the other hand, specific α7 nAChR agonists such as PNU-282987 
and PHA-543613 may stimulate α7 nAChRs in endothelial cells, and recruit Jak2/PI3K/Akt path-
way as in the case with Fig. 7.2. Activated Akt phosphorylates and inactivates glycogen synthase 
kinase-β (GSK-3β) and thereby prevents phosphorylation and degradation of β-catenin, a compo-
nent of tight junctions. Stabilization of tight junctions may be relevant to the maintenance of 
integrity of the blood-brain barrier after hemorrhagic insults (Krafft et al. 2013)
GSK-3β and prevention of apoptotic cell death events. A follow-up study by the 
same group (Krafft et al. 2013) showed that PHA-543613-induced inactivation of 
GSK-3β led to stabilization of β-catenin and tight junction proteins such as claudin-
 3 and claudin-5, which may be relevant to the preservation of blood-brain barrier 
integrity and to the inhibition of edema formation by the drug (Fig. 7.4). A more 
recent study addressed the role of Jak – signal transducer and activator of transcrip-
tion (STAT) signaling pathway in the effect of α7 nAChR stimulation (Krafft et al. 
2017). That is, α7 nAChR agonist PHA-543613 augmented phosphorylation/activa-
tion of Jak2 and STAT3 in a mouse model of ICH by autologous blood infusion, and 
Jak2 inhibitor AG490 reversed the brain tissue-preserving effect of PHA-543613 in 
a rat model of ICH based on collagenase injection.
The main focus of the brain region in preclinical ICH studies has been the stria-
tum (the caudate putamen), because the putamen is one of the most susceptible 
brain regions with regard to hypertension-associated ICH in humans, and also 
because this region is relatively easy of access by surgical operations in experimen-
tal animals. On the other hand, the relative incidence of non-hypertension- associated 
ICH that occurs in the cerebral cortex (cortical or lobar hemorrhage) has been 
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increasing in recent years, but therapeutic approaches for cortical hemorrhage have 
been poorly explored. We addressed whether nicotine can provide therapeutic effect 
in cortical hemorrhage in mice (Anan et al. 2017). Collagenase injection into the 
parietal cortex induced hemorrhage, which resulted in motor deficits in mice. Daily 
intraperitoneal administration of nicotine (1 and 2 mg/kg), with the first injection 
given at 3  h after ICH induction, significantly improved motor performance. 
Histochemical examinations on brain sections obtained 3 days after ICH demon-
strated that nicotine (2 mg/kg) significantly increased the number of surviving neu-
rons in the hematoma and decreased the number of activated microglia/macrophages 
in the peri-hematoma region. Notably, the neuroprotective effect of nicotine on cor-
tical hemorrhage was blocked by antagonists at α7 nAChRs (methyllycaconitine) 
and α4β2 nAChRs (dihydro-β-erythroidine). Therefore, the neuroprotective effect 
of nicotine in cortical hemorrhage may be mediated by both of these two receptor 
subtypes, unlike in the case with putaminal hemorrhage where α7 nAChR plays a 
dominant role.
7.4.2  Effects of nAChR Agonists on Subarachnoid 
Hemorrhage (SAH)
SAH is one of the major kinds of hemorrhagic stroke distinct from ICH. SAH is 
characterized by extravasation into the subarachnoid space, which mainly results 
from the rupture of intracranial aneurysm. At present, there is only one experimen-
tal study addressing the effect of nAChR agonist on the outcome of SAH. Duris 
et al. (2011) examined the effect of α7 nAChR agonist PNU-282987 on an endovas-
cular perforation model of SAH in rats, by administering the drug intraperitoneally 
at 1 h after perforation surgery. They showed that PNU-282987 at 12 mg/kg amelio-
rated neurological function at 24 and 72 h after SAH induction, and prevented the 
increase in brain water content at 24 h. As in the case with ICH (Krafft et al. 2012), 
α7 nAChR stimulation enhanced phosphorylation/activation of Akt and prevented 
SAH-induced activation of caspase-3, which was abrogated by PI3K inhibitor wort-
mannin. Therefore, α7 nAChRs may serve as a promising drug target also for SAH 
therapy, although detailed pharmacological profiles of neuroprotection should be 
revealed by further investigations.
7.5  Nicotine, Smoking and Stroke: Potential Associations
As nicotine is the major pharmacoactive compound contained in tobacco that can 
directly modify the functions of the nervous system and the cardiovascular system, 
potential relationship between smoking and cerebrovascular disorders suggested by 
various epidemiological investigations may deserve considerations. It should be 
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noted, however, that tobacco smoke contains many (over 4000) kinds of chemicals 
and the adverse consequences of smoking are not necessarily and solely attributable 
to the biological actions of nicotine.
With regard to ICH, current smoking is among the modifiable risk factors (An 
et al. 2017; Ariesen et al. 2003), although smoking (both current use and history of 
use) may be more strongly associated with ischemic lacunar stroke than with ICH 
(Kaplan et al. 2014). Race/population-specific influences of smoking on ICH inci-
dence have also been reported. A study by Faigle et al. (2016) showed that smoking 
was one of the predictors of mortality in white populations, but not black popula-
tions, of ICH patients. In addition, meta-analyses of the risk factors for ICH and 
ischemic stroke suggest that smoking is a risk factor more frequent in ischemic 
stroke in white population but not in Chinese population (Tsai et al. 2016). In any 
cases, whether or not nicotine is responsible for the increased risk of ICH associated 
with smoking is unknown.
Several reports addressed the association of smoking and nicotine exposure with 
the risk and the outcome of SAH.  In a case-control study on population of 
18–49  years of age, exposure to nicotine in pharmaceuticals as well as current 
smoking has been identified as a risk factor of SAH (Broderick et al. 2003). In addi-
tion, a retrospective analysis of the size of ruptured intracranial aneurysm of SAH 
patients demonstrated that the average maximal aneurysm diameter in patients with 
combined history of hypertension and smoking was significantly smaller than in 
patients with hypertension only. The latter results suggest that smoking lowers the 
threshold of aneurysm rupture in combination with hypertension. On the other 
hand, a systematic review on four independent studies concerning nicotine replace-
ment therapy for tobacco smoking in SAH patients has concluded that the therapy 
in the first 21 days does not appear to be associated with increased risk of poor 
functional outcome, death and vasospasm (Turgeon et al. 2017). Actually, there are 
reports showing better functional outcome (Carandang et al. 2011) and lower risk of 
death (Seder et al. 2011) in patients with nicotine replacement therapy than those 
without the therapy. These results imply the beneficial effects of nicotine against 
SAH pathology in humans, although more detailed and well-designed studies with 
larger sample size are clearly required for drawing definitive conclusion.
Current smoking has long been known as a strong risk factor for the incidence of 
ischemic stroke (Hawkins et al. 2002). Increased number of cigarettes smoked per 
day has been associated with increased risk of ischemic stroke in a study on 
15–49 year-old women (Bhat et al. 2008). With regard to the disease outcome, how-
ever, “smoker’s paradox” has been reported in ischemic stroke as in the case with 
myocardial infarction (Ovbiagele and Saver, 2005). For example, a study on 4305 
cases of ischemic stroke patients, smoking was associated with lower all-cause in- 
hospital mortality (Ali et al. 2013). In another study on ischemic stroke patients that 
received thrombolytic therapy by intravenous tissue plasminogen activator, smokers 
had better functional outcome in addition to better recanalization and reperfusion, 
as compared to non-smokers (Kufner et  al. 2013). A recent investigation on the 
potential causes of smoker’s paradox showed that smokers experienced their first 
ever stroke 11 years younger than non-smokers, which might explain in part the 
H. Katsuki and K. Matsumoto
131
association between smoking and better functional outcome (Hussein et al. 2017). 
Notably, subgroup analysis in the same study detected favorable outcome of current 
smokers in women at or older than 65 years (Hussein et al. 2017).
Overall, although smoking may be considered as an important risk factor for the 
occurrence of stroke episodes, contribution of nicotine to the increased risk is 
unclear. On the other hand, several lines of evidence indicate that smoking or nico-
tine treatment (as the replacement therapy) might result in favorable outcome in 
several particular cases of stroke.
7.6  Conclusion and Future Perspectives
The functional roles of nAChRs in the central nervous system beyond neurotrans-
mission have been increasingly recognized. Neuroprotective and anti-inflammatory 
effects of nicotine and other nAChR agonists are of particular interest for the devel-
opment of novel pharmacotherapies against various kinds of disorders associated 
with neurodegeneration. This chapter summarized preclinical and clinical findings 
suggesting the relationship between nicotine/nAChRs and principal types of cere-
brovascular disorders such as ischemic stroke, ICH and SAH.
Several lines of experimental approaches using in  vitro culture system and 
in vivo disease models indicated the neuroprotective and ant-inflammatory roles of 
endogenous cholinergic system against pathogenic events in ischemic stroke. These 
include exacerbation of pathology by nAChR antagonists, as well as amelioration of 
pathology by AChE inhibitors and positive allosteric modulators of nAChRs. In 
contrast, studies addressing the effects of nAChR agonists on experimental isch-
emic injury models gave conflicting results, where some studies reported beneficial 
effects but others demonstrated deleterious effects. A possible cause of these dis-
crepancies is the different procedures employed for drug administration. Namely, 
virtually all studies reporting the deleterious effects of nicotine performed continu-
ous delivery by osmotic pumps or repeated daily administration of nicotine at rela-
tively high doses. On the other hand, studies reporting beneficial effects of nicotine 
and nAChR agonists generally performed daily administration of the drugs for a few 
times or low-dose administration in the case of long-term treatment. The complex 
influences of nicotine and nAChR agonists on disease consequences of experimen-
tal ischemia models might be relevant to the complicated influences of smoking on 
the risk and the outcome of ischemic stroke patients that include “smoker’s 
paradox”.
The number of investigations on hemorrhagic stroke is much smaller than that on 
ischemic stroke, but distinct lines of experimental evidence are consistent with the 
idea that nAChRs may serve as a target for ICH therapy. Post-treatment of animal 
models of striatal (putaminal) hemorrhage with nicotine or α7 nAChR agonists 
ameliorates neurological outcome and alleviates various neuropathological changes. 
Involvement of α4β2 nAChRs in addition to α7 nAChRs in neuroprotection is sug-
gested in the case of cortical (lobar) hemorrhage model. Although smoking has been 
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reported as a risk factor for mortality in particular populations of ICH patients, its 
relationship with nicotine is not evident. Accordingly, nicotine and subtype-specific 
nAChR agonists may be considered as novel therapeutic drugs for ICH. This pro-
posal is particularly important because no effective pharmacotherapies for ICH 
directly aiming at brain tissue preservation have been established to date.
There is only one experimental study addressing the effect of nAChR agonist in 
SAH model, but according to the results, α7 nAChRs may serve as a promising 
target for therapy also for SAH. Interestingly, nicotine replacement therapy may be 
safely applicable to, and might produce beneficial outcome in, smokers after SAH.
An important concern at present is the shortage of information regarding the cel-
lular and molecular mechanisms of actions of nicotine and nAChR agonists under 
stroke conditions, although a few studies have proposed potential involvement of 
several signaling pathways such as PI3K/Akt and Jak/STAT.  Elucidation of the 
detailed mechanisms of neuroprotective and anti-inflammatory actions, in conjunc-
tion with determination of the ideal drug treatment regimens, may pave the way for 
developing novel strategies for treatment of distinct types of cerebrovascular disor-
ders, by targeting nAChRs and nAChR-mediated neurotransmission.
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Abstract Both of the two most common neurodegenerative disorders, namely 
Alzheimer’s disease (AD) and Parkinson’s disease (PD), have multiple lines of evi-
dence, from molecular and cellular to epidemiological, that nicotinic transmission 
is implicated in those pathogenesis. This review presents evidences of nicotinic ace-
tylcholine receptor (nAChR)-mediated protection against neurotoxicity induced by 
β amyloid (Aβ), glutamate, rotenone, and 6-hydroxydopamine (6-OHDA) and the 
signal transduction involved in this mechanism. Our studies clarified that survival 
signal transduction, α7 nAChR-Src family-PI3K-AKT pathway and subsequent 
upregulation of Bcl-2 and Bcl-x, would lead to neuroprotection. Recently analyzing 
the properties of galantamine, we clarified the neuroprotective pathway, which is 
mediated by enhancement of microglial α7 nAChR resulting in upregulation of Aβ 
phagocytosis. Galantamine sensitizes microglial α7 nAChRs to choline and induce 
Ca2+ influx into microglia. The Ca2+-induced intracellular signaling cascades may 
then stimulate Aβ phagocytosis through the actin reorganization. This discovery 
would facilitate further investigation of possible nAChRs enhancing drugs targeting 
not only neuronal but also microglial nAChRs.
Keywords Alzheimer’s disease · Parkinson’s disease · Nicotine · nAChR · β amyloid 
· Glutamate · Microglia · Phagocytosis
8.1  Introduction
Alzheimer’s disease (AD) pathology is characterized by the presence of two hall-
marks, senile plaques (SP) and neurofibrillary tangles (NFT), and by extensive neu-
ronal loss (Giannakopoulos et al. 1996). β amyloid (Aβ) is a major element of SP 
and one of the candidates for the cause of the neurodegeneration found in AD. It has 
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been shown that the accumulation of Aβ precedes other pathological changes and 
causes neurodegeneration and neuronal death in vivo (Yankner et al. 1990). Several 
mutations of the Aβ precursor protein (APP) are found in familial AD, and these 
mutations are involved in amyloidogenesis (Citron et al. 1992). Also, familial AD 
mutations of presenilin 1 (PS-1) enhance the generation of Aβ 1-42 (Tomita et al. 
1997). The cerebral cortex contains a dense plexus of cholinergic axon terminals 
that arise from the cells of the basal forebrain including the nucleus basalis of 
Meynert (Bigl et al. 1982; Mesulam et al. 1983). Degeneration of this cholinergic 
projection is recognized as one of the most prominent pathological changes in AD 
brain (Whitehouse et al. 1981; Rosser et al. 1982). In AD, the cholinergic system is 
affected, and a reduction in the number of nicotinic acetylcholine receptor (nAChR) 
has been reported (Shimohama et  al. 1986; Whitehouse and Kalaria 1995). ACh 
receptors are classified into two groups; nAChRs and muscarinic ACh receptors 
(mAChRs). In the brain, nAChRs show additional complexity, as there are multiple 
receptor subtypes with differing properties and functions (Clarke et  al. 1985; 
Lindstrom et al. 1995). At least nine α subunits (α2–α7, α9, and α10 in mammals; 
α8 in chicks) and three β subunits (β2–β4) have been identified in the brain. Both α 
and β subunits are required to form functional heteropentametric receptors, with the 
exception of α7–10 subunits, which apparently form functional homopentameric 
receptors. In the brain, α7 homometric and α4β2 heterometric nAChRs are the two 
major subtypes. Both α4β2 and α7 subtypes have been implicated in the mechanism 
of neuroprotection provided by nicotine (Kihara et al. 1998, 2001). It is also known 
that Aβ binds very strongly to α7 nicotinic acetylcholine receptor (nAChR) (Wang 
et  al. 2000) and up-regulation of α7 nAChR is observed in transgenic mice co- 
expressing mutant (A246E) human presenilin 1 and (K670N/M671L) APP (Dineley 
et al. 2002). Multiple lines of evidence show that neuronal nAChRs are involved in 
synaptic plasticity as well as in neuronal survival and neuroprotection. Moreover, 
presynaptic nAChRs can modulate the release of many neurotransmitters, including 
dopamine (DA), noradrenaline, serotonin, ACh, γ-aminobutyric acid (GABA), and 
glutamate. These neurotransmitter systems play an important role in cognitive and 
non-cognitive functions such as learning, memory, attention, locomotion, motiva-
tion, reward, reinforcement, and anxiety. Thus, nAChRs are considered promising 
therapeutic targets for new treatments of neurodegenerative disorders. It is also 
known that α4 and β2 nAChR genes, CHRNA4 and CHRNB2, are causative genes 
of autosomal dominant nocturnal frontal lobe epilepsy (ADNFLE) (Steinlein et al. 
1995; De Fusco et al. 2000). Analyzing the polymorphism of the nAChRs genes in 
AD patients and controls, we showed that genetic polymorphisms of the neuronal 
nAChR genes might be related to the pathogenesis of sporadic AD (Kawamata and 
Shimohama 2002). This, in conjunction with the memory-enhancing activity of 
nicotine and selective nAChR agonists such as the α7 nAChR agonist, 3-(2,4)- 
dimethoxybenzylidene anabaseine (DMXBA) (Meyer et al. 1997), suggests a sig-
nificant role of nAChRs in learning and memory. Therefore, it is generally recognized 
that the down-regulation of nAChRs is involved in the intellectual dysfunction in 
AD. Our studies showed that nAChR stimulation protected neurons from Aβ- and 
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glutamate-induced neurotoxicity. This allowed us to hypothesize that nAChRs are 
involved in a neuroprotective cascade (Kihara et al. 1997, 1998, 2001; Akaike et al. 
1994) as described in the following sections.
Parkinson’s disease (PD) is the second most common progressive neurodegen-
erative disorder next to AD. It is characterized by relatively selective degeneration 
of dopaminergic neurons in the substantia nigra and loss of dopamine in the stria-
tum resulting in resting tremor, rigidity, bradykinesia and postural instability 
(Shimohama et al. 2003; Obeso et al. 2010). Although the pathogenesis of PD is still 
unclear, it is thought that the interaction of gene and the environment plays roles in 
causing the multi-factorial disease. Rural residency, pesticides and intrinsic toxic 
agents were reported as environmental risk factors for sporadic PD. Recent studies 
revealed several mutations in familial PD genes such as α-synuclein, parkin, PINK1, 
LRRK2, DJ-1, UCHL1, ATP13A2 and GBA (glucocerebrocidase) (Hardy 2010; 
Sidransky et  al. 2009). The most reproducible epidemiological relevant factor 
against Parkinson’s disease (PD) is cigarette smoking habits (Dorn 1959; Quik 
2004). Epidemiological studies suggest that the use of pesticides increases the risk 
of PD, possibly via reduced activity of complex I in the mitochondrial respiratory 
chain in the substantia nigra (Parker et al. 1989; Mann et al. 1992; Mizuno et al. 
1998). Grady et al. examined mouse brain using in situ hybridization to characterize 
the mRNA expression pattern of nAChRs. The ventral tegmental area (VTA) and 
substantia nigra expressed high concentrations of α4 and α6 and β2, and β3 mRNAs, 
intermediate levels of α5 mRNA, and low levels of the α3 and α7 mRNAs. No sig-
nal for α2 and β4 mRNA was detected (Le Novère et al. 1996; Grady et al. 2007). 
They reviewed the subtypes of nAChRs on dopaminergic terminals of mouse stria-
tum reporting five nAChR subtypes that expressed on dopaminergic nerve termi-
nals, three of which are α6 containing subunits, namely α4α6β2β3, α6β2β3, and 
α6β2. The remaining two subtypes, α4β2, α4α5β2, are more numerous than the 
α6-containg subtypes. The α6 containing nAChRs, which do not contribute to dopa-
mine release induced by nicotine, are mainly located on dopaminergic neuronal 
terminals and probably mediating the endogenous cholinergic modulation of dopa-
mine release at the terminal level. In contrast, α4β2 nAChR represent the majority 
of functional heteromeric nAChRs on dopaminergic neuronal soma. α7 nAChRs are 
present on dopaminergic neuronal soma, contributing to nicotine reinforcement 
(Champtiaux et al. 2003). There are several studies analyzing the decline of specific 
nAChRs in PD patients. Court et  al. reported the decline of α3 subunits and no 
change of α7 subunits. Gotti et al. and Court et al. reported decreased level of α4 
subunits but Guan et al. reported not (Court et al. 2000; Gotti et al. 1997; Guan et al. 
2002). Bordia et al. reported the decline of α6 subunits in caudate and putamen. 
They further specified that the most vulnerable subtype in striatum of MPTP-treated 
mice and monkeys is α6α4β2β3 rather than α6β2β3 and further identified the spe-
cific loss of α6α4β2β3 subtype in PD brains (Bordia et al. 2007). These results seem 
to indicate that the decline of nigrostriatal specific α6 subtypes is highly specific and 
relevant to the PD pathogenesis but not is α7 subtype. Functional studies on α6 
nAChRs should be undertaken to confirm its pathological importance in PD. For 
this purpose, Drenan et  al. (2008) generated the gain-of-function α6 nAChR 
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 transgenic mouse, which turned to present locomotive hyperactivity. With low dose 
of nicotine by the way of stimulating dopamine but not GABA, its phenotype was 
exaggerated and hyperdopaminergic state in vivo was observed. Current drug ther-
apy against PD is limited to supplementing DA or enhancing dopaminergic effect. 
Some may have neuroprotective effects, but their effects remain controversial (Quik 
2004; Du et al. 2005; Iravani et al. 2006). It has also been reported that smokers 
have a lower risk for PD (De Reuck et al. 2005; Wirdefeldt et al. 2005), and nAChRs 
were decreased in the brains of PD patients (Fujita et al. 2006) and model animals 
(Quik et al. 2006a). Nicotine may upregulate DA release at striatum from nigral 
dopaminergic neurons (Morens et  al. 1995), followed by stimulation of α4β2 
nAChRs (Champtiaux et al. 2003). Furthermore, nicotine could protect mitochon-
dria and had protective effect from oxidative stress (Cormier et al. 2003; Xie et al. 
2005). In studies made in vivo, stimulation of nAChRs resulted in neuroprotection 
in PD model animals (Parain et al. 2003). Although several clinical trials to evaluate 
possible therapeutic effect of nicotine to PD patients have been conducted, whether 
nicotine has therapeutic effects on PD is still controversial. The relatively high dose 
transdermal nicotine administration might have therapeutic effect on PD patients 
(Villafane et al. 2007). In the following we present evidence for nAChR-mediated 
neuroproptection in PD models based mainly on our studies.
8.2  Alzheimer’s Disease and nAChRs
8.2.1  nAChR Enhancement Shows Neuroprotection 
Against Glutamate Toxicity
Glutamate cytotoxicity is one of the most suspected causative pathways in neurode-
generative process, namely in AD and PD. To give examples, it is also assumed that 
glutamate plays an important role in the neurodegeneration observed in hypoxic- 
ischemic brain injury (Choi 1988; Meldrum and Garthwaite 1990). Several investi-
gators have also suggested that cortical neurodegeneration in AD is attributable to 
glutamate (Maragos et al. 1986; Mattson 1988). Moreover, brief glutamate exposure 
induces delayed cell death in cultured neurons from certain brain regions, such as 
the cerebral cortex and hippocampus. In these brain regions, the N-methyl-D- 
aspartate (NMDA) glutamate receptor subtype plays a crucial role in glutamate neu-
rotoxicity. Several studies have indicated the existence of nitric oxide (NO) synthase 
in the CNS, including the cerebral cortex. NMDA receptor stimulation induces Ca2+ 
influx into cells through ligand-gated ion channels, thereby triggering NO forma-
tion. NO is also thought to diffuse to the adjacent cells, resulting in the appropriate 
physiological response and/or glutamate-related cell death (Choi 1988; Hartley and 
Choi 1989; Dawson et al. 1991).
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We examined the effects of nicotine on glutamate-induced neurotoxicity using 
primary cultures of rat cortical neurons. Cell viability was decreased by treatment 
with 1 mM glutamate for 10 min followed by incubation in glutamate-free medium 
for 1 h. Incubating the cultures with 10 μM nicotine for 24 h prior to glutamate 
exposure significantly reduced glutamate cytotoxicity. To investigate whether 
nicotine- induced neuroprotection is due to a specific effect mediated by nAChRs, 
the effects of cholinergic antagonists were examined. An addition of dihydro-β- 
erythroidine (DHβE), an α4β2 nAChR antagonist, or α-BTX, an α7 nAChR antago-
nist, to the medium containing nicotine reduced the protective effect of nicotine. We 
also examined the protection of nicotine against the effects of ionomycin, a calcium 
ionophore, and SNOC, an NO-generating agent. Incubating the cultures for 10 min 
in either 3 μM ionomycin- or 300 μM SNOC-containing medium markedly reduced 
cell viability. A 24-h pretreatment with nicotine significantly attenuated the iono-
mycin cytotoxicity, but did not affect the SNOC cytotoxicity (Akaike et al. 1994; 
Shimohama et al. 1996; Kaneko et al. 1997) (Fig. 8.1).
We have also shown that nicotinic α7 nAChRs protect against glutamate neuro-
toxicity and neuronal ischemic damage in vivo. The α7 nAChR agonist, dimethoxy-
benzylidene anabaseine (DMXBA), protected rat neocortical neurons against 
excitotoxicity administered 24 h before, but not concomitantly with, NMDA. This 
action was blocked by nicotinic but not muscarinic antagonists. DMXBA (1 mg/kg 
i.p.) also reduced infarct size in rats when injected 24 h before, but not during, focal 
ischemic insults. In a mecamylamine-sensitive manner, α7 nAChRs appear neuro-












Fig. 8.1 Proposed hypothesis for the mechanism of nAChR-mediated survival signal transduction 
against glutamate-Iinduced necrosis. The NMDA glutamate receptor subtype plays a crucial role 
in glutamate neurotoxicity. NMDA receptor stimulation induces Ca2+ influx into cells through 
ligand-gated ion channels, thereby triggering NO formation. NO would diffuse to the adjacent 
cells, resulting in the appropriate physiological response and/or glutamate-related cell death
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8.2.2  Nicotine Protects Neurons Against Aβ Toxicity In Vitro
A 48-h exposure to 20 μM neurotoxic Aβ25–35 caused a significant reduction in the 
neuronal cells of rat fetal primary culture. Simultaneous incubation of the cultures 
with nicotine and Aβ significantly reduced the Aβ-induced cytotoxicity. The protec-
tive effect of nicotine was reduced by both DHβE and α-BTX. The effect of a selec-
tive α4β2 nAChR agonist, cytisine, and a selective α7 nAChR agonist, DMXBA 
(Hunter et al. 1994), on Aβ cytotoxicity was examined. Aβ cytotoxicity was signifi-
cantly reduced when 10 μM cytisine or 1 μM DMXB was co-administered. These 
findings suggest that both α4β2 and α7 nAChR stimulation is protective against Aβ 
cytotoxicity. In addition, MK-801, an NMDA receptor antagonist, inhibited Aβ 
cytotoxicity when administrated simultaneously with Aβ, suggesting that Aβ cyto-
toxicity is mediated via the NMDA receptor, or via glutamate in cultured cortical 
neurons (Kihara et al. 1997, 1998, 2001).
Although it is regarded that PS-1 mutations enhance the generation of Aβ1–42, 
it is controversial whether Aβ is directly toxic to neurons. We found that Aβ25–35- 
induced neurotoxicity was inhibited by MK801. It can therefore be hypothesized 
that Aβ might modulate or enhance glutamate-induced cytotoxicity. Indeed, Aβ 
causes a reduction in glutamate uptake in cultured astrocytes (Harris et al. 1996), 
indicating that, to some extent, Aβ-induced cytotoxicity might be mediated via glu-
tamate cytotoxicity.
In our study (Kihara et al. 2000), incubation of the cortical neurons with both 
Aβ1–40 (1 nM) and Aβ1–42 (100 pM) for 7 days did not induce cell death. These 
are the concentrations of Aβ in the cerebrospinal fluid (CSF) of AD patients (Jensen 
et al. 1999). Although 20 μM glutamate alone did not significantly induce cell death, 
exposure to 20 μM glutamate for 24 h caused a significant reduction in the neuronal 
cells in the Aβ-treated group, showing that Aβ itself is not toxic at low concentra-
tions, but makes neurons vulnerable to glutamate. Conversely, co-incubation of the 
cultures with nicotine (50 μM for 7 days) and Aβ significantly reduced Aβ-enhanced 
glutamate cytotoxicity (Akaike et al. 1994; Shimohama et al. 1996; Kaneko et al. 
1997).
To investigate the mechanism of the protective effect of nicotine, we focused on 
the phosphatidylinositol 3-kinase (PI3K) pathway because PI3K had been shown to 
protect cells from apoptosis (del Peso et al. 1997). Long exposure to low concentra-
tions of glutamate (50 μM for 24 h) induced cytotoxicity. Incubating the cultures 
with nicotine (10 μM for 24 h) prior to glutamate exposure significantly suppressed 
glutamate cytotoxicity. Simultaneous application of LY294002, a PI3K inhibitor, 
with nicotine cancelled the protective effect of nicotine. α-BTX blocked the protec-
tion provided by nicotine and DMXB. Furthermore, this DMXBA-induced protec-
tion was also reduced by LY294002. Although α4β2 nAChR stimulation also had a 
protective effect on Aβ- and glutamate-induced cytotoxicity, this effect was not 
inhibited by LY294002, suggesting PI3K system is not directly involved in α4β2 
nAChR-mediated neuroprotection. PD98059, a mitogen-activated protein (MAP) 
kinase kinase (MEK) inhibitor, did not reduce the protective effect of nicotine, also 
suggesting that the MEK/ERK pathway is not directly involved in the protective 
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effect of nicotine. A non-receptor tyrosine kinase inhibitor, PP2, did reduce the 
protective effect of nicotine, suggesting that Src is involved in the mechanism of the 
protective effect. Cycloheximide also inhibited the protection, implying that some 
protein synthesis is necessary for this effect.
AKT is a serine/threonine protein kinase and a putative effector of PI3K.  To 
investigate the activation of AKT by nicotine through PI3K, we examined the level 
of phosphorylated AKT using an anti-phospho-specific AKT antibody. The phos-
phorylated form of AKT appeared immediately after the application of nicotine. 
Nicotine-induced AKT phosphorylation was blocked by simultaneous application 
of LY294002, but not of PD98059, indicating that PI3K, but not MAPK is involved. 
The AKT phosphorylation is blocked by α-BTX, but not by DHβE, implying that 
nicotine-induced AKT phosphorylation is mediated by α7 but not by α4β2 nAChRs. 
PP2 also blocked AKT phosphorylation, which suggests the involvement of tyrosine 
kinase. The level of total AKT protein which was detected with anti-AKT antibody 
remained unchanged.
Bcl-2 and Bcl-x proteins are anti-apoptotic proteins that can prevent cell death 
induced by a variety of toxic attacks (Zhong et al. 1993). It has been reported that 
AKT activation leads to the overexpression of Bcl-2 (Matsuzaki et  al. 1999). 
Because nicotine can activate AKT via PI3K, we examined the protein levels of 
Bcl-2 and Bcl-x. We found that treatment with nicotine for 24 h increased the levels 
of Bcl-2 and Bcl-x, and this was inhibited by LY294002, which indicates the 
involvement of the PI3K pathway in nicotine-induced Bcl-2 and Bcl-x upregulation. 
These results suggest that nAChR stimulation protects neurons from glutamate- 
induced cytotoxicity by activating PI3K, which in turn activates AKT and upregu-









Fig. 8.2 Proposed hyposis for the mechanism of nAChR-mediated survival signal transduction 
against Aβ-induced apoptosis. Nicotine-induced neuroprotection is mediated via nAChRs, espe-
cially through α7 and α4β2 receptors, and inhibited by a PI3K inhibitor and an Akt/PKB inhibitor. 
This means that nicotine activates the PI3K-Akt/PKB pathways and increase survival of neurons. 
JAK2 and Fyn are key molecules trigger activation of the PI3K-Akt/PKB pathways which lead to 
subsequent upregulation of Bcl-2 and neuroprotection
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8.2.3  Galantamine Acts As an Allosteric Potentiating Ligand 
(APL) of nAChRs and Blocks Aβ-Enhanced Glutamate 
Toxicity In Vitro
Galantamine is an acetylcholinesterase inhibitor (AChEI) that is currently used for 
the treatment of AD. Although its AChEI activity appears to be much weaker than 
other clinically available AChEIs, its therapeutic effects on cognitive function in AD 
are comparable with the other agents. Furthermore, the long term extension clinical 
trial of galantamine suggested that the cognitive benefits of galantamine are sus-
tained for at least 36 months (Raskind et al. 2004). In addition to the inhibition of 
AChE, galantamine binds to nAChRs and allosterically potentiates their synaptic 
transmission. Consequently, galantamine is called an allosteric potentiating ligand 
(APL) of nAChRs. This APL effect is present on both α7 and α4β2 nAChRs 
(Maelicke et al. 2001). Thus, galantamine could stimulate cholinergic transmission 
in two ways: (1) by inhibiting AChE and increasing AChs, and (2) by potentiating 
cholinergic transmission through the APL effect. We demonstrated that galantamine 
protected cortical neurons against Aβ-enhanced glutamate toxicity by, at least par-
tially, the α7 nAChR-PI3K-AKT pathway (Kihara et al. 2004).
8.2.4  Galantamine-Induced Aβ Clearance Mediated 
via Stimulation of Microglial nAChRs
We found that in human AD brain, microglia accumulates on Aβ deposits and 
expresses α7 nAChRs including the APL-binding site, which is recognized specifi-
cally with FK1 antibody. Treatment of rat microglia with galantamine significantly 
enhanced microglial Aβ phagocytosis, and acetylcholine competitive angatonists as 
well as FK1 antibody inhibited the enhancement.
We further demonstrated that galantamine treatment facilitated Aβ clearance in 
brains of rodent AD models. We investigate effect of daily intraperitoneal galan-
tamine (1 or 5 mg/kg) administration on Aβ clearance in rat that had received intra-
hippocampal Aβ42 (1 μg) injection. The amount of Aβ was significantly reduced by 
galantamine in a dose-dependent manner, compared with the vehicle-treated rats. 
This result suggests that galantamine may enhance microglial Aβ phagocytosis and 
promote the Aβ clearance from the Aβ-injected rat brain.
Hemizygous APdE9 mice is expressing chimeric mouse/human amyloid precur-
sor protein APPswe (mouse APP695 harboring a human Aβ domain and mutations 
K594N and M595L linked to Swedish familial AD pedigrees) and human mutated 
presenilin 1-dE9 (deletion of exon 9), and present a weak decline in spatial learning 
and memory at 9 months of age. We had administrated the mice galantamine (1 or 
5 mg/kg) from 9 months of age for 7 weeks and evaluated spatial learning and mem-
ory using water maze testing at 11 months of age. Both low and high dose galan-
tamine significantly improved the performance in the 11 months old APdE9 mice. 
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Pathological evaluation also revealed that the Aβ burden in the brains of APdE9 
mice treated with galantamine show less Aβ plaque. The measurement of amount of 
insoluble Aβ40 and Aβ42 in formic acid-extracted fraction of the brain revealed a 
significant decrease in galantamine-treated mice compared to sham treated mice.
Using primary-cultured rat microglia, we evaluated the microglial Aβ phagocy-
tosis. We treated rat microglia with 1 μM Aβ42 in the presence or absence of galan-
tamine or nicotine. Galantamine enhanced microglial Aβ phagocytosis in a 
concentration-dependent manner and phagocytosis reached the peak at 1 μM galan-
tamine. Nicotine also increased Aβ phagocytosis at the concentration of 
1000 μM. These effects were inhibited by pretreatment with the blockage of APL- 
binding site by FK1 antibody as well as with nAChR antagonists. Although 
galantamine- enhanced microglial Aβ phagocytosis was significantly inhibited by 
FK1 antibody, Fk1 antibody alone did not influence the magnitude of Aβ phagocy-
tosis in the absence of galantamine. From these findings, we can assume that the 
galantamine-enhanced microglial Aβ phagocytosis requires the combined actions of 
an acetylcholine competitive agonist and the APL for nAChRs. In fact, depletion of 
choline, an acetylcholine-competitive α7 nAChR agonist, from the culture medium 
impedes the enhancement.
We investigated whether the Ca2+ influx correlates with enhanced microglial Aβ 
phagocytosis. In the absence of galantamine or nicotine, the levels of microglial Aβ 
phagocytosis were almost the same in Ca2+ (−) or Ca2+ (+) DMEM. Galantamine and 
nicotine significantly enhanced microglial Aβ phagocytosis in Ca2+ (+) DMEM, but 
not in Ca2+ (−) condition. Similarly, inhibition of the calmodulin-dependent path-
ways for the actin reorganization by 20 μM W-7, an inhibitor of calmodulin, or 10 μM 
KN93, an inhibitor of Ca2+/CaM-dependent protein kinase II (CaMKII), abolished 
the enhancement. We evaluated other signaling cascades including JAK2- PI3K- AKT 
cascade, Fyn-PI3K-AKT cascade, MAPKK (MEK) cascade, using each inhibitor 
and concluded that they are not involved in galantamine enhanced microglial Aβ 
phagocytosis. These results suggest that Ca2+ influx through nAChRs and subsequent 
activation of CaM-CaMKII signaling cascade were involved in enhanced microglial 
Aβ phagocytosis through the actin reorganization (Takata et al. 2010) (Fig. 8.3).
8.2.5  Donepezil Promotes Internalization of NMDA Receptors 
by Stimulating α7 nAChRs and Attenuates Glutamate 
Cytotoxicity
Donepezil is one of the most widely prescribed AChEI for the treatment of AD and 
related dementias. Our group reported that in addition to up-regulating the PI3K- 
AKT pathway, there is another mechanism underlying neuroprotection by donepe-
zil, showing decreases glutamate toxicity through down-regulation of NMDA 
receptors, following stimulation of α7 nAChRs in primary rat neuron cultures (Shen 
et al. 2010).
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8.2.6  Donepezil Directly Acts on Microglia to Inhibit Its 
Inflammatory Activation
Hwang et al. reported that 5–20 μM donepezil attenuates microglial production of 
nitric oxide and tumor necrosis factor (TNF)-α, and suppressed the gene expression 
of inducible nitric oxide synthase, inteleukin-1β, and TNF-α in the microglia cul-
tures. They also confirmed donepezil inhibit inflammatory NF-kB signaling in 
microglial cell line (Hwang et al. 2010).
8.2.7  Temporal Changes of CD68 and α7nAChR Expression 
in Microglia in AD-Like Mouse Models
As shown above, activated microglia are involved in Aβ clearance and that stimula-
tion of α7nAChR in microglia enhances Aβ clearance. Nevertheless, how microglia 
and α7 nAChR in microglia are affected in AD remains unknown. The study aimed 
to collect fundamental data for considering whether microglia are potential targets 
for AD treatment and the appropriate timing of therapeutic intervention, by evaluat-
ing the temporal changes of Aβ, microglia, neurons, presynapses, and α7 nAChR by 























Fig. 8.3 Proposed pathway for microglial CaM/CaMKII/Aβ phagocytosis. Ca2+ influx through 
nAChRs and subsequent activation of CaM-CaMKII signaling cascade are involved in enhanced 
microglial Aβ phagocytosis through the actin reorganization
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model, we observed early accumulation of CD68-positive microglia at Aβ deposi-
tion sites and gradual reduction of Aβ. Microglia were closely associated with Aβ 
deposits, and were confirmed to participate in clearing Aβ. In a transgenic mouse 
model of AD, we observed an increase in Aβ deposition from 6 months of age, fol-
lowed by a gradual increase in microglial accumulation at Aβ deposit sites. Activated 
microglia in APdE9 mice showed two-step transition: a CD68-negative activated 
form at 6–9 months and a CD68-positive form from 12 months of age. In addition, 
α7 nAChR in microglia increased markedly at 6  months of age when activated 
microglia appeared for the first time, and decreased gradually coinciding with the 
increase of Aβ deposition. These findings suggest that early microglial activation is 
associated with α7 nAChR upregulation in microglia in APdE9 mice. These novel 
findings are important for the development of new therapeutic strategy for AD 
(Matsumura et al. 2015).
8.3  Parkinson’s Disease and nAChRs
8.3.1  nAChR Enhancement Shows Dopaminergic Neuronal 
Protection Against Rotenone Cytotoxicity
Rotenone is a naturally occurring complex ketone pesticide derived from the roots 
of Lonchocarpus species. It can rapidly cross over cellular membranes without the 
aid of transporters, including the blood brain barrier (BBB). Rotenone is a strong 
inhibitor of complex I, which is located at the inner mitochondrial membrane and 
protrudes into the matrix. In 2000, Betarbet et  al. (2000) demonstrated with rat 
model that chronic systemic exposure to rotenone causes many features of PD, 
including slow-progressive dopamine neuronal loss in nigrostriatal dopaminergic 
system, and Lewy body-like particles, which are primarily aggregations of 
α-synuclein (Mizuno et al. 1998; Inden et al. 2007). Rotenone works as a mitochon-
drial complex I inhibitor. Acute lethal doses of rotenone eliminate the mitochondrial 
respiratory system of the cell, resulting in an anoxic status that immediately causes 
cell death. At sub-lethal doses it causes partial inhibition of mitochondrial complex 
I, and in this situation mitochondrial dysfunction leads to increased oxidative stress, 
decreased ATP production, increased aggregation of unfolded proteins, and then 
activated apoptotic pathway(s) that result in neuronal cell death (Betarbet et  al. 
2000), resembling dopaminergic neurodegeneration in PD.
In cultures of rat fetus mesencephalic neurons, 48 h exposure to rotenone caused 
dose-dependent neurotoxicity, more evident in dopaminergic neurons than in other 
neuronal cells. This result showed that dopaminergic neurons were more vulnerable 
to rotenone-induced neurotoxicity. Simultaneous administration of nicotine resulted 
in a dose-dependent increase of the viability of dopaminergic neurons. This neuro-
protective effect was inhibited by 100 μM mecamylamine, a broad-spectrum nAChR 
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antagonist, 100 nM αBuTx and 1 μM DHβE. Nicotine-induced neuroprotection was 
therefore shown to occur via nAChRs, especially through α7 and α4β2 receptors. 
Furthermore, nicotinic neuroprotection is inhibited by LY294002, a PI3K inhibitor, 
and triciribine, an AKT/PKB inhibitor. This means that nicotine could activate the 
PI3K-AKT/PKB pathways and increase the survival of mesencephalic dopaminer-
gic cells against rotenone-induced cell death (Takeuchi et al. 2009). From our previ-
ous studies, it is known that the PI3K-AKT/PKB pathways would lead to subsequent 
upregulation of Bcl-2 and neuroprotection (Akaike et al. 2010; Shimohama 2009).
We confirmed that orally rotenone (30 mg/kg for 28 days)-treated mouse model 
showed motor deficits, dopaminergic cell death in the substantia nigra, and nerve 
terminal/axonal loss in the striatum. These findings are relevant to some previous 
reports on rotenone PD models (Schmidt and Alam 2006; Ravenstijn et al. 2008). 
Simultaneous subcutaneous administration of nicotine (0.21 mg/kg/day) prevented 
both motor deficits and dopaminergic neuronal cell loss in the substantia nigra of 
rotenone-treated mice.
8.3.2  nAChR Enhancement Show Dopaminergic Neuronal 
Protection Against 6-OHDA- Induced Hemiparkinsonian 
Rodent Model
6-hydroxydopamine (6-OHDA)’s strong neurotoxic effects were described by 
Ungerstedt in 1971, in a study presenting the first example of using a chemical agent 
to produce an animal model of PD (Ungerstedt 1971). Since 6-OHDA cannot cross 
over the BBB, systemic administration fails to induce parkinsonism. This induction 
model requires 6-OHDA to be injected into the SN, medial forebrain bundle, and 
striatum. The intrastriatal injection of 6-OHDA causes progressive retrograde neu-
ronal degeneration in the VTA and substantia nigra.
Costa et  al. evaluated the neuroprotection of nicotine in 6-OHDA-induced 
hemiparkinsonian rat model. They injected 6 μg 6-OHDA in the SN, and confirmed 
that the dopamine level in the corpus striatum was decreased nearly by half. Repeated 
subcutaneous nicotine administration at 4 h before and 20, 44 and 68 h after 6-OHDA 
injection significantly prevented the striatal dopamine loss and the protection 
reverted by nAChR antagonist. The protective effect was not achieved by one-off 
administration of nicotine before or after 6-OHDA injection (Costa et al. 2001).
Using rat 6-OHDA-induced hemiparkinsonian model, the neuroprotective effects 
of galantamine and nicotine were evaluated. 32  nmol 6-OHDA with or without 
4–120 nmol galantamine and/or 120 nmol nicotine were injected into unilateral SN 
of rats. Although methamphetamine-stimulated rotational behavior and dopaminer-
gic neuronal loss induced by 6-OHDA were not inhibited by galantamine alone, 
those were moderately inhibited by nicotine alone. In addition, 6-OHDA-induced 
neuronal loss and rotational behavior were synergistically inhibited by co-injection 
of galantamine and nicotine. These protective effects were abolished by mecamyla-
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mine, a nAChR antagonist. α7nAChR was expressed on both dopaminergic and 
non-dopaminergic neurons in the rat substantia nigra pars compacta (SNpc). A com-
bination of galantamine and nicotine greatly suppressed 6-OHDA-induced reduc-
tion of α7nAChR- immunopositive dopaminergic neurons. These results suggest 
that galantamine synergistically enhances the neuroprotective effect of nicotine 
against 6-OHDA-induced dopaminergic neuronal loss through an allosteric modu-
lation of α7nAChR activation (Yanagida et al. 2008).
To explore a novel therapy against PD through enhancement of α7 nAChR, we 
evaluated the neuroprotective effects of DMXBA in a rat 6-OHDA-induced 
hemiparkinsonian model. Microinjection of 6-OHDA into the nigrostriatal pathway 
of rats destroys dopaminergic neurons selectively. DMXBA dose-dependently 
inhibited methamphetamine-stimulated rotational behavior and dopaminergic neu-
ronal loss induced by 6-OHDA. The protective effects were abolished by methyl-
lycaconitine citrate salt hydrate, an α7 nAChR antagonist. Immunohistochemical 
study confirmed abundant α7 nAChR expression in the cytoplasm of dopaminergic 
neurons. These results indicate that DMXBA prevented 6-OHDA-induced dopami-
nergic neuronal loss through stimulating α7 nAChR in dopaminergic neurons. 
Injection of 6-OHDA elevated immunoreactivities to glial markers such as ionized 
calcium binding adaptor molecule 1, CD68, and glial fibrillary acidic protein in the 
substantia nigra pars compacta of rats. In contrast, these immunoreactivities were 
markedly inhibited by comicroinjection of DMXBA. Microglia also expressed α7 
nAChR in both resting and activated states. Hence, we hypothesize that DMXBA 
simultaneously affects microglia and dopaminergic neurons and that both actions 
lead to dopaminergic neuroprotection. The findings that DMXBA attenuates 
6-OHDA-induced dopaminergic neurodegeneration and glial activation in a rat 
model of PD raise the possibility that DMXBA could be a novel therapeutic com-
pound to prevent PD development (Suzuki et al. 2013) (Fig. 8.4).
Fig. 8.4 Proposed pathway for nAChR-mediated neuronal protection: direct effect to neurons and 
indirect effect to microglia against 6-OHDA-induced hemiparkinsonian rodent model. We hypoth-
esize that DMXBA simultaneously affects microglia and dopaminergic neurons and that both 
actions lead to dopaminergic neuroprotection
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8.3.3  α4 nAChR Modulated by Galantamine on Nigrostriatal 
Terminals Regulates Dopamine Receptor-Mediated 
Rotational Behavior
This study was designed to evaluate the allosteric effect of galantamine on nAChR 
regulation of nigrostrial dopaminergic neuronal function in the hemiparkinsonian 
rat model established by unilateral nigral 6-OHDA injection. Methamphetamine, a 
dopamine releaser, induced ipsilateral rotation, whereas dopamine agonists apo-
morphine (a non-selective dopamine receptor agonist), SKF38393 (a selective 
dopamine D1 receptor agonist), and quinpirole (a selective dopamine D2 receptor 
agonist) induced contralateral rotation. When 6-OHDA-injected rats were co-treated 
with nomifensine, a dopamine transporter inhibitor, a more pronounced and a 
remarkable effect of nicotine and galantamine was observed. Under these condi-
tions, the combination of nomifensine with nicotine or galantamine induced the 
ipsilateral rotation similar to the methamphetamine-induced rotational behavior, 
indicating that nicotine and galantamine also induce dopamine release from striatal 
terminals. Both nicotine- and galantamine-induced rotations were significantly 
blocked by flupenthixol (an antagonist of both D1 and D2 dopamine receptors) and 
mecamylamine (an antagonist of nAChRs), suggesting that galantamine modulation 
of nAChRs on striatal dopaminergic terminals regulates dopamine receptor- 
mediated movement. Immunohistochemical staining showed that α4 nAChRs were 
highly expressed on striatal dopaminergic terminals, while no α7 nAChRs were 
detected. Pretreatment with DHβE significantly inhibited nicotine- and galantamine- 
induced rotational behaviors, whereas pretreatment with methyllycaconitine was 
ineffective. Moreover, the α4 nAChR agonist ABT-418 induced ipsilateral rotation, 
while the α7nAChR agonist PNU282987 had no significant effect on rotational 
behavior. These results suggest that galantamine can enhance striatal dopamine 
release through allosteric modulation of α4 nAChRs on nigrostriatal dopaminergic 
terminals (Inden et al. 2016).
8.3.4  Neuroprotective Effect of Nicotine in MPTP-Induced 
Parkinsonian Model
In 1979 and 1983, MPTP was initially identified as a strong neurotoxin when heroin 
addicts accidentally self-administered MPTP and developed an acute form of par-
kinsonism that was indistinguishable from idiopathic PD (Davis et  al. 1979; 
Langston et al. 1983). The tragic results of MPTP poisoning in the heroin addicts led 
to the development of MPTP-induced rodent and non-human primate animal mod-
els of PD.  Jeyarasasingam et al. reported exposure of rat primary mesencephalic 
cultures to 10−7 and 10−4 M nicotine partially protect against dopaminergic neuro-
toxicity induced by 1-methyl-4-phenylpyridinium (MPP+). The optimal protective 
effect was observed when pre-exposure to nicotine for 24 h before administration of 
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MPP+. They also showed the nicotine protection was mediated by non-α7 nAChR 
stimulation but not through α7 nAChR stimulation (Jeyarasasingam et  al. 2002). 
Junyent et al. reported comparison of two prosurvival pathways, AKT pathway and 
JAK2/STAT3 pathway, in MPP+ treated cerebellar granule cell culture. Their data 
indicated that the treatment of cerebellar granule cell with MPP+ decreased both 
survival pathways. Loss of STAT3 could be a signal pathway involved in neuropro-
tection against the MPP+, whereas AKT activation, using a PTEN inhibitor, did not 
play a prominent role in neuroprotection (Junyent et al. 2010).
In MPTP-induced animal model, the neuroprotective effect of nicotine is not 
consistent probably due to different experimental methods. Besides small number 
of negative reports (Behmand and Harik 1992), several independent groups con-
firmed the neuroprotective effects of nicotine against MPTP in rodents. The pre-
treatment of nicotine is essential and post treatment did not show any neuroprotective 
effect in MPTP-induced rat as well as in primate models. There are many reports 
attributing the neuroprotective effect of cigarette smoking against MPTP cytotoxic-
ity to inhibition of monoamine oxidase B (MAO-B), which converts MPTP to active 
MPP+. But because of the fact that nicotine does not inhibit brain MAO-B, the nico-
tinic neuroprotection against MPTP cytotoxicity is not mediated through MAO-B 
inhibition. A blockade of MPP+ uptake into the dopaminergic cells via increased 
dopamine release may be the reason of the protective effect. Jasons et al. (1992) 
reported the chronic infusion of nicotine via minipumps produced a dose-related 
enhancement of MPTP-induced dopaminergic neurotoxicity in mouse, which might 
be caused by a failure of nAChRs to desensitized to the chronic nicotine exposure 
(Parain et al. 2001, 2003). Regarding to primate model, there have been only several 
papers from one group examining the nicotine-induced neuronal protection in 
MPTP-induced primate PD motor deficit model (Quik et al. 2006a, b; Bordia et al. 
2006; Huang et al. 2009). In their reports, neuroprotection was observed only when 
nicotine is given orally before the MPTP exposure. Decamp and Schneider estab-
lished stable cognitive deficit primate model injecting low dose of MPTP (0.025–
0.10 mg/kg) over a period ranging from 98 to 158 days, without the confounding 
effect of significant motor impairment. They examined the effect of nicotine, l-dopa, 
and SIB-1553A, α4β4 nAChR agonist, on spatial delayed response task perfor-
mance and reported that nicotine and SIB-1153A improved performance whereas 
l-dopa impaired (Decamp and Schneider 2009).
8.4  Neuroprotective Enhancement of nAChRs Through Four 
Pathways (Kawamata and Shimohama 2011)
 1. PI3K/AKT pathway
Our studies showed that nAChR stimulation protected neurons from Aβ-, gluta-
mate-, rotenone-, and 6-OHDA-induced neurotoxicity. From the experimental data, 
our hypothesis for the mechanism of nAChR-mediated survival signal transduction 
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is as follows: activation of α7 nAChRs stimulates the Src family, which in turn acti-
vates PI3K.  PI3K phosphorylates AKT, which causes upregulation of Bcl-2 and 
Bcl-x. α4β2 nAChR stimulation also causes neuroprotection cascade without direct 
involvement of PI3K system.
 2. JAK2/STAT3 pathway
Other properties of nicotine proposed by other groups are anti-inflammatory 
potentials and modulating innate immune pathways mainly via α7 nAChR. Nicotine 
exerts its anti-inflammatory effect in activated immune cells, macrophages and 
microglia as well as neurons, by interacting α7 nAChR. Activated α7 nAChR binds 
directory to JAK2 and triggers the JAK2/STAT3 pathway to interfere with the acti-
vation of TLR-induced NF-κB, which is responsible for pro-inflammatory cytokine 
transcription (Cui and Li 2010).
 3. MEK/ERK pathway
Importance of the MEK/ERK pathway in nicotinic neuroprotection has also been 
emphasized by several groups (Buckingham et al. 2009; Wang et al. 2003). Dajas- 
Bailador et  al. reported nicotine stimulation leads to PKA activation through α7 
nAChR and further Raf-1/MEK/ERK signaling pathway (Dajas-Bailador et  al. 
2002). Other group showed that stepwise activation of Ras/Raf-1/MEK/ERK cas-
cade provides for an increased cytoplasmic concentration of STAT3 due to an up- 
regulated expression (Arredondo et al. 2006) activating the JAK2/STAT3 pathway 
in human oral keratonocytes.
 4. Microglial CaM/CaMKII/Aβ phagocytosis pathway
In addition to known three neuroprotective pathways in neurons, we showed 
microglial Aβ clearance effect mediated through nAChRs enhancement should have 
special importance especially in AD therapy (Takata et al. 2010).
8.5  Conclusion
Targeting enhancement of nAChRs is one of the most practical therapeutic alterna-
tives against AD to date. Based on epidemiological and experimental findings, clini-
cal application of nicotinic enhancement against PD is also believed to be promising 
strategy different from ongoing dopamine replenish therapies. The underlying 
mechanisms of the neuroprotective effect induced by nicotinic stimulation were 
studied vigorously and three neuronal survival signal transductions have been eluci-
dated as reviewed here. Recently microglial CaM/CaMKII/Aβ phagocytosis path-
way is proved to be additional important neuroprotective pathway in AD models. 
Combined with other therapeutic methods under development, the enhancement of 
nAChRs would keep its position as safe and practical therapeutic alternatives against 
the progress of neurodegenerative disorders such as AD and PD.
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Chapter 9
SAK3-Induced Neuroprotection Is 
Mediated by Nicotinic Acetylcholine 
Receptors
Kohji Fukunaga and Yasushi Yabuki
Abstract Cholinergic neurotransmission plays a critical role in neuronal plasticity 
and cell survival in the central nervous system (CNS). Two types of acetylcholine 
receptors (AChRs), muscarinic AChRs (mAChRs) and nicotinic AChRs (nAChRs), 
trigger intracellular signaling through G protein activity and ion influx, respectively. 
To assess mechanisms underlying neuroprotection through nAChRs, we developed 
SAK3, a novel modulator of nAChR activity. Recently, we found that SAK3 
enhances T-type calcium channel activity, promoting ACh release in the hippocam-
pal CA1 region of olfactory-bulbectomized mice. Here, we observed potent SAK3 
neuroprotective activity in mice with 20-min bilateral common carotid artery occlu-
sion (BCCAO) or hypothyroidism. Treatment of mice with the α7 nAChR-selective 
inhibitor methyllycaconitine (0.5  mg/kg/day, p.o.) antagonized SAK3-mediated 
neuroprotection and memory improvement in BCCAO mice. Single administration 
of the anti-Graves’ disease therapeutic methimazole (MMI) to female mice dis-
rupted olfactory bulb (OB) glomerular structure, and cholinergic neurons largely 
disappeared in the medial septum followed by memory loss. Chronic SAK3 
(0.5–1 mg/kg, p.o.) administration significantly rescued the number of cholinergic 
medial septum neurons in MMI-treated mice and improved cognitive deficits seen 
in those mice. Overall, our study suggests that, in mice, the novel nAChR modulator 
SAK3 can rescue neurons impaired by transient ischemia and hypothyroidism. We 
also address mechanisms common to SAK3-induced neuroprotection in both 
conditions.
Keywords Nicotinic acetylcholine receptor · T-type calcium channel · 
Neuroprotection · Ischemia · Hypothyroidism · Methimazole · Memory · 
Alzheimer’s disease
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Akt Protein kinase B
BCCAO Bilateral common carotid artery occlusion
CNS Central nervous system
DhβE Dihydro-β-erythroidine
ERK Extracellular signal-regulated kinase
HO-1 Heme-oxygenase 1




mAChR Muscarinic ACh receptor
nAChR Nicotinic ACh receptor
OBX Olfactory-bulbectomized
PI3K Phosphatidylinositol 3 kinase
PKC Protein kinase C
RGC Retinal ganglion cell




Acetylcholine (ACh) is a major neurotransmitter in the central nervous system 
(CNS) and transduces signals via two types of ACh receptors (AChRs): muscarinic 
(mAChRs) and nicotinic (nAChRs). While mAChRs are G-protein-coupled, 
nAChRs are ligand-gated cation channels consisting of five subunits (Zdanowski 
et  al. 2015). Both AChR pathways function in learning and memory (Melancon 
et al. 2013; Pandya and Yakel 2013) and play a critical role in cell survival in in vitro 
and in vivo models (Akaike et al. 2010; Tan et al. 2014; Zdanowski et al. 2015). 
Drugs that enhance ACh concentration in the CNS, including the acetylcholine 
esterase (AChE) inhibitors donepezil, galantamine and rivastigmine, are among 
widely used therapeutics used to treat early stage Alzheimer’s Disease (AD). 
However, it remains unclear whether the effects of AChE inhibitors are mediated by 
nAChRs or mAChRs in human brain. We recently developed the lead compound of 
the AD therapeutic SAK3 (ethyl 8′-methyl-2′,4-dioxo-2-(piperidin-1-yl)-2′H- 
spiro[cyclopentane-1,3′-imidazo[1,2 a]pyridin] -2-ene-3-carboxylate) (Yabuki 
et al. 2017a, b). SAK3 primarily stimulates T-type voltage gated Ca2+ channels in 
brain, and importantly it enhances ACh release in hippocampus, thereby improving 
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memory in olfactory-bulbectomized (OBX) mice. We found that SAK3 effects on 
ACh release and memory improvement were antagonized by nAChR inhibitors, 
suggesting that SAK3 modulates nAChR. This review focuses primarily on SAK3 
neuroprotective activity mediated by nicotinic cholinergic pathways.
9.2  Neuroprotection Mediated by mAChRs
Subchronic treatment with the acetylcholinesterase inhibitor galantamine (3.5 mg/
kg, i.p.) prevents cell death and axonal injury after ocular hypertension surgery in 
rat retinal ganglion cells (RGCs), an effect blocked by the non-selective mAChR 
antagonist scopolamine, the M1-type mAChR antagonist pirenzepine, or the 
M4-type mAChR antagonist tropicamide, but not by nAChR inhibitors (Almasieh 
et al. 2010). In agreement with these results, the M1-type mAChR agonist pilocar-
pine protects RGCs from glutamate-induced neurotoxicity and ischemia/reperfu-
sion injury in rat primary retinal cultures and in rat retina (Tan et al. 2014). M1-type 
mAChR activation in PC12 cells promotes protein kinase C (PKC) activity and 
inhibits glycogen synthase kinase-3β (GSK-3β) activity, thereby increasing levels 
of NF-E2-related factor-2 (Nrf2) protein, which regulates transcription of the gene 
encoding the anti-oxidant protein hemeoxygenase I (HO-1) (Espada et al. 2009; Ma 
et al. 2013). Therefore, activation of that anti-oxidant pathway through Nrf2 stimu-
lation likely underlies mAChR-dependent neuroprotection. Likewise, the M1-type 
mAChR-selective agonist AF267B rescues rat primary hippocampal neurons 
exposed to amyloid-β (Aβ) from cell death by inhibiting increases in GSK-3β 
(Farías et al. 2004). On the other hand, the mAChR antagonist scopolamine does not 
block neuroprotection by acetylcholinesterase inhibitors on glutamate (1 mM) tox-
icity in primary rat cortical neurons (Takada-Takatori et  al. 2009). Thus, how 
mAChRs promote neuroprotection is not entirely clear.
9.3  Neuroprotective Action Mediated by nAChRs
Nine different nAChR subunits (α2-7 and β2-4) are expressed in mammalian brain, 
and in mouse brain major nAChRs are comprised of homomeric α7 AChR and het-
eromeric α4β2 complexes (Dani and Bertrand 2007; Dineley et  al. 2015; Yakel 
2013). Many studies in cultured neurons support the idea that nAChRs have neuro-
protective effects. For example, nicotine (10 μM) treatment protects cultured rat 
primary cortical neurons from cell death by glutamate (1 mM) exposure by activat-
ing α4β2 and α7 nAChRs (Kaneko et  al. 1997). In addition, the α4β2 inhibitor 
dihydro-β-erythroidine (DHβE) and α7 inhibitor methyllycaconitine (MLA) both 
block neuroprotective effects of acetylcholinesterase inhibitors on glutamate 
(1  mM)-induced excitotoxicity in cultured neurons, an effect not seen following 
treatment of cells with the mAChR antagonist scopolamine (Takada-Takatori et al. 
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2009). In vivo, galantamine treatment prevents death of gerbil hippocampal CA1 
pyramidal neurons following transient bilateral common carotid artery occlusion 
(BCCAO), an effect blocked by the non-selective nAChR inhibitor mecamylamine 
(MEC) (Lorrio et al. 2007). Combined neostigmine and anisodamine treatment are 
neuroprotective against middle cerebral artery occlusion in wild type- but not in α7 
nAChR knock-out mice (Qian et al. 2015). We recently observed that the acetylcho-
linesterase inhibitor donepezil antagonizes loss of cholinergic neurons in the medial 
septum (MS) of OBX mice through nAChR stimulation (Yamamoto and Fuknaga 
2013). In addition, Hijioka et al. (2012) reported that the α7-specific agonist PNU- 
282987 but not the α4-specific agonist RJR-2403 blocks neuronal loss following 
intracerebral hemorrhage in mouse striatum. Since MEC, DHβE and MLA do not 
block neuroprotective effects of galantamine following ocular hypertension surgery 
in rat RGCs, neuroprotection mediated by nAChRs may play a more predominant 
role in CNS than in peripheral neurons. We previously reported that galantamine 
stimulates glutamatergic and GABAnergic synaptic transmission via nAChR stimu-
lation in rat cortical neurons (Moriguchi et  al. 2009). Interestingly, galantamine 
increases hippocampal insulin-like growth factor 2 expression via the α7 nAChR in 
mice (Kita et al. 2013). Similarly, stimulation of α7 by the selective agonist PHA- 
543613 or galantamine treatment enhances α7 channel activity and improves 
Aβ-induced cognitive deficits in mice (Sadigh-Eteghad et  al. 2015). In addition, 
galantamine treatment promotes survival of newborn neurons in the hippocampal 
dentate gyrus (DG) viaα7 nAChR but not via M1 mAChR activity (Kita et al. 2014). 
Taken together, the neuroprotective effect of galantamine is mediated both by 
mAChRs and nAChRs in the CNS.
9.4  Development of the Novel nAChR Modulator SAK3
T-type calcium channels, which are encoded by the CACNA1G (Cav3.1), CACNA1H 
(Cav3.2) and CACNA1I (Cav3.3), are voltage-gated calcium channels that give rise 
to low-threshold calcium spikes, which in turn trigger burst firing mediated by 
sodium channels in many neurons (Huguenard 1996; Perez-Reyes 2003). Recently, 
we found that a novel AD therapeutic candidate, ST101 (spiro[imidazo[1,2-a]
pyridine- 3,2-indan]-2(3H)-one), increases Cav3.1 T-type calcium channel currents 
(Moriguchi et  al. 2012). ST101 accelerated ACh release in the hippocampus of 
OBX mice, an effect inhibited by the T-type calcium channel blocker mibefradil and 
by nAChR inhibitors (Yamamoto et al. 2013). Moreover, intraventricular injection 
of mecamylamine inhibited ST101-elicited neurogenesis in the hippocampal DG of 
OBX mice (Shioda et al. 2010), suggesting that ST101 may activate nAChR and 
promote ACh release. However, clinical trials showed that administration of ST101 
alone was not sufficient to improve memory deficits in AD patients (Gauthier et al. 
2015). Therefore, we sought a more potent Cav3.1 and Cav3.3 T-type calcium chan-
nel enhancer, resulting in development of SAK3 (Yabuki et al. 2017b). We found 
that SAK3 promoted more potent ACh release in mouse hippocampal CA1 than did 
ST101 (Yabuki et al. 2017b).
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9.5  SAK3-Induced Neuroprotection in Brain Ischemia
We confirmed SAK3 neuroprotection using a 20-min BCCAO mouse model. To do 
so, we administered SAK3 (at 0.1, 0.5 or 1.0 mg/kg, p.o.) orally to mice 24 h after 
BCCAO ischemia. SAK3 administration at 0.5 or 1.0  mg/kg/day significantly 
blocked loss of hippocampal CA1 neurons and memory deficits seen in BCCAO 
mice. Treatment with the α7 nAChR-selective inhibitor methyllycaconitine (MLA: 
6.0 mg/kg/day, i.p.) antagonized both neuroprotection and memory improvement 
seen in SAK3 (0.5 mg/kg/day, p.o.)-treated mice (Fig. 9.1). Since excess calcium 
influx enhances excitotoxic and proapoptotic pathways to induce ischemic neuronal 
death (Berliocchi et al. 2005; Bano and Nicotera 2007), the impact of T-type chan-
nel regulators on neuroprotection is unclear. For example, intraventricular injection 
of mibefradil and pimozide 6 h before 10-min BCCAO ischemia antagonizes hip-
pocampal injury in rats (Bancila et al. 2011). Other T-type calcium channel block-
ers, such as U-92032 and flunarizine, administered 1  h prior to BCCAO inhibit 
delayed neuronal death in the gerbil hippocampal CA1 region (Ito et al. 1994). Such 
varied effects of T-type calcium channel blockers may be due to differences in tim-
ing of drug administration. We administered SAK3 to animals 24 h after BCCAO, 
whereas others have administered T-type calcium channel blockers before brain 
ischemia (Bancila et al. 2011; Ito et al. 1994). Moreover, some T-type calcium chan-
nel inhibitors, such as mibefradil and flunarizine have affinities to other channel 
types such as L-type calcium, sodium or potassium channels (Liu et al. 1999; Bloc 
et al. 2000; McNulty and Hanck 2004). Therefore, SAK3 is neuroprotective against 
brain ischemia by a mechanism that differs from that of other drugs.
9.6  SAK3 Ameliorates Methimazole-Induced Cholinergic 
Neuronal Damage
The drug methimazole (MMI) is widely used to antagonize hyperthyroidism and 
manage Graves’ disease, an autoimmune condition promoting hyperthyroidism 
(Cano-Europa et al. 2011; Wu et al. 2013). Biochemically, MMI acts by preventing 
iodine incorporation into the thyroid hormone precursor, thyroglobulin, and thus 
interferes with conversion of thyroxine (T4) to triiodothyronine (T3) (Cooper 1984; 
Amara et al. 2012; Parisa and Fahimeh 2015). Importantly, treatment with moderate 
doses of MMI reportedly impairs olfactory function in rats, while high doses cause 
complete destruction of the olfactory epithelium (OE) (Genter et al. 1995). The OE 
is a critical site of regeneration of physically- or chemically-injured olfactory sen-
sory neurons (OSNs) (Schwob et al. 1992; Suzukawa et al. 2011). Thyroid hormone 
deficiency also causes significantly reduced levels of choline acetyltransferase 
(ChAT), a marker of cholinergic neurons, in various brain regions (Kojima et al. 
1981; Oh et al. 1991; Sawin et al. 1998). Since cholinergic neurons in the MS inner-
vate the olfactory bulb and hippocampus (Mesulam et  al. 1983a), olfactory 

































Fig. 9.1 Oral SAK3 administration antagonizes loss of CA1 neurons after BCCAO through α7 nAChR 
stimulation. (a) Representative histological sections of hippocampus in control, vehicle- administered 
BCCAO, SAK3 (0.1, 0.5 or 1.0 mg/kg, p.o.)-administered BCCAO mice or SAK3 (0.5 mg/kg, p.o.)-
administered BCCAO mice treated with MLA. Mice were sacrificed 11 days after BCCAO for histo-
pathological analysis. Scale bars: low magnification, 500 μm; high magnification, 100 μm. (b) Cell 
viability is expressed as a percent of the average number of viable hippocampal CA1 cells from control 
mice (n = 12–23 per group). Error bars represent SEM. ** p < 0.01 vs. control mice. ## p < 0.01 vs. 
vehicle-administered BCCAO mice. †† p < 0.01 vs. SAK3 (0.5 mg/kg, p.o.)-administered BCCAO 
mice. MLA, methllycaconitine (6.0 mg/kg, i.p.) treatment; SAK3 (0.1), SAK3 (0.1 mg/kg, p.o.) admin-
istration; SAK3 (0.5), SAK3 (0.5 mg/kg, p.o.) administration; SAK3 (1.0), SAK3 (1.0 mg/kg, p.o.) 
administration; and Veh, vehicle administration. (Modified from Yabuki et al. 2017a)
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bulbectomy leads to anterograde degeneration of MS cholinergic neurons and con-
comitant loss of hippocampal cholinergic nerve terminals (Han et al. 2008). Loss of 
MS cholinergic neurons is also associated with cognitive deficits seen in Alzheimer’s 
disease (Robinson et al. 2011). Indeed, single administration of MMI (75 mg/kg, 
i.p.) promotes hypothyroidism in mice, and SAK3 treatment prevents hypothyroid-
ism-induced loss of MS cholinergic neurons, thereby improving memory deficits 
seen in MMI-treated mice (Noreen et al. 2017). In humans, adult onset hypothyroid-
ism is associated with impaired spatial memory performance and cognitive function 
(Tong et al. 2007; Artis et al. 2012), although mechanisms underlying these impair-
ments remain unclear.
Our recent analysis of MMI-treated mice showed that SAK3 may be neuropro-
tective and antagonize these cognitive deficits (Fig. 9.2). We found that perturbation 
of OSN maturation by a single dose of MMI is accompanied by a decrease in the 
number of MS cholinergic neurons (Fig. 9.3), a loss that likely causes memory and 
cognitive deficits seen in these mice. Importantly, SAK3 administration to MMI- 
treated mice rescued degeneration of MS cholinergic neurons and improved deficits 
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Fig. 9.2 MMI-induced decreases in OMP expression in olfactory bulb glomeruli are antagonized 
by SAK3 administration. (a) Coronal sections of olfactory bulb from indicated control (c), MMI- 
treated, or MMI-treated and SAK3-treated (0.1, 0.5 and 1 mg/kg) mice were incubated with OMP 
antibody. (b) SAK3 treatment significantly restored OMP staining intensity (b) and increased 
glomerulus size (c) in the OB glomerular layer. Scale bar, 50 μm. Error bars represent S.E.M. 
(**p < 0.01 vs control, #p < 0.05 and ##p < 0.01 vs MMI). n = 7 per group. (Modified from Noreen 
et al. 2017)
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9.7  SAK3 Is Neuroprotective Via nAChRs
Several reports indicate that nAChR neuroprotective activity requires activation of 
protein kinase B (Akt) signaling, a critical cell survival pathway (Davis and 
Pennypacker 2016; Fan et al. 2017). The α7 but not the α4 nAChR subunit interacts 
with the non-receptor-type tyrosine kinase Fyn and janus-activated kinase 2 (JAK2) 
(Kihara et al. 2001; Shaw et al. 2002), and α7 nAChR stimulation triggers activation 
of both kinases and subsequently upregulates phosphatidylinositol 3 kinase (PI3K) 
(Kihara et al. 2001; Shaw et al. 2002). Activated PI3K in turn promotes Akt activity 
and downstream survival signaling, including Nrf2/HO-1 signaling in neurons 
(Franke et  al. 1997; Kihara et  al. 2001; Navarro et  al. 2015; Niture and Jaiswal 
2012; Shaw et  al. 2002). By contrast, α7 nAChR activation in microglia and/or 
astrocytes is neuroprotective by promoting release of anti-inflammatory cytokines 
and blocking release of inflammatory cytokines (Di Cesare et al. 2015; Shin and 
Dixon 2015). The observation that both SAK3-induced ACh release and SAK3- 
induced neuroprotection are blocked by α7 nAChR inhibitors supports the idea that 
SAK3 effects are in large part mediated by nAChRs. SAK3-induced neuroprotec-
tion is closely associated with enhanced Akt rather than ERK activities (Yabuki 
et al. 2017a, b) (Fig. 9.4). In this context, α7 nAChR activation by SAK3 adminis-
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Fig. 9.3 SAK3 administration rescues MMI-induced decreases in the number of ChAT-positive 
cells in the medial septum. Photomicrographs showing anti-ChAT staining in the medial septum 
(MS) area. (b) ChAT-positive cells were counted in the MS of control or MMI-treated mice with 
or without SAK3 administration (0.1, 0.5 and 1 mg/kg). Scale bar, 100 μm. Error bars represent 
S.E.M. (**p < 0.01 vs control, #p < 0.05 and ##p < 0.01 vs MMI). n = 7 per group. (Modified from 
Noreen et al. 2017)
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9.8  Conclusion
Here, we have discussed neuroprotective activity of AChR signaling based on anal-
ysis of the novel modulator SAK3. SAK3 enhances activity of T-type calcium chan-
nels, promoting ACh release and activating hippocampal nAChRs, which are critical 
for memory formation. However, off-target analysis is required to determine 
whether SAK3 modulates nAChRs directly or indirectly. Since SAK3 activity in the 
CNS differs from that of cholinesterase inhibitors and from the nAChR modulator 
memantine, SAK3 is an attractive candidate to antagonize CNS neurodegenerative 






























Fig. 9.4 Acute SAK3 administration rescues Akt phosphorylation in CA1 pyramidal neurons of 
BCCAO mice through α7 nAChR stimulation. (a) Representative images showing fluorescent 
immunostaining with phospho-Akt (Ser-473: green) and NeuN (red) antibodies. Phosphorylated 
Akt immunoreactivity decreased in CA1 NeuN-positive neurons 24 h after BCCAO. Treatment 
with MLA (6.0 mg/kg, i.p.) blocked SAK3-dependent increases in Akt phosphorylation in NeuN- 
positive neurons. Scale bars: 20 μm. (b) Fluorescence intensity of Akt phosphorylation was mea-
sured in the hippocampal CA1 region. Immunofluorescence intensity of phosphorylated Akt 
significantly decreased in CA1 pyramidal cells (n = 4–5 per group). Error bars represent SEM. ** 
p < 0.01 vs. control mice. # P < 0.05 vs. vehicle-administered BCCAO mice. † p < 0.05 vs. SAK3 
(0.5 mg/kg, p.o.)-administered BCCAO mice. MLA, methllycaconitine (6.0 mg/kg, i.p.) treatment; 
SAK3 (0.5), SAK3 (0.5 mg/kg, p.o.) administration; and Veh, vehicle administration. (Modified 
from Yabuki et al. 2017a)
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Chapter 10
Removal of Blood Amyloid As a Therapeutic 
Strategy for Alzheimer’s Disease: 
The Influence of Smoking and Nicotine
Nobuya Kitaguchi, Kazunori Kawaguchi, and Kazuyoshi Sakai
Abstract Accumulation of amyloid β protein (Aβ) in the brain causes cognitive 
impairment in Alzheimer’s disease (AD). The nature of the relationship between 
smoking and AD or dementia has been controversial. However, a recent meta- 
analysis revealed that smoking is a risk factor for AD. With regard to nicotinic ace-
tylcholinergic receptors (nAChRs), both AD and control patients that smoke have 
been reported to show an increase in 3H-cytisine (an α4β4 nAChR agonist) binding 
in the temporal cortex. The α7 nAChR is also a key factor in AD pathology, particu-
larly in relation to internalization of Aβs. Furthermore, there are many reports show-
ing the neuroprotective effects of nicotine. The internalization of Aβ may lead to Aβ 
clearance in the brain.
We hypothesized that an extracorporeal system that rapidly removes Aβ from the 
blood may accelerate Aβ clearance from the brain. We have reported that (1) several 
medical materials including hemodialyzers can effectively remove blood Aβ, (2) the 
concentrations of blood Aβs decreased during hemodialysis, (3) removal of blood 
Aβ enhanced Aβ influx into the blood (ideally from the brain), resulting in mainte-
nance or improvement of cognitive function, and (4) Aβ deposition in the brain of 
hemodialysis patients was significantly lower than in controls. Smoking affected 
blood Aβ removal efficiencies and brain atrophy. We believe this Extracorporeal 
Blood Aβ Removal Systems (E-BARS) may contribute as a therapy for AD.
Keywords Alzheimer’s disease · Amyloid β · Aβ · Blood purification · Hemodialysis 
· Dialyzer · HDC · E-BARS
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10.1  Introduction: Amyloid β Protein in Alzheimer’s Disease
One of the major pathological changes associated with Alzheimer’s disease (AD) is 
the deposition of amyloid β protein (Aβ) as senile plaques and an increase in Aβ 
peptides in the brain (Kuo et al. 1996; Selkoe 2001). There are several Aβ species in 
the brain and plasma that are approximately 4 kDa in weight such as the 40-amino 
acid Aβ1–40 and the 42-amino acid Aβ1–42. Aβ1–42 aggregates more easily and is more 
toxic (Hung et al. 2008), forming soluble Aβ oligomers that can cause synapse loss 
and affect long-term potentiation in hippocampal neurons (Walsh et al. 2002). One 
mechanism proposed to underlie the increase in brain Aβ is reduced Aβ clearance 
rather than enhanced Aβ production, particularly in sporadic AD cases. Aβ produc-
tion in the brains of AD patients was reported to be similar to that of normal sub-
jects, yet Aβ clearance from AD brains was approximately 30% lower than in 
controls (Mawuenyega et al. 2010). In other words, it may be possible to treat AD 
by increasing Aβ clearance from the brain.
Recently, an anti-Ab monoclonal antibody that selectively targets aggregated 
forms of Aβ, aducanumab, was reported to be effective in improving cognitive func-
tion and reducing the brain Aβ burden, as measured by brain Aβ imaging (Sevigny 
et al. 2016). Similarly to anti-Aβ antibodies (Hock et al. 2003; Sevigny et al. 2016), 
peripheral administration of albumin, another Aβ-binding substance, was effective 
in improving cognitive function in AD patients in a Phase 2 study, and is currently 
undergoing a Phase 3 trial in AD patients (Boada et al. 2009, 2016).
We hypothesized that the rapid removal of Aβ from the blood by an extracorpo-
real system (E-BARS; extracorporeal blood Aβ removal system) may act as a 
peripheral Aβ sink from the brain, as shown in Fig. 10.1 (Kawaguchi et al. 2010). 
Smoking could affect the blood flow in the brain resulting in a change in the excre-
tion of Aβ from the brain into the blood.
10.2  Smoking, Nicotine, and AD
Determining the exact nature of the relationship between smoking and AD or 
dementia has been controversial. However, a recent meta-analysis revealed that 
smoking is a risk factor for AD, as described below. These controversial findings 
may be due to the mixed effects of smoke itself and components of tobacco such as 
nicotine.
N. Kitaguchi et al.
175
10.2.1  Smoking and AD Prevalence
Sabia et al. (2008) reported that ex-smokers had a 30% lower risk of poor vocabu-
lary and low verbal fluency. However, the correlation between smoking history and 
cognitive decline was inconsistent in longitudinal analysis. Despite this ameliora-
tive effect of smoking on memory (Sabia et al. 2008), the risk of AD was reported 
to be unaffected by any measure of tobacco consumption (Garcia et  al. 2010). 
Contrary to these favorable or neutral effects of smoking on dementia, there are 
many reports showing that smoking has a deleterious influence on AD risk. Lower 
AD risk was observed in alcohol drinkers of both genders who had never smoked 
(OR = 0.37, 95% CI: 0.21, 0.65), regardless of the presence of apolipoprotein E4 
(APOε4). Ott et al. (1998) showed that smokers had an increased risk of dementia 
(relative risk 2.2 [95% CI: 1.3–3.6]) and AD (relative risk 2.3 [95% CI: 1.3–4.1]) 
compared with never smokers, based on a study of 6870 people aged 55 years and 
older. Smoking was a strong risk factor for AD in individuals without the APOε4 
allele (relative risk 4.6 [95% CI: 1.5–14.2]), but had no effect in participants with 
this allele (relative risk 0.6 [95% CI: 0.1–4.8]). By meta-analysis of 19 prospective 
studies with at least 12 months of follow-up, Anstey et al. (2007) concluded that 
elderly smokers had increased risks of dementia and cognitive decline. Current 
smokers at baseline, relative to never smokers, had risks of 1.79 (95% CI: 1.43, 
2.23) for AD and 1.78 (95% CI: 1.28, 2.47) for vascular dementia. Compared to 
those who had never smoked, current smokers at baseline also showed greater 
Fig. 10.1 Schema of the extracorporeal blood Aβ removal system (E-BARS) for the treatment of 
Alzheimer’s disease (AD). Our hypothesis: the rapid reduction of Aβ concentrations in the blood 
by apheresis technology may act as a trigger for enhancing the excretion of Aβ from the brain, 
resulting in cognitive improvement. (Taken from Kawaguchi et al. 2010 and modified)
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yearly declines in Mini-Mental State Examination scores over the follow-up period. 
Compared to former smokers, current smokers at baseline showed an increased risk 
of AD and an increased decline in cognitive ability (Anstey et al. 2007). Furthermore, 
Barnes and Yaffe (2011) reported that smoking was associated with a higher risk of 
AD (relative risk 1.59 [95% CI: 1.15, 2.20]), and that a 10% reduction in smoking 
prevalence could potentially lower AD prevalence by about 412,000 cases world-
wide and by almost 51,000 cases in the USA, while a 25% reduction in smoking 
prevalence could potentially prevent more than 1 million AD cases worldwide and 
130,000 cases in the USA.
10.2.2  AD Pathology and Smoking
Recently, an interesting animal study on AD pathology was reported that used ciga-
rette smoke rather than administration of some components of tobacco such as nico-
tine. When APP/PS1 transgenic mice were exposed to smoke from cigarettes, AD 
pathology, such as Aβ deposition and the Iba1-labeled area indicating an inflamma-
tory response, was enhanced in the cortex and hippocampus. This enhancement was 
observed in the high-dose smoking group but not in the low-dose group (Moreno- 
Gonzalez et al. 2013).
Contrary to the animal study, it has been reported that smoking reduces both 
soluble and insoluble Aβ1–40 and Aβ1–42 in the frontal cortex and Aβ1–40 in the tempo-
ral cortex and hippocampus in AD patients (Hellström-Lindahl et al. 2004).
10.2.3  Nicotinic Acetylcholinergic Receptors and Aβs
Regarding nicotinic acetylcholinergic receptors (nAChRs), both AD and control 
patients that smoked showed increased 3H-cytisine (an agonist of the α4β4 nAChR) 
binding in the temporal cortex (Hellström-Lindahl et al. 2004). Further, Aβ levels in 
the brain was reduced in this study. Therefore, these authors proposed that a selec-
tive nAChR agonist could be a novel protective therapy for AD.
The α7 nAChR is also a key factor in AD pathology, particularly in relation 
to internalization of Aβs. Soluble Aβ is known to bind to the α7 nAChR with 
high affinity (Wang et  al. 2000). By in  vitro experimentation with SH-SY5Y 
cells, Yang et al. (2014) revealed that extracellular Aβ1–42 was internalized by the 
cells and accumulated in endosomes/lysosomes and mitochondria. This inter-
nalization was mediated through an α7 nAChR-dependent pathway related to 
the activation of p38 MAPK and ERK1/2. The authors proposed that blockade 
of the α7 nAChR may have a beneficial effect by limiting intracellular accumu-
lation of amyloid in the AD brain, thereby representing a potential therapeutic 
target for AD.
N. Kitaguchi et al.
177
However, there are many articles showing the neuroprotective effects of nicotine. 
The internalization of Aβ may lead to Aβ clearance from the brain. Akaike and 
Shimohama’s research group first demonstrated the neuroprotective effect of nico-
tine on Aβ toxicity (Kihara et  al. 1997). Concomitant administration of nicotine 
with Aβ25–35 ameliorated the death of rat cortical neurons induced by Aβ toxicity. In 
addition, the selective α7 nAChR antagonist, α-bungarotoxin, blocked this neuro-
protective effect of nicotine. This group also revealed that stimulation of the α7 
nAChR protected neurons against Aβ-enhanced glutamate neurotoxicity via PI3K 
(Kihara et  al. 2001). Shimohama’s research group reported that treatment of rat 
microglia with galantamine, an acetylcholinesterase inhibitor, significantly 
enhanced microglial Aβ phagocytosis via the nAChR pathway (Takata et al. 2010). 
This group also revealed early accumulation of CD68-positive microglia at Aβ 
deposition sites and gradual reduction of Aβ in an Aβ-injected AD mouse model, 
which indicates the importance of the α7 nAChR in microglia as a therapeutic target 
in AD (Matsumura et al. 2015).
10.3  Our Hypothesis of a Therapeutic System for AD 
by Removal of Blood Aβ
As described earlier, one mechanism proposed to underlie increased brain Aβ in AD 
is reduced Aβ clearance rather than an increase in Aβ production, particularly in 
sporadic AD cases. Therefore, it may be possible to treat AD by enhancing Aβ clear-
ance from the brain. There are several known Aβ transporters such as those involved 
in the Aβ influx pathway from the brain into the blood; e.g., LRP1 or APOE 
(Donahue et al. 2006; Bell et al. 2007), and RAGE (Silverberg et al. 2010), which is 
also known to mediate an Aβ influx pathway into the brain. In addition, perivascular 
elimination of Aβ in brain capillaries has been proposed (e.g., Morris et al. 2014).
Aβ concentrations in the cerebrospinal fluid (CSF) of AD patients are almost 100 
times higher than those in plasma. Aβ concentrations in the CSF in cases of AD are 
reported to be 7.4–42.7  ng/ml for Aβ1–40 and 0.12–0.67  ng/ml for Aβ1–42 
(Schoonenboom et  al. 2005). Concentrations in the plasma of AD patients are 
reported to be 190.1 ± 61.7 pg/ml for Aβ1–40 and 23.0 ± 15.5 pg/ml for Aβ1–42 (Lopez 
et al. 2008). In brief, there are large gradients with respect to Aβ concentrations 
between the brain and plasma. Therefore, removing Aβ from the blood could accel-
erate Aβ transfer from the brain, thereby reducing the Aβ burden in the brain.
Peripheral administration of Aβ-binding substances, such as anti-Aβ antibodies, 
non-immunogenic substances, and albumin, can reduce the Aβ burden in the brain. 
However, attempts to use Aβ-binding substances in the blood in a therapeutic con-
text resulted in the formation of Aβ complexes with the binding substances inside 
the body, which were sometimes retained in the plasma for a long period of time 
(DeMattos et  al. 2001). Aβ antibodies generated by passive immunization or by 
active immunization using synthetic Aβ peptides reduced the occurrence of senile 
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plaques and somewhat improved cognitive impairment in AD patients (Schenk et al. 
1999; Hock et al. 2003). Furthermore, non-immunogenic Aβ-binding substances, 
such as GM1 ganglioside or gelsolin, also decreased the Aβ burden in the brain 
when they were peripherally injected into mouse models of AD (Matsuoka et al. 
2003). Currently, a clinical trial is in progress where AD patients are being treated 
using intravenous administration of albumin, an Aβ-binding substance (Boada et al. 
2009). In this Phase 2 trial, plasma exchange (discard) removes the plasma of AD 
patients, which contains Aβ–albumin complexes, and a new albumin solution is 
introduced into the blood as a replacement solution; the results thus far suggest that 
this therapy has improved cognitive function in AD subjects. The Phase 3 trial is 
now also underway (Boada et al. 2016).
Based on these observations, the removal of Aβ from the blood could act as 
peripheral drainage and an Aβ sink from the brain. We proposed that the E-BARS, 
which transfers Aβ out of the body, may be useful as a therapy for AD (Kawaguchi 
et al. 2010) (Fig. 10.1). The rapid reduction of Aβ concentrations in the blood could 
act as a trigger to enhance Aβ excretion from the brain, resulting in cognitive 
improvement.
10.4  Definition of Aβ Removal Activities of the Devices
The Aβ removal activities assessed in our study were: (1) the removal rate for batch 
analysis in vitro, (2–1) the removal efficiency based on the concentration change at 
pre-/post-application of the Aβ removal device, (2–2) the reduction rate of Aβ in the 
whole blood circulation, and (2–3) the filtration rate. The definitions were as 
follows:
 1. Batch analysis in vitro:




%( ) = ´ -100 1 Ab gnated time







 2. Flow analysis in vitro and the hemodialysis session
 2-1 The Aβ removal efficiency of a dialyzer was defined as follows:
Removalefficiency






Ab edialyzer device at adesignated time
concentrationof before
( )









N. Kitaguchi et al.
179
 2-2 The Aβ reduction rate for the experimental pool solution or the whole blood 


























10.5  Adsorption Devices for Blood Aβ Removal
To obtain suitable materials for the removal of blood Aβ, we firstly investigated 
adsorptive materials for therapeutic blood purification (apheresis). We employed six 
materials: hexadecyl-alkylated cellulose particles (HDC), used to remove β2- 
microglobulin in carpal tunnel syndrome; cellulose particles ligated with dextran 
sulfate (CLD); charcoal (CHA), which is commonly used therapeutically, for exam-
ple, in hepatic failure; tryptophan-ligated polyvinyl alcohol gel (TRV), used in 
Guillain–Barré syndrome; and cellulose acetate particles and non-woven polyethyl-
ene terephthalate filter, used in ulcerative colitis. Among these materials, HDC and 
CHA demonstrated a removal rate of almost 99% for both Aβ1–40 and Aβ1–42 in batch 
analysis using synthetic Aβ peptides (Fig. 10.2) (Kawaguchi et al. 2010).
HDC is used in cases where there are complications associated with hemodialy-
sis and, therefore, we were able to investigate Aβ concentrations before (pre, inlet 
of) and after (post, outlet of) HDC column in hemodialysis sessions. The high 
removal efficiency of HDC was maintained at approximately 50% for both Aβ1–40 
and Aβ1–42 during a 4-h hemodialysis session, as shown in Table 10.1.
10.6  Blood Aβ Removal by Hemodialyzers in Hemodialysis
We previously reported that hemodialyzers showed high Aβ removal activity based 
on analyses of hemodialysis patients (Kitaguchi et al. 2011, 2015; Kato et al. 2012). 
Measurements of Aβ concentrations at pre (inlet of) and post (outlet of) dialyzers 
during hemodialysis sessions revealed that the hemodialyzers effectively removed 
both Aβ1–40 and Aβ1–42 from the plasma of non-diabetic patients. Figure 10.3 shows 
the Aβ concentrations at the inlet of the dialyzers (Pre) and the outlet of the dialyz-
ers (Post) for each dialysis session (n = 57). The average removal efficiencies for 
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Aβ1–40 were 66.0% at the 1-h point and 52.0% at the 4-h point of the hemodialysis 
sessions. Those for Aβ1–42 were 61.1% and 49.2%, as shown in Fig.  10.3. The 
removal efficiency in for Aβ1–40 was significantly higher than for Aβ1–42 both at 1 h 
and at 4 h of each dialysis session (p < 0.0001 for both time points). Each dialyzer 
maintained its removal efficiency during the entire dialysis session. This indicates 
that the dialyzers had sufficient capacity for Aβ removal during the 4-h treatment.
10.7  Removal of Blood Aβs Evoked Influx of Aβs into the 
Blood
Due to the effective removal activity of the dialyzers during the hemodialysis ses-
sions (Fig.  10.3), the concentrations of blood Aβs after 4-h hemodialysis would 
have been approximately 10% of the concentrations at the starting point if there had 
been no Aβ influx into the blood (“Calcd” in Fig.  10.4). However, observed 
Fig. 10.2 Aβ removal rate in batch analysis with various adsorptives in a batch reaction for 16 h. 
HDC hexadecyl-alkylated cellulose particles, CHA charcoal, TRV tryptophan-ligated polyvinyl 
alcohol gel, CAP cellulose acetate particles, CLD cellulose particles ligated with dextran sulfate, 
NPT non-woven polyethylene terephthalate filter. HDC and CHA showed significantly higher rates 
than TRV (p  <  0.05) for Aβ1–40 removal and a higher tendency than CAP (p  <  0.1) for Aβ1–42 
removal. (Taken from Kawaguchi et al. 2010)
Table 10.1 Removal efficiencies of HDC columns in hemodialysis
Time points during a 
hemodialysis session Aβ1–40 Aβ1–42
1 h (n = 5) 51.1 ± 6.6% 44.9 ± 5.0%
4 h (n = 4) 46.1 ± 6.6% 38.2 ± 5.8%
Taken from Kawaguchi et al. (2010)
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concentrations of blood Aβs (“Obsd” in Fig. 10.4) were not decreased compared to 
“Calcd.” The differences between “Obsd” and “Calcd” were attributed to Aβ influx 
into the blood. We calculated the influx based on the differential equation described 
previously (Kitaguchi et al. 2011). The results of this simulation of 37 non-diabetic 
hemodialysis patients are shown in Fig. 10.4.
Table 10.2 shows more detailed results of the simulation of Aβ influx with 30 
non-diabetic hemodialysis patients (Kitaguchi et  al. 2015). The average removal 
efficiencies at the 1-hr point of the hemodialysis sessions were 67.3% and 51.3% for 
Aβ1–40 and Aβ1–42, respectively. Aβ influxes during 4-hr hemodialysis were calcu-
Fig. 10.3 Aβ concentrations measured at pre-/post-dialyzers at 1 and 4 h in the hemodialysis ses-
sions. Aβ removal efficiencies for both Aβ1–40 and Aβ1–42 were quite high, with both being approxi-
mately 50% or greater. (a, b) Aβ1–40.; (c, d) Aβ1–42; (a, c) at the 1-h point of the dialysis sessions; (b, 
d) at the 4-h point of the dialysis sessions. (Taken from Kato et al. 2012 and modified)
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lated as 9243 ng and 719 ng for Aβ1–40 and Aβ1–42, respectively, which were around 
five times the level of pre-existing Aβs in the blood, that is, 1952 ng and 165 ng, just 
before hemodialysis.
A similar Aβ influx into the blood was also observed in a rat study using HDC.
10.8  Are the Influxes of Aβs into the Blood from the Brain?
Recently, we reported that Aβ accumulation in the brains of hemodialysis (HD) 
patients was significantly lower than that in age-matched non-hemodialysis con-
trols, as assessed by histopathological studies (Sakai et al. 2016). Senile plaques 
stained with anti-Aβ antibodies were observed more frequently in non-HD subjects 
and were either sparse or not seen at all in HD patients (Fig. 10.5). Regarding the 
ratio of senile plaques (plaque-positive/-negative subjects), there were significantly 
fewer neuritic and cored plaques in HD patients; only 5 of 17 HD patients showed 
neuritic plaques stained with 4G8 anti- Aβ antibody, whereas 12 out of 16 non-HD 
subjects exhibited these plaques. These findings suggest that the brain may be one 
origin of the Aβ influx during the hemodialysis sessions.
Fig. 10.4 Change in the observed plasma Aβ concentrations in the whole body circulation during 
hemodialysis sessions (Obsd), and, the calculated plasma Aβ concentrations based on the Aβ 
removal efficiencies of the dialyzers assuming no Aβ influx into the blood (Calcd). The arrows 
indicate Aβ influx during the hemodialysis sessions. (Taken from Kitaguchi et  al. 2011 and 
modified)
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10.9  Effects of Hemodialysis, One of the Blood Aβ Removal 
Methods, on Cognitive Function
Renal failure is well known to cause cognitive decline. In our cross-sectional study, 
cognitive function as measured by the MMSE was impaired in renal failure patients 
who did not receive hemodialysis compared to age-matched healthy controls. 
However, MMSE scores of hemodialysis patients were similar to those of controls 
(Fig. 10.6) (Kato et al. 2012).
Figure 10.7 shows the relationship between plasma Aβ concentrations, cognitive 
function, renal function, and hemodialysis vintage (the duration of hemodialysis) 
before and after initiation of hemodialysis. Before initiation of hemodialysis, plasma 
concentrations of both Aβ1–40 and Aβ1–42 increased along with a concomitant decline 
in renal function. However, when patients were introduced to hemodialysis (after 
initiation of hemodialysis), an increase in plasma Aβ concentrations was no longer 
apparent, but there was instead a slight tendency toward a decrease. Although the 
cognitive function declined along with the decline in renal function, this was main-
tained following initiation of hemodialysis (bottom of Fig. 10.7).
In the prospective study with 18 and 36 months follow-up, average MMSE scores 
did not significantly change, as shown in Fig. 10.8a, b. However, analysis of the 
change in individual subjects revealed that most hemodialysis patients maintained 
Table 10.2 Average Aβ influx into the blood during the hemodialysis sessions
Aβ concentrations during hemodialysis sessions (n = 30)
Aβ1–40 Aβ1–42
Time point of HD 
session
0 h 1 h 4 h 0 h 1 h 4 h
Aβ concentrations 
at Pre dialyzer (pg/
ml)
750.7 517.7 361.8 63.3 50.0 41.5
Removal 
Efficiency (%) of 
Pre/Post dialyzers
67.3 51.3
Aβ removed by 
dialyzers (ng)
(0–1 h) (1–4 h) Total 
removed Aβ 
(0–4 h) (a)
(0–1 h) (1–4 h) Total 
removed Aβ 
(0–4 h) (a)
3329 6925 10,254 227 549 776
Change of Aβs in 
the blood (ng)
1952 941 Decreased 
Aβ (0–4 h) 
(b)









Taken from Kitaguchi et al. (2015)
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Fig. 10.5 Comparison of senile plaques in patients who had undergone hemodialysis (HD) with 
those who had not undergone HD (non-HD). (a) Stained with the anti-Aβ17–24 antibody 4G8; (b) 
stained with the anti-Aβ1–16 antibody DE2. The numbers of all types of Aβ deposition (diffuse, 
cored, and neuritic plaques) were significantly lower in HD patients. HD, n = 17; non-HD, n = 16. 
(Taken from Sakai et al. 2016 and modified)
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or improved their cognitive function, with the exception of patients that showed 
white matter ischemia at baseline (Fig.  10.8c). This suggests that hemodialysis, 
with Aβ removal from the blood three times a week, may have a positive effect on 
cognitive function but has almost no influence on the cognitive effects of brain 
ischemia.
Furthermore, using a database of over 200,000 hemodialysis patients in Japan, 
the risk of dementia was revealed to be significantly lower in the patient subgroup 
with a longer duration of hemodialysis in subjects without diabetes (Nakai et al. 
2018).
10.10  Effects of Smoking on Removal of Blood Aβ
We then investigated the effects of smoking on Aβ removal efficiencies in hemodi-
alysis. Subjects were non-diabetic hemodialysis patients; n = 57, 29 male and 28 
female; age, 69.4  ±  3.8  years old (59–76  years old); duration of hemodialysis, 
13.9  ±  9.4  years (1–37  years); 28 smokers and 29 non-smokers, with “smoker” 
defined as a patient who had ever smoked (former smokers and current smokers). 
Information regarding the duration of smoking, the number of cigarettes per day, 
and the brands of cigarettes were obtained by interview with each patient. The prod-
uct of the duration and the number of cigarettes per day was also used for analysis.
Interestingly, removal efficiencies for both Aβ1–40 and Aβ1–42 in smokers signifi-
cantly decreased during the 4-h hemodialysis sessions (Table 10.3). The efficiencies 
Fig. 10.6 Cognitive function deteriorated in renal failure; however, hemodialysis appeared to pro-
mote recovery or maintenance of this. AMC, age-matched healthy controls (n  =  17) (66.6 ± 
4.1 years old, 5 male, 12 female); non-HDRF, renal failure patients without hemodialysis (n = 26) 
(66.6 ± 14.7 years old, 18 male, 8 female); HDRF, renal failure patients who received hemodialysis 
three times a week (n = 57) (69.4 ± 3.8 years old, 29 male, 28 female). MMSE Mini-Mental State 
Examination. (Taken from Kato et al. 2012)
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for non-smokers showed a tendency to increase, which was insignificant, rather than 
a decrease. The reason for this difference is unclear at present. One possibility is 
that Aβ species in the blood of smokers may have certain characteristics that cause 
saturation of Aβ adsorption or clogging of the inner surface of dialyzer membranes. 
A second possibility is that Aβ species flowing into the blood during hemodialysis 
may be more difficult to remove using a dialyzer in smokers than in non-smokers.
However, there is a limitation regarding this speculation on the effects of smok-
ing. The ratio of male/female subjects was higher in smokers than in non-smokers. 
Therefore, the differences between smokers and non-smokers could be partially 
attributable to gender.
Fig. 10.7 Summary of cross-sectional study of renal failure patients before/after initiation of 
hemodialysis (HD). The central box indicates initiation of hemodialysis. Left of the central box, 
data from renal failure patients without hemodialysis (non-HDRF) are shown. Right of the central 
box, data from hemodialysis patients (with-HDRF) are shown. Vertical axis: upper, plasma Aβ1–40 
concentrations; middle, plasma Aβ1–42 concentrations; lower, the Mini-Mental State Examination 
(MMSE) score (30 indicates no mistakes). Plasma for measuring Aβ concentrations after the initia-
tion of hemodialysis was sampled at the beginning of each hemodialysis session. Horizontal axis: 
before initiation of hemodialysis, plasma creatinine concentrations (CRN), which indicate decline 
of renal function; after initiation of hemodialysis, the vintage (duration) of hemodialysis. (Data 
from Kato et al. 2012)
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10.11  Effects of Smoking on Cognitive Function and Brain 
Atrophy in Renal Failure Patients
Figure 10.9 indicates that there appears to be no clear difference between the smoker 
and non-smoker cognitive function, as measured by the MMSE, in our study with a 
small sample size. The MMSE scores of smokers were similar to those of non- 
smokers in all three groups; age-matched healthy controls (AMC, seven smokers, 
ten non-smokers), renal failure patients who did not need hemodialysis (non-HDRF, 
Fig. 10.8 Change in cognitive function of hemodialysis patients in prospective studies. (a) Mini- 
Mental State Examination (MMSE) changes over 18 months; (b) MMSE changes over 36 months; 
(c) change in MMSE from baseline for each patient. A change of −1 to 4 is regarded as maintained 
or improved. Patients whose MMSE declined by −4 and −5 showed white matter ischemia at 
baseline. (Taken from Kitaguchi et al. 2015 and modified)
Table 10.3 Effects of smoking; comparison of Aβ removal efficiencies at pre-/post dialyzers in 
hemodialysis sessions
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seven smokers, seven non-smokers), and severe renal failure patients who received 
hemodialysis three times a week (HDRF, 28 smokers, 29 non-smokers).
However, brain CT scans revealed that there were differences in brain atrophy 
between smokers and non-smokers. Frontal/temporal and temporal/parietal atro-
phies were more severe in smokers than in non-smokers, as shown in Fig. 10.10 
(p  =  0.0465 and p  =  0.0062, respectively, by the χ2 test). This suggests that the 
effects of smoking on the brain may not be sufficiently serious to affect cognitive 
function in our study, or that hemodialysis including Aβ removal from the blood 
three times a week may maintain cognitive function despite the presence of more 
severe atrophies in smokers.
Fig. 10.10 Brain atrophy in smokers and non-smokers. Frontal/temporal atrophy and temporal/
parietal atrophy was more severe in smokers than in non-smokers, as detected by brain CT scans 
(p = 0.0465 and p = 0.0062, respectively, by the χ2 test). (Taken from Kitaguchi et al. 2015)
Fig. 10.9 The cognitive function of smokers and non-smokers was similar in our study. The 
patients were the same as those represented in Fig. 10.6 except that smoking history was obtained 
from only 16 non-HDRF patients. AMC age-matched healthy controls (seven smokers, ten non- 
smokers), non-HDRF renal failure patients without hemodialysis (seven smokers, nine non- 
smokers), HDRF severe renal failure patients who received hemodialysis three times a week (28 
smokers, 29 non-smokers). MMSE Mini-Mental State Examination
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10.12  Closing
As described above, removal of blood Aβ may enhance Aβ influx into the blood 
from the brain, resulting in maintenance or improvement of cognitive function. We 
believe that the E-BARS could contribute as a therapy for Alzheimer’s disease. With 
respect to smoking, the patient’s history in this regard may have some effect on 
brain atrophy and on the forms of Aβs existing in the blood. Additional study will 
be necessary in the future to further clarify this.
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